+

US20060100369A1 - Bifunctional-modified hydrogels - Google Patents

Bifunctional-modified hydrogels Download PDF

Info

Publication number
US20060100369A1
US20060100369A1 US11/273,393 US27339305A US2006100369A1 US 20060100369 A1 US20060100369 A1 US 20060100369A1 US 27339305 A US27339305 A US 27339305A US 2006100369 A1 US2006100369 A1 US 2006100369A1
Authority
US
United States
Prior art keywords
hydrogel
polymer matrix
peg
pharmacologically
terminus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/273,393
Inventor
Weiyuan Kao
Jing Li
David Lok
Rathna Gundloori
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US11/273,393 priority Critical patent/US20060100369A1/en
Publication of US20060100369A1 publication Critical patent/US20060100369A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L101/00—Compositions of unspecified macromolecular compounds
    • C08L101/12—Compositions of unspecified macromolecular compounds characterised by physical features, e.g. anisotropy, viscosity or electrical conductivity
    • C08L101/14—Compositions of unspecified macromolecular compounds characterised by physical features, e.g. anisotropy, viscosity or electrical conductivity the macromolecular compounds being water soluble or water swellable, e.g. aqueous gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/225—Mixtures of macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
    • A61L15/325—Collagen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/60—Liquid-swellable gel-forming materials, e.g. super-absorbents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G81/00—Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
    • Y10S530/815—Carrier is a synthetic polymer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
    • Y10S530/815—Carrier is a synthetic polymer
    • Y10S530/817—Entrapped within the carrier, e.g. gel, hollow fibre

Definitions

  • the invention is directed to hydrogels modified using bifunctional reagents, use of the hydrogels to deliver drugs or other biologically-active agents to a mammal in need thereof, compositions containing the hydrogels described herein, and devices, such as wound dressings, diapers, catamenial devices, etc., incorporating the hydrogels.
  • Biomedical systems such as healing and embryonic development, operate under spatially- and temporally-controlled orchestration.
  • a myriad of signals and cells all act, in space and time, to heal a cut, for example, or to surround and neutralize a foreign body.
  • the efficacy of current materials used to construct biomedical devices is limited by a lack of multi-functional structures to complement the inherent dynamics of these biological systems.
  • biodegradable polymers have been used in burn dressings, hemostatic patches, and the like. These biodegradable polymers provide a barrier and possibly a tissue scaffold for regrowth. However, these types of dressing have no therapeutic effect. While such types of dressings provide effective barriers to physical disturbance of the wound site, scarring is still extensive.
  • An ideal functional wound dressing should have the following properties: It should be non-toxic, biocompatible, and permeable to moisture and gases to absorb wound exudate and toxins as well to maintain appropriate humidity and oxygen levels. It should be porous to prevent swelling of the wound bed and accumulation of the fluid between the wound site and the material. It should be flexible and durable and minimize local inflammation and infection, thereby promoting new vascularization, re-epithelialization, and normal healing.
  • Hydrogels are three-dimensional networks capable of absorbing copious amounts of water. Hydrogels have been explored for many uses, including drug delivery devices, wound dressing materials, contact lenses, and cell transplantation matrices. Edible hydrogels, such as gelatin, find extensive use in various food-related applications, such as texture modification, gelling, clarification of beers and wines, and as medicine capsules.
  • the invention is directed to hydrogels comprising a polymer matrix, preferably gelatin or a synthetic polymer (preferably a biodegradable polymer, although the polymer may also be non-biodegradable), modified to contain bifunctional poly(alkylene glycols) covalently bonded to the polymer matrix.
  • a polymer matrix preferably gelatin or a synthetic polymer (preferably a biodegradable polymer, although the polymer may also be non-biodegradable)
  • heterofunctional poly(alkylene glycols) covalently bonded to the polymer matrix preferably polymer matrix, preferably gelatin or a synthetic polymer (preferably a biodegradable polymer, although the polymer may also be non-biodegradable), modified to contain bifunctional poly(alkylene glycols) covalently bonded to the polymer matrix.
  • biofunctional agents i.e., pharmacologically-active agents
  • ⁇ - or ⁇ -termini i.e., the free termini
  • FIG. 4 A schematic representation of the preferred embodiment of the invention is shown in FIG. 4 .
  • Any pharmacologically-active agent can be incorporated into the hydrogel, including (by way of illustration and not limitation) vulnerary agents, hemostatic agents, antibiotics, antithelmintics, anti-fungal agents, hormones, anti-inflammatory agents, proteins, polypeptides, oligonucleotides, cytokines, enzymes, etc.
  • the hydrogels of the present invention find many uses, the preferred of which is as a functional wound dressing.
  • the hydrogel contains as a pharmacologically-active agent a vulnerary agent covalently bonded to a biodegradable polymer matrix via a differentially-modified, ⁇ - and ⁇ -substituted PEG linker.
  • hydrogels of the present invention may also be incorporated into bandages, surgical and dental wound packing material, diapers and catamenial devices, and the like.
  • novel hydrogel constructs described herein are not physical blends, which are common in the formulation of current biomedical hydrogels; hence, the chemical and physical properties of the subject hydrogels are homogenous and can be tailored to suit a particular clinical end-point requirement. Furthermore, the hydrogel constructs are mechanically stable because the components are covalently bonded. In addition, the hydrophilicity and flexibility of the porous hydrogel accommodate the absorption of wound exudate and assist the final removal of the material from the wound site (if necessary or desired). The nature of gelatin and the porosity of the construct further facilitate the exchange of gases and allow healing. Most importantly, the presence of hPEG-conjugated bioactive compounds and the loading of other pharmaceutical compounds within the matrix allows for the temporally- and spatially-controlled delivery of bioactive signals to modulate and complement the dynamics of the host healing process.
  • the present invention offers several key commercial advantages over existing products. For example, despite the extensive investigation in the development of novel wound dressing materials, very few materials are used clinically due to the multiple requirements necessary for a functional wound dressing.
  • Ideal functional wound dressings must be nontoxic, biocompatible, permeable to moisture and gases to absorb wound exudate and toxins, as well as to maintain humidity and oxygen levels.
  • the dressings should be porous to prevent swelling of the wound bed and to prevent accumulation of fluid between the wound site and the material. They should be flexible and durable. They should be biocompatible and minimize local inflammation and infection. They should promote neovascularization, re-epithelialization, and normal healing.
  • the novel multi-functional hydrogels described herein can be made to address all of the above requirements for a clinically viable wound dressing material.
  • the invention is directed to a hydrogel that comprises a polymer matrix.
  • the preferred polymer matrix contains reactive amino groups.
  • the most preferred polymer matrices are gelatin and collagen.
  • the polymer matrix is modified using a bifunctional modifier comprising a poly(alkylene glycol) molecule having a substituted or unsubstituted ⁇ -terminus and a substituted or unsubstituted ⁇ -terminus. At least one of the ⁇ - or ⁇ -termini is covalently bonded to the polymer matrix.
  • the other terminus projects into the interior of the hydrogel mass and modifies its physico-chemical properties. By controlling the nature of the ⁇ - and ⁇ -termini, the physical and chemical qualities of the resulting hydrogel can be altered.
  • the ⁇ - and ⁇ -termini are different, and thus are differentially reactive. This enables, for example, one or more pharmacologically-active agents to be covalently bonded to one of the ⁇ - or ⁇ -termini that is not bonded to the polymer matrix. Alternatively (or simultaneously), one or more pharmacologically-active agents may also be entrained within the hydrogel.
  • the polymer matrix of the hydrogel may be cross-linked with a cross-linking reagent such as glutaraldehyde.
  • Cross-linking alters the absorption characteristics and material strength of the resulting gel.
  • cross-linking may be desirable where increased mechanical strength of the gel is required.
  • the ⁇ - and/or ⁇ -termini of the hydrogel may be substituted or unsubstituted.
  • substitution is a moiety selected from the group consisting of halo, hydroxy, C 1 -C 24 -alkyl, C 1 -C 24 -alkenyl, C 1 -C 24 -alkynyl, C 1 -C 24 -alkoxy, C 1 -C 24 -heteroalkyl, C 1 -C 24 -heteroalkenyl, C 1 -C 24 -heteroalkynyl, cyano-C 1 -C 24 -alkyl, C 3 -C 10 -cycloalkyl, C 3 -C 10 -cycloalkenyl, C 3 -C 10 -cycloalkynyl, C 3 -C 10 -cycloheteroalkyl, C 3 -C 10 -cycloheteroalkenyl
  • moieties on the ⁇ -terminus and the ⁇ -terminus when substituted bear a substituent selected from the group consisting of alkyl, aryl, acyl, halogen, hydroxy, amino, alkoxy, alkylamino, acylamino, thioamido, acyloxy, aryloxy, aryloxyalkyl, mercapto, thia, aza, oxo, saturated cyclic hydrocabon, unsaturated cyclic hydrocarbon, heterocycle, aryl, and heteroaryl.
  • hydrogel comprising:
  • a bifunctional modifier comprising a compound of formula: wherein at least one of the “A” or “Z” moieties is covalently bonded to the reactive amino moieties of the polymer matrix; and wherein “A” and “Z” are independently selected from the group consisting of hydrogen, halo, hydroxy, C 1 -C 24 -alkyl, C 1 -C 24 -alkenyl, C 1 -C 24 -alkynyl, C 1 -C 24 -alkoxy, C 1 -C 24 -heteroalkyl, C 1 -C 24 -heteroalkenyl, C 1 -C 24 -heteroalkynyl, cyano-C 1 -C 24 -alkyl, C 3 -C 10 -cycloalkyl, C 3 -C 10 -cycloalkenyl, C 3 -C 10 -cycloalkynyl, C 3 -C 10 -cycloheteroalkyl,
  • a second embodiment of the invention is directed to a hydrogel as described above, with the further inclusion of a second polymer matrix.
  • the second polymer matrix interpenetrates with the first polymer matrix.
  • the first polymer matrix, with its grafted modifier molecules interpenetrates and is physically bound within a second, interpenetrating polymer matrix.
  • the second polymer matrix comprises a photopolymerized poly(acrylate), such as an ⁇ -acrylate- ⁇ -acrylate-poly(alkylene glycol), trimethylolpropane triacrylate, acrylic acid, and/or acryloyl halide.
  • the second polymer matrix may be a homo-polymer or co-polymer or two or more monomer types.
  • the interpenetrating hydrogels may further comprise a pharmacologically-active agent covalently bonded to one of the ⁇ - or ⁇ -termini that is not bonded to the first polymer matrix.
  • all of the hydrogels according to the present invention may further comprise a pharmacologically-active agent or a living cell entrained within the hydrogel.
  • a third embodiment of the invention is directed to a method of making a hydrogel as described hereinabove.
  • the method comprises reacting a polymer matrix with a bifunctional modifier comprising a poly(alkylene glycol) molecule having a substituted or unsubstituted ⁇ -terminus and a substituted or unsubstituted ⁇ -terminus, whereby at least one of the ⁇ - or ⁇ -termini is covalently bonded to the polymer matrix.
  • a fourth embodiment of the invention is directed to the method described in the previous paragraph, and further comprising contacting the first polymer matrix with a plurality of monomers and then polymerizing the monomers to yield a second polymer matrix, wherein the second polymer matrix interpenetrates with the first polymer matrix.
  • the hydrogels of the present invention can be used in any application where hydrogels are currently employed.
  • the hydrogels of the present invention find use as wound dressings, diapers, catamenial devices, and the like.
  • the hydrogels are used to administer a pharmacologically-active agent to a patient in need of the pharmacologically-active agent.
  • the pharmacologically-active agent either is covalently bonded within the gel or entrained within the gel.
  • the gel is then administered to the patient, as by packing it into a surgical or traumatic wound.
  • the hydrogels of the present invention are also useful as scaffolds to support living cells.
  • the hydrogels of the present invention can be used as biomechanical devices.
  • the hydrogels will support living cells within the bulk of the gel, thereby providing a three-dimensional support network in which the cells can grow and proliferate.
  • Hydrogels according to the present invention that contain cells can be implanted into a patient in need of such cells.
  • FIG. 1 A summary of the chemical reactions and structure of critical intermediates and final products of M-PEG, CN-PEG, COOH-PEG, or PT-PEG.
  • FIGS. 2A and 2B HPLC chromatogram of (2A) evaporative light scattering detector signals and (2B) UV signals at 254 nm for PEGdiols and various XPEGmA. Samples were analyzed with a reverse phase HPLC system (10% to 100% acetonitrile at a flow rate of 1 ml/min in 30 min with Jordi 500 A column on a Gilson system) coupled to UV/Vis (200 nm and 254 nm), photodiode array, and evaporative light scattering detectors.
  • a reverse phase HPLC system (10% to 100% acetonitrile at a flow rate of 1 ml/min in 30 min with Jordi 500 A column on a Gilson system
  • UV/Vis 200 nm and 254 nm
  • photodiode array photodiode array
  • evaporative light scattering detectors evaporative light scattering detectors
  • FIGS. 3A and 3B Surface hydrophilicity of the XPEGmA-co-Ac-co-TMPTA network containing XPEGmA of various concentration, terminal moiety, and molecular weight.
  • FIG. 4 A schematic representation of hydrogels according to the present invention.
  • FIG. 6 A schematic representation of an interpenetrating network hydrogel according to the present invention.
  • Poly(alkylene glycols) such as poly(ethylene glycol) (PEG) are employed extensively in a number of medical and pharmaceutical fields due to their low toxicity, good biocompatibility, and excellent solubility (1-5) .
  • PEG poly(ethylene glycol)
  • the following description shall be limited to gels modified by bifunctional poly(ethylene glycol) molecules. The invention, however, will function with equal success using any poly(alkylene glycol).
  • the bifunctional modifier comprise a poly(alkylene glycol) of the formula: where “m” is an integer of from 2 to 8; “n” is an integer equal to or greater than 100; and “A” and “Z” are as described above.
  • “m” equals 2 and “n” is sufficiently large to yield a PEG molecule having a molecular weight of roughly 100,000 Da.
  • “n” is greater than 2,000.
  • the “n” substituent may also be sufficiently large to yield a PEG molecule having a molecular weight greater than 1 ⁇ 10 6 Da, in which case “n” is greater than roughly 20,000.
  • the present invention thus is drawn to novel hydrogels that use bifunctional PEGs and hetero-bifunctional PEGs (“hPEGs”) as covalent grafts to modify the physical and biological properties of hydrogels.
  • hPEGs bifunctional PEGs and hetero-bifunctional PEGs
  • These bifunctional PEGS having improved reactivity and physicochemical properties can thus be used to modify polymer matrices in general, and proteinaceous matrices in particular, to yield novel hydrogels.
  • These novel hydrogels are useful in wide array of biomaterial and biopharmaceutical compositions and devices that include a hydrogel component, including time-release vehicles, wound dressings and packing, bandages, burn dressings, catamenial devices, diapers, etc.
  • hPEGs are classified into two general categories: 1) statistical terminal modification of PEG precursors; and 2) ethylene oxide polymerization methods using special initiators. (6-9) Although various hPEGs are currently available commercially (e.g., from Shearwater Corporation, Huntsville, Ala.), their high cost and limited quantity greatly restricts the extensive utilization of such materials by laboratories in developing novel biomaterials for various applications. In developing the present invention, a number of synthetic schemes were developed to produce a library of hPEG compounds based on the statistical terminal modification method.
  • PEG-diol is available in a host of different molecular weights, and from a large number of international suppliers (including Shearwater Corporation).
  • polymer networks having diverse physicochemical and surface properties were developed. These networks can be used to study cell-material interaction. (10-13)
  • hPEGs were utilized to modify a polymer matrix to yield novel hydrogels.
  • the effect of hPEG concentration, molecular weight, and terminal chemical functionality on the surface hydrophobicity and cell interaction with the hydrogels was investigated and is presented in the Examples.
  • PEG modifications e.g., carboxylic acids of the poly-acrylic acid backbone and the functional group at the dangling terminus of hPEG grafted at the pendent chain configuration
  • PEG modifications can be employed to bind several distinct types of biofunctional molecules such as peptides and pharmaceutics to the hydrogel.
  • the polymer matrix is a modified gelatin.
  • the use of gelatin is not incidental.
  • Gelatin is a well-characterized, FDA approved, biodegradable biomaterial.
  • hydrogels made from modified gelatin are likely to pass regulatory muster due to the known safety of gelatin.
  • the hydrophilicity and porosity of gelatin was modified using ampholytic moieties such as ethylenediaminetetracetic dianhydride (EDTAD).
  • EDTAD ethylenediaminetetracetic dianhydride
  • the resulting polymer backbone can be cross-linked with small amounts of glutaraldehyde and subsequently loaded with pharmaceutical agents such as antibiotic drugs.
  • the water-uptake, swelling, degradation, and drug release kinetics of the resulting hydrogel can be controlled by varying the amount of cross-linking and the extent of EDTAD modification.
  • hydrogel was then grafted with various hPEGs, as described hereinbelow.
  • hPEGs hPEG-modified gelatin hydrogels
  • synthetic polymer networks containing human white blood cells and fibroblasts were examined, both in vitro and in vivo.
  • the terminal group of the hPEGs has also been used to link bioactive peptides to the hydrogel matrix, thereby to control the interaction of host cells such as white blood cells and to enhance favorable biological interactions. It has been demonstrated in the Examples that the molecular interaction of several bioactive oligopeptides in modulating white blood cell behavior and host interaction in vitro and in vivo can thus be modified.
  • the resulting hydrogels can be used a functional wound dressings, bandages, and the like. These functional wound dressings are suitable for use both internally and externally.
  • the gelatin-hPEG hydrogels of the present invention have been tested in a subcutaneous caged implant model.
  • hydrogels of the present invention are not physical blends.
  • the present hydrogels are chemically and physically homogenous and can be tailored to suit a particular clinical endpoint requirement.
  • the hydrogel is mechanically stable because the components are covalently bonded together. Additionally, the hydrophilicity and flexibility of the porous hydrogel accommodates the absorption of wound exudate, blood, etc., and assists in the final removal of material from the wound site.
  • gelatin and the porosity of the construct also facilitates the exchange of gases and promotes rapid healing.
  • the presence of hPEG-conjugated bioactive compounds within the hydrogel matrix itself adds qualitative value and control to the wound healing process.
  • hPEGs heterobifunctional PEGs
  • the hPEGs were then used to make modified polymer hydrogels having various surface and physicochemical properties.
  • Extensive NMR and HPLC analyses confirmed the chemical structure of hPEG.
  • the hydrophilicity of the polymer network was predominantly dependent on the hPEG concentration, with the molecular weight of the starting, unmodified PEG and the terminal functional groups also playing roles.
  • Adherent human fibroblast density on the hydrogels remained constant with increasing hPEG concentration in the gel formulation but decreased rapidly on hydrogels containing 0.8 to 1.25 g/ml of hPEGs. This trend was independent of the hPEG terminal moiety and molecular weight. No adherent cells were observed on all sample gels containing 2.5 g/ml or more of hPEGs.
  • ETAD ethylene diaminetetracetic dianhydride
  • IPN interpenetrating network hydrogel
  • TMPTA trimethylolpropane triacrylate (i.e., 2-ethyl-2-(hydroxymethyl)-1,3-propanediol triacrylate, CAS No. 15625-89-5)
  • XPEGmA hPEG with acrylate ⁇ -terminal and ⁇ -terminal of different moiety
  • alkyl by itself or as part of another substituent, means, unless otherwise stated, a fully saturated, straight, branched chain, or cyclic hydrocarbon radical, or combination thereof, and can include di- and multi-valent radicals, having the number of carbon atoms designated (e.g., C 1 -C 10 means from one to ten carbon atoms, inclusive).
  • alkyl groups include, without limitation, methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl, cyclohexyl, (cyclohexyl)ethyl, cyclopropylmethyl, and homologs and isomers thereof, for example, n-pentyl, n-hexyl, n-heptyl, n-octyl, and the like.
  • alkyl unless otherwise noted, also includes those derivatives of alkyl defined in more detail below as “heteroalkyl” and “cycloalkyl.”
  • alkenyl means an alkyl group as defined above containing one or more double bonds.
  • alkenyl groups include vinyl, 2-propenyl, crotyl, 2-isopentenyl, 2-(butadienyl), 2,4-pentadienyl, 3-(1,4-pentadienyl), etc., and the higher homologs and isomers.
  • alkynyl means an alkyl or alkenyl group as defined above containing one or more triple bonds.
  • alkynyl groups include ethynyl, 1- and 3-propynyl, 3-butynyl, and the like, including the higher homologs and isomers.
  • alkylene alkenylene
  • alkynylene alone or as part of another substituent means a divalent radical derived from an alkyl, alkenyl, or alkynyl group, respectively, as exemplified by —CH 2 CH 2 CH 2 CH 2 —.
  • alkyl, alkenyl, alkynyl, alkylene, alkenylene, and alkynylene groups will have from 1 to 24 carbon atoms. Those groups having 10 or fewer carbon atoms are preferred in the present invention.
  • “Substituted” refers to a chemical group as described herein that further includes one or more substituents, such as lower alkyl, aryl, acyl, halogen (e.g., alkylhalo such as CF 3 ), hydroxy, amino, alkoxy, alkylamino, acylamino, thioamido, acyloxy, aryloxy, aryloxyalkyl, mercapto, thia, aza, oxo, both saturated and unsaturated cyclic hydrocarbons, heterocycles and the like.
  • substituents such as lower alkyl, aryl, acyl, halogen (e.g., alkylhalo such as CF 3 ), hydroxy, amino, alkoxy, alkylamino, acylamino, thioamido, acyloxy, aryloxy, aryloxyalkyl, mercapto, thia, aza, oxo, both saturated and
  • These groups may be attached to any carbon or substituent of the alkyl, alkenyl, alkynyl, alkylene, alkenylene, and alkynylene moieties. Additionally, these groups may be pendent from, or integral to, the carbon chain itself.
  • heteroalkyl by itself or in combination with another term, means, unless otherwise stated, a stable, saturated or unsaturated, straight, branched chain, or cyclic hydrocarbon radical, or combinations thereof, consisting of the stated number of carbon atoms and from one to three heteroatoms selected from the group consisting of O, N, Si, and S, and wherein the nitrogen and sulfur atoms may optionally be oxidized and the nitrogen heteroatom(s) may optionally be quaternized.
  • the heteroatom(s) O, N and S may be placed at any interior position of the heteroalkyl group.
  • the heteroatom Si may be placed at any position of the heteroalkyl group, including the position at which the alkyl group is attached to the remainder of the molecule.
  • Examples include —CH 2 —CH 2 —O—CH 3 , —CH 2 —CH 2 —NH—CH 3 , —CH 2 —CH 2 —N(CH 3 )—CH 3 , —CH 2 —S—CH 2 —CH 3 , —CH 2 —CH 2 —S (O)—CH 3 , —CH 2 —CH 2 —S (O) 2 —CH 3 , —CH ⁇ CH—O—CH 3 , —Si(CH 3 ) 3 , —CH 2 —CH ⁇ N—OCH 3 , and —CH ⁇ CH—N(CH 3 )—CH 3 .
  • heteroalkyl Up to two heteroatoms may be consecutive, such as in —CH 2 —NH—O—CH 3 and —CH 2 —O—Si(CH 2 ) 3 .
  • heteroalkyl Explicitly included within the term “heteroalkyl” are those radicals that could also be described as “heteroalkylene” (i.e., a divalent radical, see next paragraph), and “heterocycloalkyl” (i.e., containing a cyclic group).
  • heteroalkyl also explicitly includes unsaturated groups (i.e., heteroalkenyls and heteroalkynyls).
  • heteroalkylene by itself or as part of another substituent means a divalent radical derived from heteroalkyl, as exemplified by —CH 2 —CH 2 —S—CH 2 CH 2 —and —CH 2 —S—CH 2 —CH 2 —NH—CH 2 —.
  • heteroalkylene groups heteroatoms can also occupy either or both of the chain termini. Still further, for alkylene and heteroalkylene linking groups, no orientation of the linking group is implied.
  • aryl is used herein to refer to an aromatic substituent, which may be a single aromatic ring or multiple aromatic rings which are fused together, linked covalently, or linked to a common group such as a diazo, methylene or ethylene moiety.
  • the common linking group may also be a carbonyl as in benzophenone.
  • the aromatic ring(s) may include, for example phenyl, naphthyl, biphenyl, diphenylmethyl and benzophenone, among others.
  • aryl encompasses “arylalkyl” and “substituted aryl.”
  • the aryl ring may be mono-, di-, tri-, tetra-, or penta-substituted. Larger rings may be unsubstituted or bear one or more substituents.
  • “Substituted aryl” refers to aryl as just described including one or more functional groups such as lower alkyl, acyl, halogen, alkylhalo (e.g., CF 3 ), hydroxy, amino, alkoxy, alkylamino, acylamino, acyloxy, phenoxy, mercapto, and both saturated and unsaturated cyclic hydrocarbons which are fused to the aromatic ring(s), linked covalently or linked to a common group such as a diazo, methylene, or ethylene moiety.
  • the linking group may also be a carbonyl such as in cyclohexyl phenyl ketone.
  • substituted aryl encompasses “substituted arylalkyl.”
  • acyl is used to describe a ketone substituent, —C(O)R, where R is substituted or unsubstituted alkyl, alkenyl, alkynyl, or aryl as defined herein.
  • carbonyl is used to describe an aldehyde substituent.
  • carboxy refers to an ester substituent or carboxylic acid, i.e., —C(O)O— or —C(O)—OH.
  • halogen or “halo” is used herein to refer to fluorine, bromine, chlorine and iodine atoms.
  • hydroxy is used herein to refer to the group —OH.
  • amino is used to designate NRR′, wherein R and R′ are independently H, alkyl, alkenyl, alkynyl, aryl or substituted analogs thereof.
  • Amino encompasses “alkylamino,” denoting secondary and tertiary amines, and “acylamino” describing the group RC(O)NR′.
  • alkoxy is used herein to refer to the —OR group, where R is alkyl, alkenyl, or alkynyl, or a substituted analog thereof. Suitable alkoxy radicals include, for example, methoxy, ethoxy, t-butoxy, etc.
  • alkoxyalkyl refers to ether substituents, monovalent or divalent, e.g. —CH 2 —O—CH 3 and —CH 2 —O—CH 2 —.
  • gelatin as used herein means any and all kinds of gelatin, of any type (e.g., Type A from pork, with an isoelectric point between about 7.0 and 9.0, and Type B from beef with an isoelectric point of approximately 5.0), from any source, of any bloom value, acid- or alkaline-treated, etc., without limitation.
  • the “bloom strength” of a gelatin is defined as the force required for a plunger of defined shape and size to make a 4 mm depression in a gel that has been prepared at 6.67% w/w concentration and chilled at 10° C. in a bloom jar for 16-18 hours. The force is recorded in grams.
  • gelatin is available from a host of commercial suppliers.
  • gelatin is generally available with bloom strengths ranging from about 50-300 bloom.
  • Such gelatins are available from, for example, Leiner Davis Gelatin, a wholly-owned subsidiary of Goodman Fielder Ingredients of Sydney, Australia. Gelatins having bloom values outside this range are also available as specialty chemicals and are included within the scope of the term “gelatin.” For example a zero bloom (non-gelling) gelatin is available from Great Lakes Gelatin Co., Grayslake, Ill.
  • collagen as used herein means any and all kinds of collagen, of any type, from any source, without limitation.
  • polymer matrix encompasses any type of polymer matrix that can function as a hydrogel, including, without limitation, gelatin, calcium alginate, calcium/sodium alginate, collagen, oxidized regenerated cellulose, carboxymethylcellulose, amino-modified celluloses, such as 6-deoxy-6-(4-aminophenyl)-amino-2(3)-O-tosylcellulose, whey protein gels, and the like.
  • photopolymerizable acrylate refers to any acrylate-containing molecule capable of being photopolymerized, without limitation.
  • bis-diacrylate-PEGs i.e., poly(alkylene glycol) molecules having an ⁇ -acrylate moiety and an ⁇ -acrylate moiety.
  • TMPTA is also a photopolymerizable acrylate.
  • PEG-diols can be purchased essentially as a commodity item, in large amounts and at relatively inexpensive prices.
  • the first step in modifying the ⁇ - and ⁇ -termini of the PEG-diols is to convert them in aldehyde groups. This is very easily accomplished by treating the PEG-diol with acetic anhydride: The reaction is very facile and quantitative.
  • the molecule can be further modified using any of the routes shown in FIG. 1 , among many others.
  • the PEG-diol can be converted into an ⁇ -hydroxy- ⁇ -carboxy-PEG, which can then be converted into an ⁇ -acrylate- ⁇ -carboxy-PEG.
  • the PEG-diol can be converted into a ⁇ -hydroxy- ⁇ -cyanoethyl-PEG, which can then, in turn, be converted into a ⁇ -acrylate- ⁇ -cyanoethyl-PEG.
  • the PEG-diol can be directly converted, by simple halogenation of the hydroxy group to ⁇ -hydroxy- ⁇ -halo-PEG.
  • the PEG diol can also be tosylated and acrylated to thereby yield ⁇ -acrylate- ⁇ -tosylated-PEG.
  • the tosyl group can be exchanged for a succinimidyl or phthalimidyl or other nitrogen-containing heterocycle group.
  • ⁇ -Hydroxy- ⁇ -methoxy-PEG can be converted directly into ⁇ -acrylate- ⁇ -methoxy-PEG. See FIG. 1 . (See also Hern & Hubbell, (1998) J. Biomed. Mater. Res. 39:266-276; Morpurgo et al. (1996) App. Biochem. Biotech. 56:59-72; and Abuchowski et al. (1984) Cancer Biochem. Biophys. 7:175-186.)
  • ⁇ -hydroxy- ⁇ -glutarate-PEG can be synthesized by treating a PEG-diol with glutaric anhydride and glutaric acid in THF with gentle heating:
  • the glutaric anhydride and the glutaric acid are added and the solution gently heated to 55° C.
  • the solution is maintained at that temperature, with stirring, for one day.
  • the solution is then cooled to room temperature and filtered.
  • the filtrate is then precipitated in cold hexane, the resulting precipitate is then removed by filtration, and dried in a vacuum to yield the desired product, generally a mixture of PEG-bis-glutarate and ⁇ -hydroxy- ⁇ -glutarate-PEG.
  • the two can be separated chromatographically (see the Examples).
  • the glutarate group can be further reacted to add a nitrogen-containing heterocycle, such as a succinimidyl group by reacting the.
  • a nitrogen-containing heterocycle such as a succinimidyl group
  • the N-hydroxy-succinimide is added and the solution cooled to 0° C.
  • the dicyclohexylcarbodiimide (DCC) is added dropwise and the solution stirred for one day and filtered.
  • the filtrate is precipitated by adding cold hexane.
  • the resulting precipitate is filtered and dried in a vacuum.
  • This yields the desired product generally a mixture of PEG-bis-N-succinimidylglutarate and ⁇ -glutarate- ⁇ -succinimidylglutarate-PEG (or ⁇ -hydroxy- ⁇ -succinimidylglutarate-PEG, depending upon the starting material chosen).
  • the two can be separated chromatographically (see the Examples).
  • the ⁇ -hydroxy- ⁇ -succinimidylglutarate can be further reacted to yield ⁇ -acrylate- ⁇ -succinimidylglutarates by reacting the ⁇ -hydroxy- ⁇ -succinimidylglutarate with acrylic acid in the presence of TEA.
  • the PEG molecules may also be modified to introduce other amide bonds into the molecule.
  • the formation of an amide bond is, of course, extremely useful in modifying the PEG molecule to contain an amino acid, peptide, or protein terminus.
  • ⁇ -succinimidylglutarate- ⁇ -tryptophanylglutarate PEG can be synthesized by dissolving the peptide or amino acid in 0.1 M 2-(N-morpholino)-ethanesulfonic acid (MES) at 0° C.
  • MES 2-(N-morpholino)-ethanesulfonic acid
  • ⁇ , ⁇ -Bis-N-succinimidylglutarate-PEG is added dropwise to the solution with constant stirring. The reaction is allowed to continue at 0° C.
  • reaction solution is then dialyzed against 50 volumes of deionized water and the resulting solution lyophilized. This yields the desired ⁇ -N-succinimidylglutarate- ⁇ -tryptophanylglutarate in rougly 40% yield.
  • the modified PEGs can be attached to a polymer matrix containing amino-reactive groups using the same procedure as in the previous paragraph, thereby grafting the modified PEG to the amino-reactive groups of the polymer matrix. See also the Examples.
  • the mono- or dialdehyde-PEG is first dissolved in water.
  • a separate aqueous solution of NaCNBH 3 is also prepared.
  • the two solutions are then added simultaneously to a dilute (5%) solution of gelatin in water.
  • the reaction is allowed to proceed overnight with gentle heating (50 to 60° C.).
  • the modified gelatin is then separated by filtration.
  • ⁇ -Methoxy, ⁇ -hydroxy-PEG is commercially available (Shearwater).
  • a polymer matrix preferably gelatin
  • the PEG molecule may be bis-modified, using the same type of moiety.
  • the ⁇ -terminus of the PEG may have a different moiety than the ⁇ -terminus.
  • IPNs Interpenetrating Network Hydrogels
  • the above described PEG-modified hydrogels can also be used as a first polymer matrix in an interpenetrating network of two distinct polymer matrices.
  • the PEG-modified hydrogels as described above are admixed with a polymerizable mixture of monomers. A polymerization reaction is then initiated, whereby the mixture of monomers polymerizes in situ, thereby forming a second polymer matrix that interpenetrates with the first polymer matrix.
  • the plurality of monomers that forms the second polymer matrix is polymerizable by a means other than chemical initiation.
  • Chemically polymerizable monomers are, however, within the scope of the invention.
  • the monomers are photopolymerizable.
  • the monomers are admixed with the first polymer matrix.
  • the mixture is then exposed to a suitable wavelength of radiation (e.g., infrared, visible, or ultraviolet) that will result in a photo-initiated polymerization reaction.
  • the source for the radiation can be any source that generates radiation of the required wavelength, such as lamps (incandescent, fluorescent, ion discharge, etc.), lasers (CO 2 , Ne—Ne, etc.), and light-emitting diodes.
  • the preferred photopolymerizable monomers are acrylates, diacrylates, and poly(acrylates) (including PEG-acrylates, PEG-diacrylates, and TMPTA), acrylic acid, and acryloyl halides, such as acryloyl chloride, and mixtures thereof.
  • the polymerization reaction will, of course, result in the second polymer matrix being a co-polymer.
  • the second polymer matrix may comprise a homo-polymer matrix or a co-polymer matrix of any description (e.g., alternating, block, or graft co-polymers).
  • FIG. 6 is a schematic representation of interpenetrating network hydrogels according to the present invention.
  • the gels can contain living cells or pharmcalogically-active agents, or both.
  • M-PEG ⁇ -methyl- ⁇ -acrylate PEGs
  • monomethoxy PEGs (2 kDa or 5 kDa, purchased from Fluka, a division of Sigma-Aldrich) were dissolved in dry tetrahydrofuran (THF) solution followed by the addition of triethylamine (TEA, 2 eq.) and acryloyl chloride (AC, 4 eq.) (14) at room temperature under Ar for 10 min, filtered, dried by rotary evaporation, re-dissolved in CH 2 Cl 2 , and precipitated in cold hexane. The final product was filtered, dried, and stored in vacuo at room temperature.
  • THF dry tetrahydrofuran
  • AC acryloyl chloride
  • PEG-diols (2 kDa or 5 kDa) (1 eq.) were dissolved in dry CH 2 Cl 2 solution followed by the addition of TEA (4 eq.) and p-toluenesulfonyl chloride (2 eq.) (19) and stirred under Ar for 8 hr at room temperature. Solvent was removed by rotary evaporation to obtain yellowish white solids.
  • the solid product (mainly ⁇ -tosyl- ⁇ -acrylate-PEG) was filtered, dried in vacuo, dissolved (1 eq.) in CH 2 Cl 2 , followed by the addition of potassium phthalimide (3 eq.) (20) and refluxed for 18 hr.
  • the solution was filtered, dried via rotary evaporation to remove solvents, re-dissolved into CH 2 Cl 2 , precipitated in cold hexane, filtered, dried, and stored in vacuo at room temperature.
  • heterobifunctional PEGs were employed as a component in the formation of hydrogels to investigate the influence of hPEG concentration, molecular weight, and terminal moiety on the surface hydrophilicity and cell interaction.
  • the hPEGs were utilized in the hydrogel formulation following procedures described hereinabove. See also references (10-13).
  • the network thus formed is a random copolymer of Ac, TMPTA, and hPEG, with, for example, an acrylate ⁇ -terminal and an ⁇ -terminal of a different chemical moiety (XPEGmA).
  • XPEGmAs were grafted to a gelatin polymer matrix with various dangling terminal functional groups and incorporated throughout the polymer matrix by copolymerizing the acrylate terminal into a randomly polymerized network of Ac and TMPTA.
  • This type of polymer network containing M-PEG is nonionic, low swelling, glassy when dry, optically transparent, and colorless.
  • 10-13) In spite of the relatively high mass fraction of M-PEGs present, minimal swelling was observed for the polymer due to the highly cross-linked and hydrophobic nature of the TMPTA network. Differential scanning calorimetry analysis showed that these materials are completely amorphous and the M-PEG component is completely phase-mixed in the cross-linked TMPTA matrix. (10)
  • the surface hydrophilicity of XPEGmA-co-Ac-co-TMPTA networks was quantified with an underwater air bubble captive system.
  • the hydrogel was completely suspended in water that was maintained at a physiologically-relevant temperature of 37.5° C.
  • the gels so formed were then evaluated for their interaction with cultured cells.
  • Human neonatal dermal fibroblasts at a concentration of 75,000 per 1 ml of Fibroblast Basal Medium with human fibroblast growth factor-b (0.5 mg/ml), insulin (0.5 mg/ml), and 5% fetal bovine serum (Clonetics, San Diego, Calif.) were incubated with the XPEGmA-co-Ac-co-TMPTA network.
  • adherent cell morphology and density were manually quantified using a computer-assisted video analysis system coupled to an inverted light microscope.
  • PT-PEG showed an approximate 65% conversion with about 5% of the final product containing another acrylate side-product (e.g., ⁇ -tosyl- ⁇ -acrylate-PEG).
  • COOH-PEG showed an approximate 60% conversion with an additional 10% of other acrylated side-products (e.g., ⁇ -hydroxyl- ⁇ -acrylate-PEG and bis-acrylate-PEG).
  • heterobifunctional intermediates and final products of XPEGmA are stable under storage in vacuo at room temperature and can be modified further by a broad range of chemical methods for various applications.
  • the phthalimide group is a good protecting group that can be hydrolyzed to form primary amines.
  • a previously developed polymer network formulation was adopted to elucidate the effect of the PEG chemistry on the surface characteristics of the resulting hydrogels.
  • Polymer networks containing various XPEGmAs at several concentrations and different molecular weights were transparent or translucent.
  • the network surface hydrophilicity was quantified using an under water contact angle system and was found to be dependent of three factors: the molecular weight of the starting material PEG, the dangling terminal functional group, and the concentration of the XPEGmA in the network (see Table 3 and FIGS. 3A and 3B ).
  • the different terminal moiety of XPEGmA showed a variable effect on the surface hydrophilicity when compared with that of M-PEG of given molecular weight and concentration.
  • the XPEGmA concentration in the network formulation showed various correlations with hydrophilicity. Because XPEGmA was employed in the network formation without further purification, the potential effect of differential percent conversion of acrylated hPEG on surface hydrophilicity must be addressed. M-PEG showed a 100% conversion and the network containing M-PEG demonstrated no changes in surface hydrophilicity with increasing M-PEG concentration. Whereas for other XPEGmAs, various correlations among hydrophilicity and the type, percent conversion (ca. 60 to 100%), and concentration were observed. Hence, it was concluded that the percent conversion of XPEGmA within 60 to 100% did not affect the dependency of XPEGmA concentrations on hydrophilicity. These analyses determined that the network surface hydrophilicity was predominately influenced by the XPEGmA concentration in the network formulation with the molecular weight and the terminal moiety playing lesser roles.
  • XPEGmA-co-Ac-co-TMPTA networks containing various XPEGmAs at several concentrations were employed to determine the effect of surface characteristics of the gel on human fibroblast adhesion. All adherent cells showed extensive pseudopodial extension and cytoplasmic spreading, with some cells exhibiting polar cell body morphology. The results (see Table 4) showed that adherent cell density was primarily dependent on the XPEGmA concentration in the network formulation. Specifically, adherent cell density decreased with increasing XPEGmA concentration at all culture time. No adherent cell was observed on networks containing XPEGmA concentration between 1.25 to 2.5 g/ml at all culture times.
  • the results of this Example show that the presence of two distinct chemical moieties (i.e., carboxylic acids of the poly-acrylic acid backbone and the distinct functional group at the dangling terminus of XPEGmA grafted at the pendent chain configuration) within the hydrogels can be employed to bind (covalently) two or more distinct types of biofunctional molecules such as peptides and pharmaceutics by employing distinct chemical methodologies.
  • the high content of PEGs in this system reduced protein adsorption and effectively eliminated nonspecific cell adhesion that would occur as a result, thus permitting the modulating of cellular function mediated uniquely by the multiple immobilized biofunctional agent (10-13).
  • the invention thus provides multi-functional hydrogels that can be used, for example, to study complex biological systems and to deliver therapeutic agents locally and systemically.
  • This Example explores the swelling and drug release kinetics of various gelatin-based hydrogels.
  • the hydrogels were cross-linked by various means, and contained various modifications of the gelatin backbone.
  • the effect of pH on the drug release kinetics of these gels was also investigated.
  • cross-linking gelatin produces a hydrogel of high molecular weight and reduces or prevents gelatin dissolution.
  • the cross-linking agents used in this Example were: 0.1%, 0.01%, and 0.001% (v/v) glutaraldehyde aqueous solutions, and self-cross-linking via liquid nitrogen immersion followed by baking.
  • the backbone modifications to the gelatin were the addition of polyethylene glycol (PEG) or ethylenediaminetetraacetic dianhydride (EDTAD) or both.
  • PEG polyethylene glycol
  • EDTAD ethylenediaminetetraacetic dianhydride
  • PEG diol Aldrich, M n 2 kD
  • PEG dialdehyde PEGdial
  • the composition of PEG dialdehyde was confirmed using the reverse-phase HPLC system and parameters as described in Example 1. This reaction produces a mixed product of PEG monoaldehyde and PEG dialdehyde.
  • PEG dialdehyde had an elution time of approximately 11.5 min. and was approximately 80 wt % of the final product.
  • the lysyl amino groups of gelatin samples (Sigma, St. Louis, Mo.; Type A, from porcine skin, 300 bloom, cell culture tested) were modified by PEGdial to form PEG-modified gelatin (PG).
  • Gelatin samples were also modified using EDTAD (Aldrich) to form EDTAD-modified gelatin (EG).
  • Still further gelatin samples were modified with PEGdial and EDTAD to yield PEG-modified-EDTAD-modified gelatin (P/EG).
  • PG or P/EG was created by adding PEGdial dissolved in 10 ml of H 2 O (Milli-Q synthesis, 18.2 M ⁇ -cm, Millipore) and NaCNBH 3 dissolved in 10 ml of H 2 O separately and simultaneously to a 5% (w.v) gelatin or EG solution at 50 to 60° C. for 24 hours in a wt ratio of gelatin/EG: PEGdial: NaCNBH 3 of (1:0.66:0.186).
  • the theoretical maximum percent modification using this method is 100% modification of gelatin lysyl residues, based on an average 300 bloom gelatin molecular weight and average lysine content of the gelatin. See, e.g., Merck Index, 12 th Ed.
  • hydrogels 10% (w/v in H 2 O) solutions of gelatin (G), 10% PG, 40% EG and 60% P/EG were heated to approximately 70° C. and poured into petri dishes (60 ⁇ 15 mm, Cole-Parmer) to a thickness of 6 mm and allowed to set at room temperature overnight. Hydrogels were cut into 1 cm diameter circular discs or into 0.5 ⁇ 0.5 cm squares, and cross-linked with 0.1, 0.01 or 0.001% (v/v in H 2 O) gluteraldehyde ( Electron Microscopy Sciences, EM grade, 10% (v/v) aqueous solution) for 6 hours with gentle shaking. Cross-linked hydrogels were washed with H 2 O ten times for 3-5 min.
  • Washed hydrogels were left overnight in H 2 O for continued leaching of the gluteraldehyde. Hydrogels were then dried at room temperature in ambient air for 48 hours and weighed. Separately, hydrogels of 10% by wt gelatin were dried in ambient air for 48 hours, frozen in liquid nitrogen for 30 seconds to 1 minute and then baked at 130-135° C. for 8.5 hours (self-cross linked; LN 2 -baked G). Not all hydrogel formulations withstood the cross-linking, washing and drying steps, mainly due to hydrolysis.
  • the hydrogel formulations that were included in the swelling/degradation and in vitro drug release studies were the 0.1% glutaraldehyde cross-linked G, PG, EG, and P/EG gels; the 0.01% glutaraldehyde cross-linked G, PG, and EG gels; the 0.001% glutaraldehyde cross-linked G and PG gels; and the self-cross linked LN 2 -baked G. Swelling study results for P/EG hydrogels and in vitro and in vivo drug release studies are ongoing and results are not included here.
  • each hydrogel was loaded with chlorhexidine digluconate (CHD; Sigma, 20% (w/v) aqueous solution) using the same drug loading density used for dexamethasone in the in vivo studies (150 ⁇ g/kg/day, dosage of 21 d). Assuming a rat weight of 0.2 kg, this loading density is equivalent to 630 ⁇ g/hydrogel. Based on the maximum swelling weight ratios from the swelling studies, each hydrogel was loaded with 35 ⁇ L of CHD (18 mg/ml), a volume well below the maximum volume the hydrogel could absorb. Hydrogels (0.5 ⁇ 0.5 ⁇ 0.6 cm) were placed into individual wells in a 48-well tissue culture plate. CHD was added to each well, and the hydrogels were allowed to absorb the drug solution overnight (approximately 15 hours) with gentle shaking.
  • CHD chlorhexidine digluconate
  • hydrogels were placed in 5 ml of aqueous solutions of pH 4.5, pH 7.0 or pH 7.4 in a water bath at 37° C. Aqueous solutions were created by adjusting the pH of H 2 O with dilute HCl and NaOH. Hydrogels were transferred to fresh aqueous solutions at approximately 3 and 6 wks. Swollen hydrogels were weighed at 2, 4, and 6 hours, 1, 2, 3, 4, and 5 days, and 1, 2, 3, 4, 5, 6, 7, and 8 weeks to characterize the swelling/degradation kinetics. Extreme care was taken to preserve the integrity of the hydrogels at every step in the weighing process.
  • the swelling weight ratio at each time point for each hydrogel was calculated as: (W s ⁇ W d )/W d , where W s is the weight of the swollen gel and W d is the weight of the dry gel (in grams).
  • the maximum swelling weight ratio that occurred over 8 weeks and the time it occurred was also calculated (R max & T max respectively).
  • the last attainable swelling weight ratio (due to hydrogel dissolution) and the time it occurred was also calculated (R fail & T fail respectively).
  • Statistical analysis was performed using ANOVA and Tukey multiple comparisons tests (p ⁇ 0.05).
  • the inflammatory exudates that collected in the cages were withdrawn and analyzed for the quantitative evaluation of cellular and humoral response to implantation using standard hematology techniques.
  • the distributions of lymphocyte, monocyte, and polymorphonuclear leukocyte (PMN) subpopulations in the exudates were determined.
  • the implanted materials were retrieved for analysis of changes in the sample physiochemical composition (e.g., percent mass loss).
  • Percent modification of the lysyl residues in gelatin by PEG and/or EDTAD was quantified using the TNBS method: The PG was found to be 10% modified, the EG 40% modified, and the P/EG 60% modified. All results reported here incorporate materials from the same batch of modified gelatin (i.e. 8% PG, 42% EG).
  • the host inflammatory reaction is a normal response to injury and the presence of foreign objects.
  • the magnitude and duration of the inflammatory process have a direct impact on biomaterial biostability and biocompatability.
  • this Example investigates the performance of gels fabricated according to the present invention that include fibronectin-derived biomimetic oligopeptides.
  • Fibronectin in known to adsorb on a variety of biomaterials and play an important role in the host-foreign body reaction.
  • the RGD (SEQ. ID. NO: 1) and PHSRN (SEQ. ID. NO: 2) amino acid sequences are particularly interesting because these sequences are present on adjacent loops of two connecting FIII modules and bind synergistically to a host of integrins.
  • Oligopeptides were designed based on the primary and tertiary structure of human plasma fibronectin to study the structure-functional relationship of RGD and PHSRN regions of fibronectin in regulating the host inflammatory response and macrophage behavior in vivo.
  • Peptides included RGD and PHSRN sequences alone or in combination.
  • the tertiary structure of fibronectin was utilized as a guide in the formulation of peptides.
  • the distance between the PHSRN sequence and the RGD sequence within the natural fibronectin molecule in solution was approximated using the structural coordinates archived in the SwissProt Database® (sequence FINC_HUMAN P02751).
  • a hexamer of glycine (G 6 ) of approximately the same length was used to link the two bioactive sequences in both possible orientations.
  • a terminal trimeric glycine domain (G 3 ) was employed as a spacer in all peptides.
  • Oligopeptides were synthesized using solid-resin methods on an automated peptide synthesizer (Millipore) using conventional 9-fluorenylmethyloxycarbonyl chemistry without further purification and with a final coupling efficiency of approximately ⁇ 85% purity.
  • Peptides were characterized and analyzed using mass spectroscopy and reverse phase HPLC coupled to photodiode array, evaporative light scatter, and UV/Vis detectors.
  • G 3 RGDG SEQ. ID. NO: 3
  • G 3 PHSRNG SEQ. ID. NO: 4
  • G 3 RGDG 6 PHSRNG SEQ. ID. NO: 5
  • G 3 PHSRNG 6 RGDG SEQ. ID. NO: 6
  • G 3 RDGG SEQ. ID. NO: 7
  • the gels used in this Example were random co-polymers of monomethoxy polyethyeneglycol monoacrylate (mPEGmA), acrylic acid (Ac), trimethylolpropane triacrylate (TMPTA). As noted above, these gels are hydrophilic, nonionic, low swelling, glassy, optically transparent, and colorless. Differential scanning calorimetry analysis showed that these materials are completely amorphous and the mPEGmA component is completely phase-mixed in the cross-linked TMPTA matrix. The bioactive oligopeptides were grafted onto mPEGmA-co-Ac-co-TMPTA hydrogels and the resulting gels mediated cell adhesion in a receptor-peptide specific manner.
  • mPEGmA monomethoxy polyethyeneglycol monoacrylate
  • Ac acrylic acid
  • TMPTA trimethylolpropane triacrylate
  • the peptide surface density was found to be dependent on the number of amino acids per peptide. For example pentapeptides were grafted at 66 ⁇ 6 pmol/cm 2 surface density; whereas, peptides containing 30 residues were grafted at approximately one-fifth of that surface density.
  • oligopeptides containing one bioreactive region i.e., G 3 RGDG, G3PHSRNG, and G 3 RDGG
  • mPEGmA-co-Ac-co-TMPTA networks grafted with or without fibronectin-derived peptides were placed in sterile water for at least 48 hours to remove low molecular weight leachable residual molecules from the polymerization process and to achieve hydration equilibrium.
  • the polymer samples were then inserted under sterile conditions into an autoclaved cylindrical cage measured 3.5 cm long, 1 cm in diameter, and constructed from medical grade stainless steel wire mesh. Cages containing various polymer samples were subcutaneously implanted at the back of 3-month old female Sprague-Dawley rats.
  • the inflammatory exudate that collects in the cage was withdrawn at 4, 7, 10, 14, and 21 days post-implantation and analyzed for the quantitative evaluation of cellular and humoral response to the test material using standard and conventional hematology techniques. Specifically, the distribution of lymphocyte, monocyte, and PMN subpopulations in the exudate was determined. The presence of a high concentration of PMNs in the inflammatory exudate indicates an acute inflammatory response, which occurs from the onset of implantation and attenuates with time. This is followed by the chronic inflammatory response, which is characterized by the presence of a high concentration of monocytes and lymphocytes in the exudate.
  • the cage implant system allows the host inflammatory reaction to the test sample to be observed as a function of time and material property.
  • a drop of each exudate sample was also cultured on brain-heart infusion agar plates to check for incidence of infection. No infection was observed at any retrieval time for any sample.
  • test polymer samples were retrieved and the adherent cell morphology and density were quantified using a video analysis system coupled to a light microscope.
  • N x p ax-3 (1 ⁇ p)
  • p the probability of cell fusion or the ratio of the number of cell fusion to the initial adherent macrophage density
  • a is a constant relating to the number of nuclei per FBGC to the cell area (FBGC/mm 2 ) and has been found to be constant for various clinically relevant biomaterials under different mechanical stress conditions. See Kao et al. (1994) J. Biomed. Mater. Res. 28:73-79; Kao et al. (1995) J.
  • d 0 is the calculated density of adherent macrophages that participate in the FBGC formation process (macrophages/mm 2 ), d f the measured adherent macrophage density at 4 days post-implantation (macrophages 1 mm ⁇ 2 ), t the implantation time (week), and k the inverse rate constant of cell fusion (mm 2 cell ⁇ week ⁇ 1 ).
  • mPEGmA-co-Ac-co-TMPTA gels within the cage showed a constant total leukocyte concentration from 4 to 21 days of implantation.
  • the presence of the gels increased monocyte concentration and lowered lymphocyte concentration at days 4 and 7 when compared with that of empty cage controls, suggesting a comparable level of chronic inflammatory response that turned toward resolution but with an altered leukocyte sob-population distribution.
  • Adherent macrophage density on implanted mPEGmA-co-AC-co-TMPTA networks grafted with or without fibronectin-derived oligopeptides was quantified at different retrieval times. In general, adherent macrophages on all surfaces decreased with increasing implantation time (see Table 8). Adherent macrophage densities for all samples were comparable and were higher than respective values of G 3 RDGG or “no grafted peptide” controls at each retrieval time up to 14 days post-implantation. Adherent macrophage density on all samples was comparable from 21 to 70 days post-implantation. Adherent macrophages on all surfaces showed an extensive spread morphology with pseudopodial extension. These results indicate that peptides containing RGD and/or PHSRN motifs do not affect adherent macrophage density.
  • FBGC density increased with increasing implantation time for all samples except that on surfaces grafted with G 3 RGDG or G 3 PHSRNG 6 RGDG at which the adherent FBGC density remained constant with increasing implantation time (data not shown).
  • the average FBGC size increased with increasing implantation time for all samples (data not shown).
  • the calculaitons also showed that the density of adherent macrophages that participate in the FBGC formation was significantly higher for mPEGmA-co-Ac-co-TMPTA gels grafted with G 3 PHSRNG, and G 3 PHSRNG 6 RGDG than that for gels grafted with G 3 RDGG nonspecific controls and gels without peptide grafting.
  • b Represents p ⁇ 0.05 vs. respective values of “empty cage” controls.
  • c Represents p ⁇ 0.05 vs. respective values of “no grafted peptide” controls.
  • d Represents p ⁇ 0.05 vs. respective values at day 4 of the same sample type.
  • Adherent macrophage density on cage-implanted mPEGmA-co-AC-co-TMPTA networks grafted with various fibronectin-derived oligopeptides a Adherent macrophage density ( ⁇ 10 macrophages/mm 2 ) at various post-implantation time (days) Peptide 4 7 14 21 35 70 G 3 RGDG 138 ⁇ 22 b 85 ⁇ 12 b,c 33 ⁇ 12 b,c 15 ⁇ 3 c 14 ⁇ 2 c 4 ⁇ 2 c G 3 PHSRNG 124 ⁇ 12 b 57 ⁇ 10 b,c 31 ⁇ 11 b,c 10 ⁇ 0 c 9 ⁇ 1 c 4 ⁇ 2 c G 3 EGDG 6 PHSRNG 126 ⁇ 8 b 58 ⁇ 12 b,c 23 ⁇ 4 b,c 14 ⁇ 4 c 6 ⁇ 5 c 0 ⁇ 0 c G 3 PHSRNG 6 RGDG 183 ⁇ 27
  • Interpenetrating networks are hydrogels synthesized by reacting a first polymer around a second material to form an intermeshing structure.
  • IPNs are free of cross-linkers used to create other biomedical hydrogels.
  • photopolymerization has the advantages that the desired amount of drug can be easily loaded into the matrix, and the cross-linking density, which can affect the drug release rate, can be controlled.
  • IPNs can be formed in situ and used in places less suitable for prefabricated materials.
  • the focus of this Example was to investigate the swelling and drug release kinetics of gelatin-based IPNs of varying gelating backbone modification, weight percent of gelatin, pH, and the molecular weight of polyethylene glycol diacrylate (PEGdA). Based on our results, these IPNs are quite suitable for tissue scaffolds and drug release vehicles.
  • PEGdA polyethylene glycol diacrylate
  • PEG Polyethyleneglycol
  • Aldrich 2, 4.6, and 8 kDa
  • acrylolyl chloride Aldrich
  • TEA Aldrich
  • the final PEGdA product purity was checked with the same reverse phase HPLC system as used in Example 1.
  • the elution time of the PEGdA was approximately 13.2 minutes with a purity of approximately 100 wt % PEGdA.
  • mPEG Monomethoxypolyethyleneglycol
  • Aldrich acetic anhydride
  • DMSO DMSO
  • the reaction takes 8 to 24 hours and was monitored periodically with HPLC.
  • the mPmA had an elution time of approximately 11.9 minutes and a purity close to 75 wt % mPmA.
  • the compositions of PEGdA and mPEGmonoaldehyde were also confirmed with 1 H-NMR.
  • mPmA sodium cyanoborohydride
  • the percent of the gelatin lysyl residues modified by EDTAD and/or mPmA was determined using the trinitrobenzene sulfonic acid spectrophotometric method.
  • the IPNs used in this study were prepared from the same modified gelatins.
  • IPNs were created using modified and unmodified gelatin, PEGdA (2, 4.6, or 8 kDa molecular weight), initiator (2,2-dimethoxy-2-phenylacetophenone, DMPA), and a long wavelength UV source.
  • Gelatin was dissolved in deionized water with heat (80° C.) to form a 20 wt % gelatin solution.
  • PEGdA was dissolved in deionized water, without heat, in an aluminum foil wrapped glass vial to form a 100 wt % PEGdA solution. The gelatin solution was then added to the PEGdA solution and the mixture was agitated thoroughly.
  • DMPA was then added to the gelatin/PEGdA mixture and this final mixture was again agitated and then heated (80° C.) throughout the rest of the procedure.
  • IPNs were created through injection molding.
  • the final gelatin/PEGdA/DMPA mixture was injected with a Pasteur pipette into a Teflon mold that was clamped between 2 glass slides.
  • the mold has the approximate dimensions of 20 mm long by 10 mm wide by 1.6 mm thick.
  • the mold/IPN mixture was then irradiated with UV light from the top and bottom for approximately 3 minutes. During this time, the UV light initiates the cross-linking of PEGdA, entrapping the gelatin within the PEGdA cross-links.
  • the mold/IPN was allowed to cool before the IPN was removed from the mold.
  • IPNs were named based on the weight percent of gelatin, the type of gelatin, the weight percent of PEGdA, and the molecular weight of the PEGdA used to synthesize the IPN.
  • 4G6P2k indicates 40 wt % gelatin, 60 wt % PEGdA, 2 kDa PEGdA.
  • the following key describes the code used to identify IPN formulations.
  • Each formulation is identified by a code of the formula “XYZk”, where X is the wt % gelatin, Y is the type of gelatin, Z is the wt % PEGdA, and k is the molecular weight of the PEGdA:
  • the swelling/degradation kinetics of the IPNs were characterized by weighing swollen IPNs at predetermined times (up to 8 weeks).
  • the IPNs were added to test tubes containing 5 ml deionized water with environmental pHs of 4.5, 7.0, and 7.4.
  • the test tubes were then placed in water baths at 37° C.
  • the samples were removed with extreme caution from the test tubes using a bent spatula, blotted dry, weighed, and then placed back in the same test tube. This was done until the sample had degraded completely or until the sample had degraded into too many pieces and they could no longer be removed from the test tube.
  • the swelling weight ratio at each time point for each IPN was calculated as: (W a ⁇ W o /W o ), where W s is the weight of the swollen IPN and W o is the original weight of the IPN.
  • the maximum swelling weight ratio that occurred over 8 weeks and the time it occurred was calculated (R max , T max ).
  • the last attainable swelling weight ratio (due to IPN degradation) and the time it occurred was also calculated (R fail , T fail ).
  • the level of host biocompatibility and inflammatory reaction of the IPNs was determined via the in vivo subcutaneous cage implant system described in the previous Examples. IPNs were placed inside cylindrical (1 cm diameter by 3.5 cm long) medical grade stainless steel wire mesh cages. These cages along with empty cages, controls, were implanted subcutaneously at the back of 3-month old female Sprague-Dawley rats. Inflammatory exudates that collected in the cages were withdrawn at 4, 7, 14, and 21 days post-implantation and analyzed for the quantitative evaluation of cellular and humoral response to the IPN samples using standard hematology techniques. Using these techniques the distributions of polymorphonuclear leukocyte (PMN), lymphocyte, and monocyte subpopulations in the exudates were determined. In addition to the host response, the degradation of the IPNs was determined as percent weight lost ((final IPN weight/initial IPN weight) ⁇ 100).
  • PMN polymorphonuclear leukocyte
  • lymphocyte lymphocyte
  • the IPNs fabricated as described hereinabove were opaque, flexible, rubbery, and slightly tacky.
  • the opacity increased with decreasing gelatin concentration and with increasing PEGdA molecular weight.
  • Increasing the gelatin concentration increased the flexibility and the tackiness of the IPN.
  • the flexibility of the IPNs also seemed to increase with increasing PEGdA molecular weight.
  • the mechanical properties of the IPNs were tested using ASTM testing standards.
  • the IPNs for mechanical testing were made in a similar fashion as stated above, however the molds used were made of polydimethylsiloxane and the IPN final dimensions were 280 mm thick, 11 mm gauge length, and 2 mm neck width (the dimensions required for ASTM D38-98 type IV specimens).
  • the IPNs were subjected to tensile testing per ASTM D638-98 standards, using an Instron Model 5548 testing machine.
  • T fail The time to reach R fail (T fail ) was not affected by increasing the molecular weight of PEGdA or by modifying the gelatin.
  • IPNs 40 wt % gelatin, 60 wt % PEGdA 2 kDa (4G6P2K) IPNs were used in a preliminary in vivo study.
  • Acute inflammation is followed by a high concentration of monocytes and lymphocytes in the exudates, chronic inflammation.
  • the study showed that there was a statistically higher inflammatory response to the IPNs after 4, 7, and 14 days of implantation compared to the empty cage controls.
  • the study also revealed that almost 70% of the sample mass was lost after 4 days, and decreased another 10% after 21 days.
  • the Example illustrates that IPNs made according to the present invention can serve as tissue scaffolds and drug delivery vehicles.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Materials Engineering (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
  • Macromonomer-Based Addition Polymer (AREA)

Abstract

Disclosed are hydrogels wherein a polymer matrix is modified to contain a bifunctional poly(alkylene glycol) molecule covalently bonded to the polymer matrix. The hydrogels can be cross-linked using, for example, glutaraldehyde. The hydrogels may also be crosslinked via an interpenetrating network of a photopolymerizable acrylates. The hydrogels may also be modified to have pharmacologically-active agents covalently bonded to the poly(alkylene glycol) molecules or entrained within the hydrogel. Living cells may also be entrained within the hydrogels.

Description

    PRIORITY
  • Priority is hereby claimed to provisional application Ser. No. 60/285,782, filed 23 Apr. 2001, the entire contents of which is incorporated herein.
    • FEDERAL FUNDING
  • This invention was made with United States government support awarded by the following agencies: NIH HL63686. The United States has certain rights in this invention.
    • FIELD OF THE INVENTION
  • The invention is directed to hydrogels modified using bifunctional reagents, use of the hydrogels to deliver drugs or other biologically-active agents to a mammal in need thereof, compositions containing the hydrogels described herein, and devices, such as wound dressings, diapers, catamenial devices, etc., incorporating the hydrogels.
    • INCORPORATION BY REFERENCE
  • All of the reference listed in the “References” section are incorporated herein.
    • BACKGROUND
  • Biological systems, such as healing and embryonic development, operate under spatially- and temporally-controlled orchestration. A myriad of signals and cells all act, in space and time, to heal a cut, for example, or to surround and neutralize a foreign body. The efficacy of current materials used to construct biomedical devices is limited by a lack of multi-functional structures to complement the inherent dynamics of these biological systems.
  • For example, most wound dressings provide nothing more than a simple barrier to shield the wound and to prevent foreign objects from entering the would. Other newer types of dressings also include antibiotics to prevent sepsis at the wound site. However, these dressings do not address, for example, the exudation which occurs from a wound. Thus, these dressings must be changed often.
  • Certain biodegradable polymers have been used in burn dressings, hemostatic patches, and the like. These biodegradable polymers provide a barrier and possibly a tissue scaffold for regrowth. However, these types of dressing have no therapeutic effect. While such types of dressings provide effective barriers to physical disturbance of the wound site, scarring is still extensive.
  • Despite the extensive investigation of novel wound dressing materials, very few materials are in current clinical use. An ideal functional wound dressing should have the following properties: It should be non-toxic, biocompatible, and permeable to moisture and gases to absorb wound exudate and toxins as well to maintain appropriate humidity and oxygen levels. It should be porous to prevent swelling of the wound bed and accumulation of the fluid between the wound site and the material. It should be flexible and durable and minimize local inflammation and infection, thereby promoting new vascularization, re-epithelialization, and normal healing.
  • Hydrogels are three-dimensional networks capable of absorbing copious amounts of water. Hydrogels have been explored for many uses, including drug delivery devices, wound dressing materials, contact lenses, and cell transplantation matrices. Edible hydrogels, such as gelatin, find extensive use in various food-related applications, such as texture modification, gelling, clarification of beers and wines, and as medicine capsules.
    • SUMMARY OF THE INVENTION
  • The invention is directed to hydrogels comprising a polymer matrix, preferably gelatin or a synthetic polymer (preferably a biodegradable polymer, although the polymer may also be non-biodegradable), modified to contain bifunctional poly(alkylene glycols) covalently bonded to the polymer matrix. Heterobifunctional, poly-C1-C6-poly(alkylene glycol) molecules, preferably poly(ethylene glycol) molecules (hPEGs), each having an α-terminus and an ω-terminus, are bonded to the polymer backbone via covalent bonds involving either of the α- or ω-termini. One or more biofunctional agents (i.e., pharmacologically-active agents) are then bonded to the other of the α- or ω-termini (i.e., the free termini) of the hPEGs, thereby yielding a modified, pharmacologically active, homogenous, and covalently-assembled hydrogel. A schematic representation of the preferred embodiment of the invention is shown in FIG. 4.
  • Any pharmacologically-active agent, without limitation, can be incorporated into the hydrogel, including (by way of illustration and not limitation) vulnerary agents, hemostatic agents, antibiotics, antithelmintics, anti-fungal agents, hormones, anti-inflammatory agents, proteins, polypeptides, oligonucleotides, cytokines, enzymes, etc.
  • The hydrogels of the present invention find many uses, the preferred of which is as a functional wound dressing. In this preferred embodiment, the hydrogel contains as a pharmacologically-active agent a vulnerary agent covalently bonded to a biodegradable polymer matrix via a differentially-modified, α- and ω-substituted PEG linker.
  • The hydrogels of the present invention may also be incorporated into bandages, surgical and dental wound packing material, diapers and catamenial devices, and the like.
  • The novel hydrogel constructs described herein are not physical blends, which are common in the formulation of current biomedical hydrogels; hence, the chemical and physical properties of the subject hydrogels are homogenous and can be tailored to suit a particular clinical end-point requirement. Furthermore, the hydrogel constructs are mechanically stable because the components are covalently bonded. In addition, the hydrophilicity and flexibility of the porous hydrogel accommodate the absorption of wound exudate and assist the final removal of the material from the wound site (if necessary or desired). The nature of gelatin and the porosity of the construct further facilitate the exchange of gases and allow healing. Most importantly, the presence of hPEG-conjugated bioactive compounds and the loading of other pharmaceutical compounds within the matrix allows for the temporally- and spatially-controlled delivery of bioactive signals to modulate and complement the dynamics of the host healing process.
  • The present invention offers several key commercial advantages over existing products. For example, despite the extensive investigation in the development of novel wound dressing materials, very few materials are used clinically due to the multiple requirements necessary for a functional wound dressing. Ideal functional wound dressings must be nontoxic, biocompatible, permeable to moisture and gases to absorb wound exudate and toxins, as well as to maintain humidity and oxygen levels. The dressings should be porous to prevent swelling of the wound bed and to prevent accumulation of fluid between the wound site and the material. They should be flexible and durable. They should be biocompatible and minimize local inflammation and infection. They should promote neovascularization, re-epithelialization, and normal healing. The novel multi-functional hydrogels described herein can be made to address all of the above requirements for a clinically viable wound dressing material.
  • Thus in a first embodiment, the invention is directed to a hydrogel that comprises a polymer matrix. The preferred polymer matrix contains reactive amino groups. The most preferred polymer matrices are gelatin and collagen. The polymer matrix is modified using a bifunctional modifier comprising a poly(alkylene glycol) molecule having a substituted or unsubstituted α-terminus and a substituted or unsubstituted ω-terminus. At least one of the α- or ω-termini is covalently bonded to the polymer matrix. The other terminus projects into the interior of the hydrogel mass and modifies its physico-chemical properties. By controlling the nature of the α- and ω-termini, the physical and chemical qualities of the resulting hydrogel can be altered.
  • Additionally, in the preferred embodiment, the α- and ω-termini are different, and thus are differentially reactive. This enables, for example, one or more pharmacologically-active agents to be covalently bonded to one of the α- or ω-termini that is not bonded to the polymer matrix. Alternatively (or simultaneously), one or more pharmacologically-active agents may also be entrained within the hydrogel.
  • The polymer matrix of the hydrogel may be cross-linked with a cross-linking reagent such as glutaraldehyde. Cross-linking alters the absorption characteristics and material strength of the resulting gel. Thus, cross-linking may be desirable where increased mechanical strength of the gel is required.
  • As noted above, the α- and/or ω-termini of the hydrogel may be substituted or unsubstituted. When substituted, it is preferred that the substitution is a moiety selected from the group consisting of halo, hydroxy, C1-C24-alkyl, C1-C24-alkenyl, C1-C24-alkynyl, C1-C24-alkoxy, C1-C24-heteroalkyl, C1-C24-heteroalkenyl, C1-C24-heteroalkynyl, cyano-C1-C24-alkyl, C3-C10-cycloalkyl, C3-C10-cycloalkenyl, C3-C10-cycloalkynyl, C3-C10-cycloheteroalkyl, C3-C10-cycloheteroalkenyl, C3-C10-cycloheteroalkynyl, acyl, acyl-C1-C24-alkyl, acyl-C1-C24-alkenyl, acyl-C1-C24-alkynyl, carboxy, C1-C24-alkylcarboxy, C1-C24-alkenylcarboxy, C1-C24-alkynylcarboxy, carboxy-C1-C24-alkyl, carboxy-C1-C24-alkenyl, carboxy-C1-C24-alkynyl, aryl, aryl-C1-C24-alkyl, aryl-C1-C24-alkenyl, aryl-C1-C24-alkynyl, heteroaryl, heteroaryl-C1-C24-alkyl, heteroaryl-C1-C24-alkenyl, heteroaryl-C1-C24-alkynyl, sulfonate, arylsulfonate, and heteroarylsulfonate.
  • Moreover, these moieties themselves may be further substituted. Thus, the moieties on the α-terminus and the ω-terminus when substituted bear a substituent selected from the group consisting of alkyl, aryl, acyl, halogen, hydroxy, amino, alkoxy, alkylamino, acylamino, thioamido, acyloxy, aryloxy, aryloxyalkyl, mercapto, thia, aza, oxo, saturated cyclic hydrocabon, unsaturated cyclic hydrocarbon, heterocycle, aryl, and heteroaryl.
  • More specifically, the invention is directed to a hydrogel comprising:
  • a polymer matrix containing reactive amino acid moieties; and
  • a bifunctional modifier comprising a compound of formula:
    Figure US20060100369A1-20060511-C00001
    wherein at least one of the “A” or “Z” moieties is covalently bonded to the reactive amino moieties of the polymer matrix; and wherein “A” and “Z” are independently selected from the group consisting of hydrogen, halo, hydroxy, C1-C24-alkyl, C1-C24-alkenyl, C1-C24-alkynyl, C1-C24-alkoxy, C1-C24-heteroalkyl, C1-C24-heteroalkenyl, C1-C24-heteroalkynyl, cyano-C1-C24-alkyl, C3-C10-cycloalkyl, C3-C10-cycloalkenyl, C3-C10-cycloalkynyl, C3-C10-cycloheteroalkyl, C3-C10-cycloheteroalkenyl, C3-C10-cycloheteroalkynyl, acyl, acyl-C1-C24-alkyl, acyl-C1-C24-alkenyl, acyl-C1-C24-alkynyl, carboxy, C1-C24-alkylcarboxy, C1-C24-alkenylcarboxy, C1-C24-alkynylcarboxy, carboxy-C1-C24-alkyl, carboxy-C1-C24-alkenyl, carboxy-C1-C24-alkynyl, aryl, aryl-C1-C24-alkyl, aryl-C1-C24-alkenyl, aryl-C1-C24-alkynyl, heteroaryl, heteroaryl-C1-C24-alkyl, heteroaryl-C1-C24-alkenyl, heteroaryl-C1-C24-alkynyl, sulfonate, arylsulfonate, and heteroarylsulfonate; “m” is an integer of from 2 to 8; and “n” is an integer equal to or greater than 100. In the preferred embodiment, “m” equals 2 and “n” is greater than 2,000.
  • A second embodiment of the invention is directed to a hydrogel as described above, with the further inclusion of a second polymer matrix. In this embodiment, the second polymer matrix interpenetrates with the first polymer matrix. Thus, the first polymer matrix, with its grafted modifier molecules, interpenetrates and is physically bound within a second, interpenetrating polymer matrix. In the preferred second embodiment, the second polymer matrix comprises a photopolymerized poly(acrylate), such as an α-acrylate-ω-acrylate-poly(alkylene glycol), trimethylolpropane triacrylate, acrylic acid, and/or acryloyl halide. The second polymer matrix may be a homo-polymer or co-polymer or two or more monomer types.
  • As in the first embodiment, the interpenetrating hydrogels may further comprise a pharmacologically-active agent covalently bonded to one of the α- or ω-termini that is not bonded to the first polymer matrix.
  • Likewise, all of the hydrogels according to the present invention may further comprise a pharmacologically-active agent or a living cell entrained within the hydrogel.
  • A third embodiment of the invention is directed to a method of making a hydrogel as described hereinabove. The method comprises reacting a polymer matrix with a bifunctional modifier comprising a poly(alkylene glycol) molecule having a substituted or unsubstituted α-terminus and a substituted or unsubstituted ω-terminus, whereby at least one of the α- or ω-termini is covalently bonded to the polymer matrix.
  • A fourth embodiment of the invention is directed to the method described in the previous paragraph, and further comprising contacting the first polymer matrix with a plurality of monomers and then polymerizing the monomers to yield a second polymer matrix, wherein the second polymer matrix interpenetrates with the first polymer matrix. This embodiment allows for the in situ formation of interpenetrating polymer networks
  • The hydrogels of the present invention can be used in any application where hydrogels are currently employed. Thus, the hydrogels of the present invention find use as wound dressings, diapers, catamenial devices, and the like. In one embodiment, the hydrogels are used to administer a pharmacologically-active agent to a patient in need of the pharmacologically-active agent. In this use, the pharmacologically-active agent either is covalently bonded within the gel or entrained within the gel. The gel is then administered to the patient, as by packing it into a surgical or traumatic wound.
  • The hydrogels of the present invention are also useful as scaffolds to support living cells. Thus, the hydrogels of the present invention can be used as biomechanical devices. The hydrogels will support living cells within the bulk of the gel, thereby providing a three-dimensional support network in which the cells can grow and proliferate. Hydrogels according to the present invention that contain cells can be implanted into a patient in need of such cells.
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1. A summary of the chemical reactions and structure of critical intermediates and final products of M-PEG, CN-PEG, COOH-PEG, or PT-PEG. (1) sodium/naphthalene, THF, room temperature; (2) ethyl bromoacetate, TEA, THF, room temperature; (3) sodium hydroxide solution, reflux; (4) AC, TEA, THF, 10 min room temperature; (5) sodium ethoxide (or sodium metal), CH2Cl2, room temperature; (6) acrylonitrile room temperature; (7) AC, TEA, THF, 10 min room temperature; (8) TEA, thionyl bromide, toluene, reflux; (9) p-toluenesulfonylchloride, TEA, CH2Cl2, room temperature; (10) AC, TEA, THF, 10 min room temperature; (11) potassium phthalimide, CH2Cl2, reflux; (12) AC, TEA, THF, 10 min room temperature
  • FIGS. 2A and 2B. HPLC chromatogram of (2A) evaporative light scattering detector signals and (2B) UV signals at 254 nm for PEGdiols and various XPEGmA. Samples were analyzed with a reverse phase HPLC system (10% to 100% acetonitrile at a flow rate of 1 ml/min in 30 min with Jordi 500 A column on a Gilson system) coupled to UV/Vis (200 nm and 254 nm), photodiode array, and evaporative light scattering detectors.
  • FIGS. 3A and 3B. Surface hydrophilicity of the XPEGmA-co-Ac-co-TMPTA network containing XPEGmA of various concentration, terminal moiety, and molecular weight. (3A) 2 KDa XPEGmA and (3B) 5 KDa XPEGmA. Legend: ♦=M-PEG; ▪=CN-PEG; ▴=COOH-PEG; and ●=PT-PEG.
  • FIG. 4. A schematic representation of hydrogels according to the present invention.
  • FIG. 5. Graph depicting representative swelling/degradation kinetics. Time in hours is shown on the X-axis; swelling ratio is shown on the Y-axis. Key: G, 0.01% glutaraldehyde cross-linked=♦; 10% PG, 0.01% glutaraldehyde cross-linked=▪; 40% EG, 0.01% glutaraldehyde cross-linked=▴.
  • FIG. 6. A schematic representation of an interpenetrating network hydrogel according to the present invention.
    • DETAILED DESCRIPTION OF THE INVENTION
  • Poly(alkylene glycols), such as poly(ethylene glycol) (PEG), are employed extensively in a number of medical and pharmaceutical fields due to their low toxicity, good biocompatibility, and excellent solubility(1-5). For sake of expository brevity, the following description shall be limited to gels modified by bifunctional poly(ethylene glycol) molecules. The invention, however, will function with equal success using any poly(alkylene glycol).
  • Thus, it is preferred that the bifunctional modifier comprise a poly(alkylene glycol) of the formula:
    Figure US20060100369A1-20060511-C00002
    where “m” is an integer of from 2 to 8; “n” is an integer equal to or greater than 100; and “A” and “Z” are as described above. In the preferred embodiment, “m” equals 2 and “n” is sufficiently large to yield a PEG molecule having a molecular weight of roughly 100,000 Da. Thus, it is preferred that “n” is greater than 2,000. The “n” substituent may also be sufficiently large to yield a PEG molecule having a molecular weight greater than 1×106 Da, in which case “n” is greater than roughly 20,000.
  • While having good biocompatibility and solubility, the hydroxyl groups in PEG-diols or monomethoxy-PEGs have very limited chemical activity. The present invention thus is drawn to novel hydrogels that use bifunctional PEGs and hetero-bifunctional PEGs (“hPEGs”) as covalent grafts to modify the physical and biological properties of hydrogels. These bifunctional PEGS having improved reactivity and physicochemical properties can thus be used to modify polymer matrices in general, and proteinaceous matrices in particular, to yield novel hydrogels. These novel hydrogels are useful in wide array of biomaterial and biopharmaceutical compositions and devices that include a hydrogel component, including time-release vehicles, wound dressings and packing, bandages, burn dressings, catamenial devices, diapers, etc.
  • Currently, the synthesis of hPEGs is classified into two general categories: 1) statistical terminal modification of PEG precursors; and 2) ethylene oxide polymerization methods using special initiators.(6-9) Although various hPEGs are currently available commercially (e.g., from Shearwater Corporation, Huntsville, Ala.), their high cost and limited quantity greatly restricts the extensive utilization of such materials by laboratories in developing novel biomaterials for various applications. In developing the present invention, a number of synthetic schemes were developed to produce a library of hPEG compounds based on the statistical terminal modification method.
  • A distinct benefit of the various reaction schemes is that they use as a starting material commercially-available PEG-diols. PEG-diol is available in a host of different molecular weights, and from a large number of international suppliers (including Shearwater Corporation).
  • Moreover, the synthetic strategy is streamlined so modifications to various intermediates results in the formulation of different hPEG products.
  • Using the hPEGs of the present invention, polymer networks having diverse physicochemical and surface properties were developed. These networks can be used to study cell-material interaction.(10-13)
  • In the Examples that follow, hPEGs were utilized to modify a polymer matrix to yield novel hydrogels. The effect of hPEG concentration, molecular weight, and terminal chemical functionality on the surface hydrophobicity and cell interaction with the hydrogels was investigated and is presented in the Examples.
  • Multiple heterogeneous PEG modifications (e.g., carboxylic acids of the poly-acrylic acid backbone and the functional group at the dangling terminus of hPEG grafted at the pendent chain configuration) can be employed to bind several distinct types of biofunctional molecules such as peptides and pharmaceutics to the hydrogel.
  • These components therefore are highly useful as functional wound dressings. In the preferred embodiment, the polymer matrix is a modified gelatin. The use of gelatin is not incidental. Gelatin is a well-characterized, FDA approved, biodegradable biomaterial. Thus, hydrogels made from modified gelatin are likely to pass regulatory muster due to the known safety of gelatin.
  • The hydrophilicity and porosity of gelatin was modified using ampholytic moieties such as ethylenediaminetetracetic dianhydride (EDTAD). The resulting polymer backbone can be cross-linked with small amounts of glutaraldehyde and subsequently loaded with pharmaceutical agents such as antibiotic drugs. The water-uptake, swelling, degradation, and drug release kinetics of the resulting hydrogel can be controlled by varying the amount of cross-linking and the extent of EDTAD modification.
  • To improve its biocompatibility and mechanical properties, the hydrogel was then grafted with various hPEGs, as described hereinbelow.
  • To investigate the functional properties of these novel biomaterials, the interaction of hPEGs, hPEG-modified gelatin hydrogels, and synthetic polymer networks containing human white blood cells and fibroblasts were examined, both in vitro and in vivo. The terminal group of the hPEGs has also been used to link bioactive peptides to the hydrogel matrix, thereby to control the interaction of host cells such as white blood cells and to enhance favorable biological interactions. It has been demonstrated in the Examples that the molecular interaction of several bioactive oligopeptides in modulating white blood cell behavior and host interaction in vitro and in vivo can thus be modified.
  • The resulting hydrogels can be used a functional wound dressings, bandages, and the like. These functional wound dressings are suitable for use both internally and externally. The gelatin-hPEG hydrogels of the present invention have been tested in a subcutaneous caged implant model.
  • One notable aspect of the hydrogels of the present invention is that the polymer constructs are not physical blends. The present hydrogels are chemically and physically homogenous and can be tailored to suit a particular clinical endpoint requirement. The hydrogel is mechanically stable because the components are covalently bonded together. Additionally, the hydrophilicity and flexibility of the porous hydrogel accommodates the absorption of wound exudate, blood, etc., and assists in the final removal of material from the wound site.
  • The nature of gelatin and the porosity of the construct also facilitates the exchange of gases and promotes rapid healing. Most importantly, the presence of hPEG-conjugated bioactive compounds within the hydrogel matrix itself adds qualitative value and control to the wound healing process.
  • As described hereinbelow, a synthetic scheme was developed to created a library of heterobifunctional PEGs (hPEGs) having two distinct terminal moieties. The hPEGs were then used to make modified polymer hydrogels having various surface and physicochemical properties. Extensive NMR and HPLC analyses confirmed the chemical structure of hPEG. The hydrophilicity of the polymer network was predominantly dependent on the hPEG concentration, with the molecular weight of the starting, unmodified PEG and the terminal functional groups also playing roles. Adherent human fibroblast density on the hydrogels remained constant with increasing hPEG concentration in the gel formulation but decreased rapidly on hydrogels containing 0.8 to 1.25 g/ml of hPEGs. This trend was independent of the hPEG terminal moiety and molecular weight. No adherent cells were observed on all sample gels containing 2.5 g/ml or more of hPEGs.
  • Abbreviations and Definitions:
  • “Ac”=acrylic acid
  • “AC”=acryloyl chloride (CAS No. 814-68-6)
  • “CHD”=chlorhexidine digluconate
  • “CN-PEG”=α-cyanoethyl-ω-acrylate-PEG
  • “COOH-PEG”=α-carboxyl-ω-acrylate-PEG
  • “EDTAD”=ethylene diaminetetracetic dianhydride
  • “hPEG”=heterobifunctional PEG
  • “IPN”=interpenetrating network hydrogels
  • “mPmA”=α-methyl-ω-aldehyde-PEG
  • “mPEG”=α-methoxy-PEG
  • “M-PEG”=α-methyl-ω-acrylate-PEG
  • “PEG” and “PEG diol”=polyethylene glycol
  • “PEGdA”=PEG-diacrylate
  • “PEG dial”=α-aldehyde-ω-aldehyde-PEG
  • “PT-PEG”=α-phthalimide-ω-acrylate-PEG
  • “TEA”=triethylamine
  • “THF”=tetrahydrofuran
  • “TMPTA”=trimethylolpropane triacrylate (i.e., 2-ethyl-2-(hydroxymethyl)-1,3-propanediol triacrylate, CAS No. 15625-89-5)
  • “XPEGmA”=hPEG with acrylate ω-terminal and α-terminal of different moiety
  • The term “alkyl,” by itself or as part of another substituent, means, unless otherwise stated, a fully saturated, straight, branched chain, or cyclic hydrocarbon radical, or combination thereof, and can include di- and multi-valent radicals, having the number of carbon atoms designated (e.g., C1-C10 means from one to ten carbon atoms, inclusive). Examples of alkyl groups include, without limitation, methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl, cyclohexyl, (cyclohexyl)ethyl, cyclopropylmethyl, and homologs and isomers thereof, for example, n-pentyl, n-hexyl, n-heptyl, n-octyl, and the like. The term “alkyl,” unless otherwise noted, also includes those derivatives of alkyl defined in more detail below as “heteroalkyl” and “cycloalkyl.”
  • The term “alkenyl” means an alkyl group as defined above containing one or more double bonds. Examples of alkenyl groups include vinyl, 2-propenyl, crotyl, 2-isopentenyl, 2-(butadienyl), 2,4-pentadienyl, 3-(1,4-pentadienyl), etc., and the higher homologs and isomers.
  • The term “alkynyl” means an alkyl or alkenyl group as defined above containing one or more triple bonds. Examples of alkynyl groups include ethynyl, 1- and 3-propynyl, 3-butynyl, and the like, including the higher homologs and isomers.
  • The terms “alkylene,” “alkenylene,” and “alkynylene,” alone or as part of another substituent means a divalent radical derived from an alkyl, alkenyl, or alkynyl group, respectively, as exemplified by —CH2CH2CH2CH2—.
  • Typically, alkyl, alkenyl, alkynyl, alkylene, alkenylene, and alkynylene groups will have from 1 to 24 carbon atoms. Those groups having 10 or fewer carbon atoms are preferred in the present invention. The term “lower” when applied to any of these groups, as in “lower alkyl” or “lower alkylene,” designates a group having eight or fewer carbon atoms.
  • “Substituted” refers to a chemical group as described herein that further includes one or more substituents, such as lower alkyl, aryl, acyl, halogen (e.g., alkylhalo such as CF3), hydroxy, amino, alkoxy, alkylamino, acylamino, thioamido, acyloxy, aryloxy, aryloxyalkyl, mercapto, thia, aza, oxo, both saturated and unsaturated cyclic hydrocarbons, heterocycles and the like. These groups may be attached to any carbon or substituent of the alkyl, alkenyl, alkynyl, alkylene, alkenylene, and alkynylene moieties. Additionally, these groups may be pendent from, or integral to, the carbon chain itself.
  • The term “heteroalkyl,” by itself or in combination with another term, means, unless otherwise stated, a stable, saturated or unsaturated, straight, branched chain, or cyclic hydrocarbon radical, or combinations thereof, consisting of the stated number of carbon atoms and from one to three heteroatoms selected from the group consisting of O, N, Si, and S, and wherein the nitrogen and sulfur atoms may optionally be oxidized and the nitrogen heteroatom(s) may optionally be quaternized. The heteroatom(s) O, N and S may be placed at any interior position of the heteroalkyl group. The heteroatom Si may be placed at any position of the heteroalkyl group, including the position at which the alkyl group is attached to the remainder of the molecule. Examples include —CH2—CH2—O—CH3, —CH2—CH2—NH—CH3, —CH2—CH2—N(CH3)—CH3, —CH2—S—CH2—CH3, —CH2—CH2—S (O)—CH3, —CH2—CH2—S (O)2—CH3, —CH═CH—O—CH3, —Si(CH3)3, —CH2—CH═N—OCH3, and —CH═CH—N(CH3)—CH3. Up to two heteroatoms may be consecutive, such as in —CH2—NH—O—CH3 and —CH2—O—Si(CH2)3. Explicitly included within the term “heteroalkyl” are those radicals that could also be described as “heteroalkylene” (i.e., a divalent radical, see next paragraph), and “heterocycloalkyl” (i.e., containing a cyclic group). The term “heteroalkyl” also explicitly includes unsaturated groups (i.e., heteroalkenyls and heteroalkynyls).
  • The term “heteroalkylene” by itself or as part of another substituent means a divalent radical derived from heteroalkyl, as exemplified by —CH2—CH2—S—CH2CH2—and —CH2—S—CH2—CH2—NH—CH2—. For heteroalkylene groups, heteroatoms can also occupy either or both of the chain termini. Still further, for alkylene and heteroalkylene linking groups, no orientation of the linking group is implied.
  • The term “aryl” is used herein to refer to an aromatic substituent, which may be a single aromatic ring or multiple aromatic rings which are fused together, linked covalently, or linked to a common group such as a diazo, methylene or ethylene moiety. The common linking group may also be a carbonyl as in benzophenone. The aromatic ring(s) may include, for example phenyl, naphthyl, biphenyl, diphenylmethyl and benzophenone, among others. The term “aryl” encompasses “arylalkyl” and “substituted aryl.” For phenyl groups, the aryl ring may be mono-, di-, tri-, tetra-, or penta-substituted. Larger rings may be unsubstituted or bear one or more substituents.
  • “Substituted aryl” refers to aryl as just described including one or more functional groups such as lower alkyl, acyl, halogen, alkylhalo (e.g., CF3), hydroxy, amino, alkoxy, alkylamino, acylamino, acyloxy, phenoxy, mercapto, and both saturated and unsaturated cyclic hydrocarbons which are fused to the aromatic ring(s), linked covalently or linked to a common group such as a diazo, methylene, or ethylene moiety. The linking group may also be a carbonyl such as in cyclohexyl phenyl ketone. The term “substituted aryl” encompasses “substituted arylalkyl.”
  • The term “acyl” is used to describe a ketone substituent, —C(O)R, where R is substituted or unsubstituted alkyl, alkenyl, alkynyl, or aryl as defined herein.
  • The term “carbonyl” is used to describe an aldehyde substituent. The term “carboxy” refers to an ester substituent or carboxylic acid, i.e., —C(O)O— or —C(O)—OH.
  • The term “halogen” or “halo” is used herein to refer to fluorine, bromine, chlorine and iodine atoms.
  • The term “hydroxy” is used herein to refer to the group —OH.
  • The term “amino” is used to designate NRR′, wherein R and R′ are independently H, alkyl, alkenyl, alkynyl, aryl or substituted analogs thereof. “Amino” encompasses “alkylamino,” denoting secondary and tertiary amines, and “acylamino” describing the group RC(O)NR′.
  • The term “alkoxy” is used herein to refer to the —OR group, where R is alkyl, alkenyl, or alkynyl, or a substituted analog thereof. Suitable alkoxy radicals include, for example, methoxy, ethoxy, t-butoxy, etc. The term “alkoxyalkyl” refers to ether substituents, monovalent or divalent, e.g. —CH2—O—CH3 and —CH2—O—CH2—.
  • The term “gelatin” as used herein means any and all kinds of gelatin, of any type (e.g., Type A from pork, with an isoelectric point between about 7.0 and 9.0, and Type B from beef with an isoelectric point of approximately 5.0), from any source, of any bloom value, acid- or alkaline-treated, etc., without limitation. The “bloom strength” of a gelatin is defined as the force required for a plunger of defined shape and size to make a 4 mm depression in a gel that has been prepared at 6.67% w/w concentration and chilled at 10° C. in a bloom jar for 16-18 hours. The force is recorded in grams. Commercially, gelatin is available from a host of commercial suppliers. At commodity amounts and prices, gelatin is generally available with bloom strengths ranging from about 50-300 bloom. Such gelatins are available from, for example, Leiner Davis Gelatin, a wholly-owned subsidiary of Goodman Fielder Ingredients of Sydney, Australia. Gelatins having bloom values outside this range are also available as specialty chemicals and are included within the scope of the term “gelatin.” For example a zero bloom (non-gelling) gelatin is available from Great Lakes Gelatin Co., Grayslake, Ill.
  • Likewise, the term “collagen” as used herein means any and all kinds of collagen, of any type, from any source, without limitation. Cross-linked collagen, esterified collagen, and chemically-modified collagen, such as that taught by U.S. Pat. No. 4,390,519, are included with the term “collagen.”
  • The term “polymer matrix” encompasses any type of polymer matrix that can function as a hydrogel, including, without limitation, gelatin, calcium alginate, calcium/sodium alginate, collagen, oxidized regenerated cellulose, carboxymethylcellulose, amino-modified celluloses, such as 6-deoxy-6-(4-aminophenyl)-amino-2(3)-O-tosylcellulose, whey protein gels, and the like.
  • The term “photopolymerizable acrylate” refers to any acrylate-containing molecule capable of being photopolymerized, without limitation. Expressly included within this definition are bis-diacrylate-PEGs, i.e., poly(alkylene glycol) molecules having an α-acrylate moiety and an ω-acrylate moiety. TMPTA is also a photopolymerizable acrylate.
  • Modified PEGs:
  • Commercial PEG-diols can be purchased essentially as a commodity item, in large amounts and at relatively inexpensive prices. The first step in modifying the α- and ω-termini of the PEG-diols is to convert them in aldehyde groups. This is very easily accomplished by treating the PEG-diol with acetic anhydride:
    Figure US20060100369A1-20060511-C00003
    The reaction is very facile and quantitative.
  • With the PEG-dialdehyde in hand, the molecule can be further modified using any of the routes shown in FIG. 1, among many others. For example, as shown in FIG. 1, the PEG-diol can be converted into an α-hydroxy-ω-carboxy-PEG, which can then be converted into an α-acrylate-ω-carboxy-PEG. Or the PEG-diol can be converted into a α-hydroxy-ω-cyanoethyl-PEG, which can then, in turn, be converted into a α-acrylate-ω-cyanoethyl-PEG.
  • The PEG-diol can be directly converted, by simple halogenation of the hydroxy group to α-hydroxy-ω-halo-PEG. The PEG diol can also be tosylated and acrylated to thereby yield α-acrylate-ω-tosylated-PEG. The tosyl group can be exchanged for a succinimidyl or phthalimidyl or other nitrogen-containing heterocycle group. α-Hydroxy-ω-methoxy-PEG can be converted directly into α-acrylate-ω-methoxy-PEG. See FIG. 1. (See also Hern & Hubbell, (1998) J. Biomed. Mater. Res. 39:266-276; Morpurgo et al. (1996) App. Biochem. Biotech. 56:59-72; and Abuchowski et al. (1984) Cancer Biochem. Biophys. 7:175-186.)
  • Thus, for example, α-hydroxy-ω-glutarate-PEG can be synthesized by treating a PEG-diol with glutaric anhydride and glutaric acid in THF with gentle heating:
    Figure US20060100369A1-20060511-C00004
  • The glutaric anhydride and the glutaric acid are added and the solution gently heated to 55° C. The solution is maintained at that temperature, with stirring, for one day. The solution is then cooled to room temperature and filtered. The filtrate is then precipitated in cold hexane, the resulting precipitate is then removed by filtration, and dried in a vacuum to yield the desired product, generally a mixture of PEG-bis-glutarate and α-hydroxy-ω-glutarate-PEG. The two can be separated chromatographically (see the Examples).
  • The glutarate group can be further reacted to add a nitrogen-containing heterocycle, such as a succinimidyl group by reacting the. α-hydroxy-6-glutarate-PEG with N-hydroxy-succinimide in the presence of a water-soluble carbodiimide:
    Figure US20060100369A1-20060511-C00005
  • The N-hydroxy-succinimide is added and the solution cooled to 0° C. The dicyclohexylcarbodiimide (DCC) is added dropwise and the solution stirred for one day and filtered. The filtrate is precipitated by adding cold hexane. The resulting precipitate is filtered and dried in a vacuum. This yields the desired product, generally a mixture of PEG-bis-N-succinimidylglutarate and α-glutarate-ω-succinimidylglutarate-PEG (or α-hydroxy-ω-succinimidylglutarate-PEG, depending upon the starting material chosen). The two can be separated chromatographically (see the Examples).
  • The α-hydroxy-ω-succinimidylglutarate can be further reacted to yield α-acrylate-ω-succinimidylglutarates by reacting the α-hydroxy-ω-succinimidylglutarate with acrylic acid in the presence of TEA.
    Figure US20060100369A1-20060511-C00006
  • The PEG molecules may also be modified to introduce other amide bonds into the molecule. The formation of an amide bond is, of course, extremely useful in modifying the PEG molecule to contain an amino acid, peptide, or protein terminus. Thus, for example α-succinimidylglutarate-ω-tryptophanylglutarate PEG can be synthesized by dissolving the peptide or amino acid in 0.1 M 2-(N-morpholino)-ethanesulfonic acid (MES) at 0° C. α,ω-Bis-N-succinimidylglutarate-PEG is added dropwise to the solution with constant stirring. The reaction is allowed to continue at 0° C. for 1 hour and then allowed to come to room temperature with constant stirring for 4 hours. The reaction solution is then dialyzed against 50 volumes of deionized water and the resulting solution lyophilized. This yields the desired α-N-succinimidylglutarate-ω-tryptophanylglutarate in rougly 40% yield.
  • The modified PEGs can be attached to a polymer matrix containing amino-reactive groups using the same procedure as in the previous paragraph, thereby grafting the modified PEG to the amino-reactive groups of the polymer matrix. See also the Examples. In short, the mono- or dialdehyde-PEG is first dissolved in water. A separate aqueous solution of NaCNBH3 is also prepared. The two solutions are then added simultaneously to a dilute (5%) solution of gelatin in water. The reaction is allowed to proceed overnight with gentle heating (50 to 60° C.). The modified gelatin is then separated by filtration.
  • Using these various synthetic schemes, the following modified PEG molecules have been made and used to modify gelatin to yield novel hydrogels that fall within the scope of the present invention:
    Series 1: Alpha-Methoxy Heterobifunctional PEG Derivatives:
    Figure US20060100369A1-20060511-C00007
    Figure US20060100369A1-20060511-C00008
    Series 1 Chemistry:
  • 1.1. α-Methoxy, ω-hydroxy-PEG is commercially available (Shearwater).
  • 1.2. To synthesize α-methoxy, (ω-tosyl PEG, PEG (1 eq.) was dissolved in dry methylene chloride MC followed by addition of p-toluenesulfonylchloride (1 eq.) and triethylamine (1 eq.). The solution was stirred at room temperature for 48 hr, precipitated in cold hexane, collected by filtration and dried in vacuum oven for 24 hr.
  • 1.3. To synthesize α-methoxy, ω-phthalimidyl PEG, α-methoxy, ω-tosyl PEG (1 eq.) from series 1-2 and potassium phthalimide (1.2 eq.) were dissolved in toluene and stirred at 50° C. for 20 hr. The solution was cooled down, filtered and the filtrate was precipitated in cold hexane, collected by filtration and dried in vacuum oven for 24 hr.
  • 1.4. To synthesize α-methoxy, ω-cyanoalkyl PEGs, PEG (1 eq.) was dissolved in dry MC solution followed by the addition of fine sodium metal (1.5 eq.) and stirred for 12 hr at room temperature. Excess amount of acrylonitrile was added to the solution, stirred for 12 hr, filtered, and dried by rotary evaporation.
  • 1.5. To synthesize α-methoxy, ω-carboxy PEG, PEG (1 mol) was dissolved in dry THF. Sodium (1.2 eq.) and naphthalene (1.2 eq.) were dissolved in dry THF and stirred under argon for 1 hr. The sodium/naphthalene solution was added dropwise to the PEG solution and the solution was stirred under argon for 4 hr.
  • Ethyl bromoacetate (1.2 eq.) was then added and the solution was stirred under argon for 12 hr. The solution was filtered and the filtrate was precipitated in cold hexane, collected by filtration and dried in vacuum oven for 24 hr. The dried substance was dissolved in deionized water followed by addition of sodium hydroxide (1 eq.). The solution was stirred at 40° C. for two hr, extracted by MC or two times and evaporated by rotary evaporation.
  • 1.6. To synthesize α-methoxy, ω-glutarate PEG, PEG (1 eq.) was dissolved in dry THF followed by addition of glutaric anhydride (1.5 eq.) and glutaric acid (0.001 eq.). The solution was stirred at 70° C. for 48 hr, cooled down, precipitated in cold hexane, collected by filtration and dried in vacuum oven for 24 hr.
  • 1.7. To synthesize α-methoxy, ω-triethoxysilane PEG, α-methoxy, ω-acrylate PEG (1 eq.) from series 2-8 was dissolved in dry THF followed by addition of triehyoxysilane (5 eq.) and chloroplatinic acid (a grain). The solution was stirred at 60° C. for 48 hr, cooled down, precipitated in cold hexane, collected by filtration and dried in vacuum oven for 24 hr.
  • 1.8. To synthesize α-methoxy, ω-acrylate PEG, PEG (1 eq.) was dissolved in dry THF followed by the addition of acryloyl chloride (2 eq.) and triethylamine (2.2 eq.). The solution was stirred at room temperature for 2 hr, filtered and the filtrate was precipitated in cold hexane, collected by filtration and dried in vacuum oven for 24 hr.
  • 1.9. To synthesize α-methoxy, ω-aldehyde PEG, PEG (1 eq.) was dissolved in DMSO and the solution was added dropwise to the acetic anhydride (20 eq.) and stirred at room temperature for 2 hr. Ether was then added to the solution and stirred for 5 min at room temperature and placed in the −20° C. freezer for 5 minutes to precipitate. The precipitate was collected by filtration and then dissolved in minimal amounts of methylene chloride and reprecipitated likewise twice by ether. The precipitate was dried in vacuum oven for 24 hr.
  • 1.10. To synthesize α-methoxy, ω-halo PEG, PEG (1 eq.) was dissolved in toluene followed by addition of triethylamine (1.2 eq.). The solution was stirred at 60° C. for 30 min followed by addition of thionyl bromide (1.2 eq.) and stirred at 60° C. for 1 hr. The hot solution was filtered through celite and the filtrate was kept in refrigerator at −4° C. for 24 hr. The precipitate was collected by filtration and dried in vacuum oven for 24 hr.
  • 1.11. To synthesize α-methoxy, ω-succinimidylglutarate-PEG, α-methoxy, ω-glutarate PEG (1 eq.) from series 1.6 and dicyclohexylcarbodiimide (DCC 1.2 eq.) was dissolved in dry THF respectively. N-hydroxy succinimide (1.2 eq.) was added to the PEG solution followed by dropwise addition of DCC solution. The mixture solution was stirred at room temperature for 6 hr, filtered and the filtrate was precipitated in cold hexane, collected by filtration and dried in a vacuum oven for 3 days and then stored under argon at −4° C. in the refrigerator.
  • 1.12. To synthesize α-methoxy, ω-succinimidylglutrate PEG, α-methoxy, ω-succinimidylglutrate PEG (1 eq.) from series 1.11 was dissolved in DMF followed by addition of tryptophan (1.5 eq.). The solution was stirred under argon for 24 hrs, dialyzed in deionized water and dried by lyophilizer for 3 days.
    Series 2: Alpha-Hydroxy Heterobifunctional PEG Derivatives:
    Figure US20060100369A1-20060511-C00009
    Figure US20060100369A1-20060511-C00010
    Series 2 Chemistry:
  • 2.1. PEG is commercially available.
  • 2.2. To synthesize α-hydroxy, ω-tosyl PEG, PEG (1 eq.) was dissolved in dry methylene chloride followed by addition of p-toluenesulfonylchloride (1 eq.) and triethylamine (1 eq.). The solution was stirred at room temperature for 48 hr, precipitated in cold hexane, collected by filtration and dried in vacuum oven for 24 hr.
  • 2.3. To synthesize α-hydroxy, ω-phthalimidyl PEG, α-hydroxy, ω-tosyl PEG (1 eq.) from series 2.2 and potassium phthalimide (1.2 eq.) were dissolved in toluene and stirred at 50° C. for 20 hr. The solution was cooled down, filtered and the filtrate was precipitated in cold hexane, collected by filtration and dried in a vacuum oven for 24 hr.
  • 2.4. To synthesize α-hydroxy, (o-cyanoalkyl PEGs, PEG (1 eq.) was dissolved in dry methylene chloride solution followed by the addition of fine sodium metal (1.2 eq.) and stirred for 12 hr at room temperature. Excess amount of acrylonitrile was added to the solution, stirred for 12 hr, filtered, and dried by rotary evaporation.
  • 2.5. To synthesize α-hydroxy, ω-carboxy PEG, PEG (1 mol) was dissolved in dry THF, sodium (1.2 eq.) and naphthalene (1.2 eq.) were dissolved in dry THF and stirred under argon for 1 hr. The sodium/naphthalene solution was added dropwise to the PEG solution, the solution was stirred under argon for 4 hr. Ethyl bromoacetate (1.2 eq.) was then added and the solution was stirred under argon for 12 hr. The solution was filtered and the filtrate was precipitated in cold hexane, collected by filtration and dried in vacuum oven for 24 hr. The dried substance was dissolved in deionized water followed by addition of sodium hydroxide (1 eq.). The solution was stirred at 40° C. for two hr, extracted by methylene chloride for two times and evaporated by rotary evaporation.
  • 2.6. To synthesize α-hydroxy, ω-glutarate PEG, PEG (1 eq.) was dissolved in dry THF followed by addition of glutaric anhydride (1.5 eq.) and glutaric acid (0.001 eq.). The solution was stirred at 70° C. for 48 hr, cooled down, precipitated in cold hexane, collected by filtration and dried in vacuum oven for 24 hr.
  • 2.7. To synthesize α-hydroxy, ω-triethoxysilane PEG, α-hydroxy, ω-acrylate PEG (1 eq.) from series 2.8 was dissolved in dry THF followed by addition of triehyoxysilane (5 eq.) and chloroplatinic acid (a grain). The solution was stirred at 60° C. for 48 hr, cooled down, precipitated in cold hexane, collected by filtration and dried in vacuum oven for 24 hr.
  • 2.8. To synthesize α-hydroxy, ω-acrylate PEG, PEG (1 eq.) was dissolved in dry THF followed by the addition of acryloyl chloride (1.5 eq.) and triethylamine (1.7 eq.). The solution was stirred at room temperature for 2 hr, filtered and the filtrate was precipitated in cold hexane, collected by filtration and dried in vacuum oven for 24 hr.
  • 2.9. To synthesize α-hydroxy, ω-aldehyde PEG, PEG (1 eq.) was dissolved in DMSO and the solution was added dropwise to the acetic anhydride (20 eq.) and stirred at room temperature for 2 hr. Ether was then added to the solution and stirred for 5 min at room temperature and placed in the −20° C. freezer for 5 minutes to precipitate. The precipitate was collected by filtration and then dissolved in minimal amounts of methylene chloride and reprecipitated likewise twice by ether. The precipitate was dried in vacuum oven for 24 hr.
  • 2.10. To synthesize α-hydroxy, ω-halo PEG, PEG (1 eq.) was dissolved in toluene followed by addition of triethylamine (1.2 eq.). The solution was stirred at 60° C. for 30 min followed by addition of thionyl bromide (1.2 eq.) and stirred at 60° C. for 1 hr. The hot solution was filtered through celite and the filtrate was kept in refrigerator at −4° C. for 24 hr. The precipitate was collected by filtration and dried in vacuum oven for 24 hr.
  • 2.11. To synthesize α-hydroxy, ω-succinimidylglutrate PEG, α-hydroxy, ω-glutarate PEG (1 eq.) resulted from series 2.6 and dicyclohexylcarbodiimide (DCC 1.2 eq.) were dissolved in dry THF respectively. N-hydroxy succinimide (1.2 eq.) was added to the PEG solution followed by dropwise addition of DCC solution. The mixture solution was stirred at room temperature for 6 hr, filtered and the filtrate was precipitated in cold hexane, collected by filtration and dried in vacuum oven for 3 days and then stored under argon at −4° C. in the refrigerator.
  • 2.12. To synthesize α-hydroxy, ω-tryptophanylglutrate PEG, a-hydroxy, w-succinimidylglutrate PEG (1 eq.) from series 2.11 was dissolved in DMF followed by addition of tryptophan (1.5 eq.). The solution was stirred under argon for 24 hrs, dialyzed in deionized water and dried by lyophilizer for 3 days.
    Series 3: Alpha-Acrylate Heterobifunctional PEG Derivatives:
    Figure US20060100369A1-20060511-C00011
    Figure US20060100369A1-20060511-C00012
  • 3.1. To synthesize α-acylate, ω-tosyl PEG, α-hydroxy, ω-tosyl PEG (1 eq.) from series 2.2 was dissolved in dry THF followed by addition of acryloyl chloride (2 eq.) and triethylamine (2.2 eq.). The solution was stirred at room temperature for 2 hr, filtered and the filtrate was precipitated in cold hexane, collected by filtration and dried in vacuum oven for 24 hr.
  • 3.2. To synthesize α-acylate, ω-phthalimidyl PEG, α-acylate, ω-tosyl PEG (1 eq.) from series 3.1 and potassium phthalimide (2 eq.) were dissolved in toluene and stirred at 50° C. for 20 hr. The solution was cooled down, filtered and the filtrate was precipitated in cold hexane, collected by filtration and dried in vacuum oven for 24 hr.
  • 3.3. To synthesize α-acylate, ω-cyanoalkyl PEGs, α-hydroxy, ω-acrylate PEG (1 eq.) from series 2.8 was dissolved in dry methylene chloride solution followed by the addition of fine sodium metal (1.5 eq.) and stirred for 12 hr at room temperature. Excess amount of acrylonitrile was added to the solution, stirred for 12 hr, filtered, and dried by rotary evaporation.
  • 3.4. To synthesize α-acylate, ω-carboxy PEG, α-hydroxy, ω-carboxy PEG (1 eq.) from series 2.5 was dissolved in dry THF followed by addition of acryloyl chloride (1.2 eq.) and triethylamine (1.5 eq.). The solution was stirred at room temperature for 2 hr, filtered and the filtrate was precipitated in cold hexane, collected by filtration and dried in vacuum oven for 24 hr.
  • 3.5. To synthesize α-acylate, ω-acryloylcarboxy PEG, ω-carboxy PEG (1 eq.) from series 2.5 was dissolved in dry THF followed by addition of acryloyl chloride (3 eq.) and triethylamine (3.5 eq.). The solution was stirred at room temperature for 2 hr, filtered and the filtrate was precipitated in cold hexane, collected by filtration and dried in vacuum oven for 24 hr.
  • 3.6. To synthesize α-acylate, ω-glutarate PEG, α-hydroxy, ω-glutarate PEG (1 eq.) from series 2.6 was dissolved in dry THF followed by addition of acryloyl chloride (1.2 eq.) and triethylamine (1.5 eq.). The solution was stirred at room temperature for 2 hr, filtered and the filtrate was precipitated in cold hexane, collected by filtration and dried in vacuum oven for 24 hr.
  • 3.7. To synthesize α-acylate, ω-acryloylglutarate PEG, α-hydroxy, ω-glutarate PEG (1 eq.) from series 2.6 was dissolved in dry THF followed by addition of acryloyl chloride (3 eq.) and triethylamine (3.5 eq.). The solution was stirred at room temperature for 2 hr, filtered and the filtrate was precipitated in cold hexane, collected by filtration and dried in vacuum oven for 24 hr.
  • 3.8. To synthesize α-acrylate, ω-acrylate PEG, PEG (1 eq.) was dissolved in dry THF followed by the addition of acryloyl chloride (3 eq.) and triethylamine (3.5 eq.). The solution was stirred at room temperature for 2 hr, filtered and the filtrate was precipitated in cold hexane, collected by filtration and dried in vacuum oven for 24 hr.
  • 3.9. To synthesize α-acylate, ω-triethoxysilane PEG, α-hydroxy, ω-triethoxysilane PEG (1 eq.) from series 2.7 was dissolved in dry THF followed by the addition of acryloyl chloride (1.2 eq.) and triethylamine (1.5 eq.). The solution was stirred at room temperature for 2 hr, filtered and the filtrate was precipitated in cold hexane, collected by filtration and dried in vacuum oven for 24 hr.
  • 3.10. To synthesize α-acylate, ω-aldehyde PEG, α-hydroxy, ω-aldehyde PEG (1 eq.) from series 2.9 was dissolved in dry TUF followed by the addition of acryloyl chloride (1.2 eq.) and triethylamine (1.5 eq.). The solution was stirred at room temperature for 2 hr, filtered and the filtrate was precipitated in cold hexane, collected by filtration and dried in vacuum oven for 24 hr.
  • 3.11. To synthesize α-acylate, ω-halo PEG, α-hydroxy, ω-halo PEG (1 eq.) from series 2.10 was dissolved in dry THF followed by the addition of acryloyl chloride (1.2 eq.) and triethylamine (1.5 eq.). The solution was stirred at room temperature for 2 hr, filtered and the filtrate was precipitated in cold hexane, collected by filtration and dried in vacuum oven for 24 hr.
  • 3.12. To synthesize α-acylate, (o-succinimidylglutrate PEG, α-hydroxy, ω-succinimidylglutrate PEG (1 eq.) from series 2.11 was dissolved in dry THF followed by the addition of acryloyl chloride (1.2 eq.) and triethylamine (1.5 eq.). The solution was stirred at room temperature for 2 hr, filtered and the filtrate was precipitated in cold hexane, collected by filtration and dried in vacuum oven for 24 hr.
  • 3.13. To synthesize α-acylate, ω-succinimidylglutrate PEG, α-hydroxy, ω-tryptophanylglutrate PEG (1 eq.) from series 2.12 was dissolved in dry THF followed by the addition of acryloyl chloride (1.2 eq.) and triethylamine (1.5 eq.). The solution was stirred at room temperature for 2 hr, filtered and the filtrate was precipitated in cold hexane, collected by filtration and dried in vacuum oven for 24 hr.
  • Series 4: Homo-Bifunctional PEG Derivatives: Modified PEGS wherein the α and the ω termini have the same functional groups can also be fabricated using the same approach. Thus, using the chemistries described herein, bis-acrylate, bis-tosylate, bis-phthalimidyl, bis-cyanoalkyl, bis-carboxylate, bis-acryloylcarboxylate, bis-glutarate, bis-acryloylglutarate, bis-trialkoxysilane, bis-aldehyde, bis-N-succinimidyl, and bis-tryptophanylglutarate derivatives can be fabricated.
  • Thus, according to the present invention, a polymer matrix, preferably gelatin, is modified to contain one or more of the modified PEG molecules disclosed herein. The PEG molecule may be bis-modified, using the same type of moiety. Or, the α-terminus of the PEG may have a different moiety than the ω-terminus. Both versions of the modified PEG molecules, as incorporated into a hydrogel, fall within the scope of the present invention.
  • Interpenetrating Network Hydrogels (IPNs):
  • The above described PEG-modified hydrogels can also be used as a first polymer matrix in an interpenetrating network of two distinct polymer matrices. In this aspect of the invention, the PEG-modified hydrogels as described above are admixed with a polymerizable mixture of monomers. A polymerization reaction is then initiated, whereby the mixture of monomers polymerizes in situ, thereby forming a second polymer matrix that interpenetrates with the first polymer matrix.
  • It is much preferred that the plurality of monomers that forms the second polymer matrix is polymerizable by a means other than chemical initiation. Chemically polymerizable monomers are, however, within the scope of the invention. In the preferred embodiment, the monomers are photopolymerizable. Thus, the monomers are admixed with the first polymer matrix. The mixture is then exposed to a suitable wavelength of radiation (e.g., infrared, visible, or ultraviolet) that will result in a photo-initiated polymerization reaction. The source for the radiation can be any source that generates radiation of the required wavelength, such as lamps (incandescent, fluorescent, ion discharge, etc.), lasers (CO2, Ne—Ne, etc.), and light-emitting diodes.
  • The preferred photopolymerizable monomers are acrylates, diacrylates, and poly(acrylates) (including PEG-acrylates, PEG-diacrylates, and TMPTA), acrylic acid, and acryloyl halides, such as acryloyl chloride, and mixtures thereof. When a plurality of different monomers is admixed with the first polymer matrix, the polymerization reaction will, of course, result in the second polymer matrix being a co-polymer. Thus, the second polymer matrix may comprise a homo-polymer matrix or a co-polymer matrix of any description (e.g., alternating, block, or graft co-polymers).
  • FIG. 6 is a schematic representation of interpenetrating network hydrogels according to the present invention. The gels can contain living cells or pharmcalogically-active agents, or both.
    • EXAMPLES
  • The following Examples are included herein solely to provide a more complete and consistent understanding of the invention disclosed and claimed herein. The Examples do not limit the scope of the invention in any fashion.
    • Example 1 Synthesis and Characterization of Heterobifunctional PEGs
  • All reagents were purchased from Sigma-Aldrich (St. Louis, Mo.) unless stated otherwise. A summary of the chemical reactions and structure of critical intermediates and final products is presented in FIG. 1.
  • To synthesize α-methyl-ω-acrylate PEGs (M-PEG), monomethoxy PEGs (2 kDa or 5 kDa, purchased from Fluka, a division of Sigma-Aldrich) were dissolved in dry tetrahydrofuran (THF) solution followed by the addition of triethylamine (TEA, 2 eq.) and acryloyl chloride (AC, 4 eq.)(14) at room temperature under Ar for 10 min, filtered, dried by rotary evaporation, re-dissolved in CH2Cl2, and precipitated in cold hexane. The final product was filtered, dried, and stored in vacuo at room temperature.
  • To synthesize α-cyanoethyl-ω-acrylate-PEGs (CN-PEG), PEG-diols (2 kDa or 5 kDa) (1 eq.) were dissolved in dry CH2Cl2 solution followed by the addition of fine sodium metal (2 eq.) stirred for 12 hr at room temperature. An excess amount of acrylonitrile was added into the solution(15,16), stirred for 12 hr, filtered, and dried by rotary evaporation. The product thus formed (i.e., α-nitrile-ω-hydroxy-PEG) was dissolved in dry THF, followed by the addition of TEA (2 eq.) and AC (4 eq.). The solution was stirred under Ar for 10 min at room temperature. Triethylammonium chloride was removed by filtration and the solvent was removed by rotary evaporation. The final product was re-dissolved into CH2Cl2, precipitated in cold hexane, filtered, and stored in vacuo at room temperature.
  • To synthesize α-carboxyl-ω-acrylate-PEGs (COOH-PEG), sodium (3.5 eq) in mineral oil was dried, dissolved in dried THF with naphthalene (3.5 eq), and stirred for 1 hr under Ar at room temperature.(17) The sodium/naphthalene solution thus formed was added drop wise into PEG-diols (2 kDa or 5 kDa) (1 eq.) dissolved in dried THF under Ar for 4 hr. Ethyl bromoacetate (4 eq) was added to the ionized PEG solution, stirred for 12 hr, filtered, precipitated in cold hexane, and re-dissolved in distilled water (1 eq) with sodium hydroxide (3 eq)(18), followed by reflux for 24 hr at room temperature. Solvent was removed by rotary evaporation and the solid was re-dissolved in CH2Cl2, filtered, precipitated in cold hexane, dried in vacuo. The solid of mainly α-carboxyl-ω-hydroxyl-PEGs (1 eq.) was dissolved in dried THF followed by the addition of TEA (2 eq.) and AC (4 eq), stirred at room temperature for 10 min under Ar, filtered, precipitated in cold hexane, filtered, dried, and stored in vacuo at room temperature.
  • To synthesize α-phthalimide-ω-acrylate-PEGs (PT-PEG), PEG-diols (2 kDa or 5 kDa) (1 eq.) were dissolved in dry CH2Cl2 solution followed by the addition of TEA (4 eq.) and p-toluenesulfonyl chloride (2 eq.)(19) and stirred under Ar for 8 hr at room temperature. Solvent was removed by rotary evaporation to obtain yellowish white solids. This mixture of PEG-diols, α-hydroxyl-ω-tosyl-PEGs, and bis-tosyl-PEG (1 eq.) was dissolved in dry THF, followed by the addition of TEA (2 eq.) and AC (4 eq.), stirred at room temperature under Ar for 10 min, filtered to remove triethylammonium chloride, dried via rotary evaporation to remove solvents, re-dissolved into CH2Cl2, and precipitated in cold hexane. The solid product (mainly α-tosyl-ω-acrylate-PEG) was filtered, dried in vacuo, dissolved (1 eq.) in CH2Cl2, followed by the addition of potassium phthalimide (3 eq.)(20) and refluxed for 18 hr. The solution was filtered, dried via rotary evaporation to remove solvents, re-dissolved into CH2Cl2, precipitated in cold hexane, filtered, dried, and stored in vacuo at room temperature.
  • All intermediates and final products were analyzed with 1H- and 13C-NMR with samples dissolved in CDCl3 and with a reverse-phase HPLC system (10% to 100% acetonitrile at a flow rate of 1 ml/min in 60 min with a Jordi 500 Å column on a Gilson system) coupled to an automated multi-sample sampler-fraction collector. Detectors included UV/Vis (200 and 254 nm), photodiode array, and evaporative light scattering detectors.
  • The above-described heterobifunctional PEGs (hPEGs) were employed as a component in the formation of hydrogels to investigate the influence of hPEG concentration, molecular weight, and terminal moiety on the surface hydrophilicity and cell interaction. The hPEGs were utilized in the hydrogel formulation following procedures described hereinabove. See also references (10-13). The network thus formed is a random copolymer of Ac, TMPTA, and hPEG, with, for example, an acrylate ω-terminal and an α-terminal of a different chemical moiety (XPEGmA).
  • Specifically, XPEGmAs were grafted to a gelatin polymer matrix with various dangling terminal functional groups and incorporated throughout the polymer matrix by copolymerizing the acrylate terminal into a randomly polymerized network of Ac and TMPTA.(10-13) This type of polymer network containing M-PEG is nonionic, low swelling, glassy when dry, optically transparent, and colorless.(10-13) In spite of the relatively high mass fraction of M-PEGs present, minimal swelling was observed for the polymer due to the highly cross-linked and hydrophobic nature of the TMPTA network. Differential scanning calorimetry analysis showed that these materials are completely amorphous and the M-PEG component is completely phase-mixed in the cross-linked TMPTA matrix.(10)
  • The surface hydrophilicity of XPEGmA-co-Ac-co-TMPTA networks was quantified with an underwater air bubble captive system. The hydrogel was completely suspended in water that was maintained at a physiologically-relevant temperature of 37.5° C. An air bubble was placed at the down side of the gel and the contact angle was measured using a modified computer-assisted video contact angle system (AST Inc). Measurement was made at six randomly selected areas, averaged, and repeated three times on three different polymer samples (n=3). Because the air bubble contact angle was measured through the aqueous phase and performed under water, the value obtained is essentially the water-receding contact angle; furthermore, the higher the contact angle, the higher is the hydrophilicity of the film.
  • The gels so formed were then evaluated for their interaction with cultured cells. Human neonatal dermal fibroblasts at a concentration of 75,000 per 1 ml of Fibroblast Basal Medium with human fibroblast growth factor-b (0.5 mg/ml), insulin (0.5 mg/ml), and 5% fetal bovine serum (Clonetics, San Diego, Calif.) were incubated with the XPEGmA-co-Ac-co-TMPTA network. At 2, 24, and 48 hr thereafter, adherent cell morphology and density were manually quantified using a computer-assisted video analysis system coupled to an inverted light microscope.
  • All experimental results are expressed in mean±standard deviation (S.D.).
  • Each sample was independently repeated three times (n=3). Comparative analyses were performed with Statview® 4.5 using analysis of variance and Fisher's protected least significant difference test at 95% confidence level (p<0.05).
  • 13C-NMR chemical shifts for M-PEG, CN-PEG, COOH-PEG, and PT-PEG intermediates and final products synthesized from 2 kDa PEG precursors are listed in Table 1.
    TABLE I
    —C-NMR chemical shifts (ppm) for M-PEG. CN-PEG, COOH-PEG. and PT-PEG
    critical intermediates and final products synthesized from 2K Da PEG-diol precursors
    Chemical Shifts of Designated Carbon (in superscript) with
    Compounds with the Following General Structure Chemical Group of
    n-CH2 Cα1 Cβ1 Cα2 Cβ2 C(1) C(2) C(3) C(4) C(5) C(6) C(7) Terminal Y
    Y-C(α1)H2C(β1)H2O(CH2CH2O)nC(β1)H2C(α2)H2OH
    70.4 61.3 72.4 61.3 72.4 — — — — — — — -OH
    70.5 30.3 71.2 62.9 72.3 — — — — — — — -Br
    70.4 19.8 66.2 62.3 72.4 119.0 — — — — — — -C(1)N
    70.4 68.2 70.2 61.3 72.4 53.7 171.2 — — — — — -OC(1)H2C(2)OOH
    70.4 64.4 71.8 61.6 69.7 58.2 — — — — — — -OC(1)H3
    70.5 68.6 69.2 61.6 72.5 163.6 114.7 131.6 130.0 21.8 — —
    Figure US20060100369A1-20060511-C00013
    Y-C(α1)H2C(β1)H2O(CH2CH2O)nC(β1)H2OC(1)OC(2)HC(3)H2
    70.5 64.6 71.1 63.9 68.2 165.3 130.6 128.2 58.2 — — — -OC(4)H3
    169.5
    70.4 18.6 66.5 64.3 68.7 165.9 130.6 128.0 117.7 — — — -C(4)N
    169.2
    70.5 68.5 70.8 64.6 68.4 166.0 130.9 128.2 53.6 170.3 — — -OC(4)H2C(5)OOH
    169.5
    70.5 37.2 67.8 170.6 63.8 68.8 167.8 130.9 128.2 168.0 132.1 123.1 133.9
    Figure US20060100369A1-20060511-C00014
  • For all samples, the methyl stretch and the “b” carbon of the PEG chains were observed at approximately 68 to 72 ppm; whereas, the “a” carbon shift was highly dependent on the terminal group (Y). For compounds with a general structure of HOCH2CH2O(CH2CH2O)aCH2CH2—Y, where Y is —OH, —Br, —CN, —OCH2COOH, —OCH3, or tosyl group, the assigned carbon showed signals at the corresponding chemical shift. For the final acrylated product with a general chemical structure of X—CH2CH2O(CH2CH2O)aCH2CH2OCOCHCH2, where X is: —OCH3, —CN, —OCH2COOH, or phthalimide, three unique chemical shifts were observed that correspond to the three carbons of the acrylate group. Specifically, the chemical shifts for —COO— stretch and —CHCH2 stretch were observed at 165.3 to 170.6 and 128.0 to 130.9 ppm, respectively. In addition, appropriate chemical shifts were observed for the assigned carbon for each terminal group (Y). Similar NMR results were obtained when 5 kDa PEGs were utilized in lieu of 2 kDa PEGs as precursors in the synthesis scheme for all compounds shown in Table 1.
  • To determine percent conversions of the final product of M-PEG, CN-PEG, COOH-PEG, and PT-PEG, HPLC analyses performed (Table 2 and FIGS. 2A and 2B) from various HPLC detectors were utilized to elucidate the chemical structure of each individual peak of a given chromatogram. In addition, each fraction was collected with an automated fraction collector and re-analyzed using 1H and 13C NMR to ascertain further the chemical composition(s) of each collected fraction. Results showed 100% conversion for M-PEG from the PEG starting material. CN-PEG showed approximately 65% conversion with no other acrylated side products. PT-PEG showed an approximate 65% conversion with about 5% of the final product containing another acrylate side-product (e.g., α-tosyl-ω-acrylate-PEG). COOH-PEG showed an approximate 60% conversion with an additional 10% of other acrylated side-products (e.g., α-hydroxyl-ω-acrylate-PEG and bis-acrylate-PEG).
    TABLE 2
    Comparison of HPLC retention time, normalized peak area,
    and percent conversion for M-PEG, CN-PEG, COOH-PEG, and
    PT-PEG synthesized from 2K Da PEG-diol precursors
    PEG Retention Normalized Conversion UV PEG Derivative
    Product Time (min) Peak Area Factor (%) Signal Identification
    PEG-diol 16 1.0 1 no α-melhyl-ω-hydroxyl
    M-PEG 21 1.0 100 strong α-methyl-ω-acrylate
    CN-PEG 21 1.1 13 strong bis-ethylcyano
    23 5.2 63 strong α-ethylcyano-ω-acrylate
    24 2.0 24 no α-nitrile-ω-hydroxy
    COOH-PEG 11 2.5 14 no bis-carboxyl
    13 2.3 13 no α-carboxyl-ω-hydroxyl
    15 10.1 57 weak α-carboxyl-ω-acrylate
    16 1 6 no bis-hydroxyl
    19 1.2 7 weak α-hydroxyl-ω-acrylate
    23 0.6 3 weak bis-acrylate
    PT-PEG 22 2.0 7 weak α-tosyl-ω-acrylate
    24 8.1 26 strong bis-phthalimide
    26 19.5 64 strong α-phthalimide-ω-acrylate
  • These results validate the synthesis of the XPEGmAs that were employed as a main component in the hydrogel synthesis. Based on the gel synthesis scheme, hPEG containing one or more acrylate groups will be covalently incorporated into the network; whereas, those without any acrylate groups will be removed from the network after the equilibration step in water as a part of the network formation procedure. Although the final product of each XPEGmA was not further purified prior to the polymer synthesis, the low concentration of other acrylated side products plays a minimal role in the network composition.
  • These heterobifunctional intermediates and final products of XPEGmA are stable under storage in vacuo at room temperature and can be modified further by a broad range of chemical methods for various applications. For example, the phthalimide group is a good protecting group that can be hydrolyzed to form primary amines.
  • A previously developed polymer network formulation was adopted to elucidate the effect of the PEG chemistry on the surface characteristics of the resulting hydrogels. Polymer networks containing various XPEGmAs at several concentrations and different molecular weights were transparent or translucent. The network surface hydrophilicity was quantified using an under water contact angle system and was found to be dependent of three factors: the molecular weight of the starting material PEG, the dangling terminal functional group, and the concentration of the XPEGmA in the network (see Table 3 and FIGS. 3A and 3B).
    TABLE 3
    Surface hydrophilicity of the XPEGmA-co-Ac-co-TMPTA
    network containing XPEGmA of various concentration,
    molecular weight, and terminal moiety
    XPEGmA XPEGmA concentration in the network formulation (g/ml)
    type 0.2 0.4 0.8 1.25 2.5
    2K (Da)
    M-PEG 37 ± 8 34 ± 6 37 ± 4 34 ± 2 29 ± 5
    CN-PEG 46 ± 4 32 ± 2 † 36 ± 5 † 37 ± 2 † 39 ± 2 †§
    COOH-PEG 44 ± 3 42 ± 6 38 ± 6 † 46 ± 7 § 43 ± 4 §
    PT-PEG 23 ± 4 § 45 ± 4 †§ 40 ± 6 † 38 ± 2 † 41 ± 2 †§
    5K (Da)
    M-PEG 41 ± 6 45 ± 6 ‡ 51 ± 7 ‡ 42 ± 5 ‡ 47 ± 1 ‡
    CN-PEG 46 ± 5 32 ± 2 †§ 36 ± 7 †§ 37 ± 1 †§ 39 ± 3 †§
    COOH-PEG 51 ± 3 ‡§ 42 ± 2 † 39 ± 1 †§ 43 ± 4 † 44 ± 4 †
    PT-PEG 46 ± 4 ‡ 46 ± 1 51 ± 7 40 ± 3 † 39 ± 2 †§
  • First, when a given concentration of XPEGmA containing a given dangling terminal group in the network was considered, an increase in the molecular weight of the terminal group significantly lowered the hydrophilicity of networks containing M-PEG (0.4 to 2.5 g/ml), COOH-PEG (0.2 g/ml), or PT-PEG (0.2 g/ml). For other networks, the molecular weight of XPEGmA did not significantly affect the hydrophilicity.
  • Second, the different terminal moiety of XPEGmA showed a variable effect on the surface hydrophilicity when compared with that of M-PEG of given molecular weight and concentration.
  • Third, the XPEGmA concentration in the network formulation showed various correlations with hydrophilicity. Because XPEGmA was employed in the network formation without further purification, the potential effect of differential percent conversion of acrylated hPEG on surface hydrophilicity must be addressed. M-PEG showed a 100% conversion and the network containing M-PEG demonstrated no changes in surface hydrophilicity with increasing M-PEG concentration. Whereas for other XPEGmAs, various correlations among hydrophilicity and the type, percent conversion (ca. 60 to 100%), and concentration were observed. Hence, it was concluded that the percent conversion of XPEGmA within 60 to 100% did not affect the dependency of XPEGmA concentrations on hydrophilicity. These analyses determined that the network surface hydrophilicity was predominately influenced by the XPEGmA concentration in the network formulation with the molecular weight and the terminal moiety playing lesser roles.
  • Next, XPEGmA-co-Ac-co-TMPTA networks containing various XPEGmAs at several concentrations were employed to determine the effect of surface characteristics of the gel on human fibroblast adhesion. All adherent cells showed extensive pseudopodial extension and cytoplasmic spreading, with some cells exhibiting polar cell body morphology. The results (see Table 4) showed that adherent cell density was primarily dependent on the XPEGmA concentration in the network formulation. Specifically, adherent cell density decreased with increasing XPEGmA concentration at all culture time. No adherent cell was observed on networks containing XPEGmA concentration between 1.25 to 2.5 g/ml at all culture times. These trends were independent of the XPEGmA molecular weight and terminal moiety. No direct mechanistic correlation can be made between network surface hydrophilicity and adherent cell density because several interrelated complex parameters (e.g., XPEGmA chemicophysical properties, adsorption of serum adhesion-mediating proteins, etc.) contribute to these two phenomena. However, the adherent cell density decreased with increasing XPEGmA concentration for all samples.
    TABLE 4
    Adherent human dermal fibroblast density on the XPEGmA-co-Ac-co-TMPTA network containing
    XPEGmA of various concentration, molecular weight, and terminal moiety
    Culture Time (hr)
    2 hr 24 hr 48 hr
    XPEGmA XPEGmA concentration in the network formulation (g/ml)
    type 0.2 0.4 0.8 1.25 2.5 0.2 0.4 0.8 1.25 2.5 0.2 0.4 0.8 1.25 2.5
    2K (Da)
    M-PEG 3 ± 2 3 ± 2 0 0 0 5 ± 2 2 ± 1 0 0 0 3 ± 2 4 ± 2 1 ± 1 0 0
    CN-PEG 5 ± 4 2 ± 1 1 ± 1 0 0 3 ± 2 4 ± 3 1 ± 1 1 ± 1 0  5 ± 34 4 ± 3 3 ± 1 5 ± 2 0
    COOH-PEG 2 ± 1 1 ± 0 1 ± 1 0 0 3 ± 1 2 ± 1 6 ± 4 0 ± 0 0 3 ± 2 1 ± 1 1 ± 1 1 ± 1 0
    PT-PEG 2 ± 1 2 ± 1 1 ± 1 1 ± 0 0 1 ± 0 3 ± 2 3 ± 2 0 0 3 ± 1 2 ± 1 3 ± 3 0 ± 0 0
    5K (Da)
    M-PEG 3 ± 1 3 ± 2 0 0 0 3 ± 3 3 ± 2 1 ± 1 0 0 2 ± 1 3 ± 2 1 ± 1 0 0
    CN-PEG 2 ± 2 1 ± 1 1 ± 0 0 0 4 ± 3 5 ± 4 0 ± 0 2 ± 1 0 3 ± 2 3 ± 2 0 ± 0 2 ± 2 0
    PT-PEG 3 ± 1 1 ± 0 0 ± 0 0 0 2 ± 1 2 ± 2 0 ± 0 0 0 3 ± 1 3 ± 2 1 ± 1 0 0
    COOH-PEG 4 ± 0 1 ± 1 1 ± 0 0 0 4 ± 2 2 ± 1 1 ± 0 1 ± 0 0 2 ± 1 3 ± 1 1 ± 0 0 ± 0 0

    All values are expressed in ×100 cells/mm2 (rounded-off for clarity, mean ± S.D., n = 3).
  • The results of this Example show that the presence of two distinct chemical moieties (i.e., carboxylic acids of the poly-acrylic acid backbone and the distinct functional group at the dangling terminus of XPEGmA grafted at the pendent chain configuration) within the hydrogels can be employed to bind (covalently) two or more distinct types of biofunctional molecules such as peptides and pharmaceutics by employing distinct chemical methodologies. Furthermore, the high content of PEGs in this system reduced protein adsorption and effectively eliminated nonspecific cell adhesion that would occur as a result, thus permitting the modulating of cellular function mediated uniquely by the multiple immobilized biofunctional agent (10-13). The invention thus provides multi-functional hydrogels that can be used, for example, to study complex biological systems and to deliver therapeutic agents locally and systemically.
    • Example 2 Drug Release Kinetics
  • This Example explores the swelling and drug release kinetics of various gelatin-based hydrogels. The hydrogels were cross-linked by various means, and contained various modifications of the gelatin backbone. The effect of pH on the drug release kinetics of these gels was also investigated.
  • As noted above, cross-linking gelatin produces a hydrogel of high molecular weight and reduces or prevents gelatin dissolution. The cross-linking agents used in this Example were: 0.1%, 0.01%, and 0.001% (v/v) glutaraldehyde aqueous solutions, and self-cross-linking via liquid nitrogen immersion followed by baking. The backbone modifications to the gelatin were the addition of polyethylene glycol (PEG) or ethylenediaminetetraacetic dianhydride (EDTAD) or both. PEG has low immunogenicity and cytotoxicity. EDTAD has low toxicity and the lysyl residues of gelatin can be modified with EDTAD in a relatively fast reaction following facile procedures. See Hwang & Damodaran (1996) J. Agric. Food. Chem. 44:751-758. Also, modifying gelatin with EDTAD introduces polyanionic molecules into the gelatin chain, thereby improving the swelling capability of the gelatin hydrogels. The pHs investigated in this Example were pH 4.5, pH 7.0 and pH 7.4. Based on the swelling/degradation and drug release kinetics of these hydrogels under the stated conditions anid in vivo analysis, these- hydrogels are suitable as support matrices for the regeneration of rat neutral stem cells and as a drug carrier in mediating inflammation in vivo.
  • PEG diol (Aldrich, M n 2 kD) was converted to PEG dialdehyde (PEGdial) by reacting PEG with acetic anhydride in DMSO in a molar ratio of 1:80:140 for 4 hours at 25° C. The composition of PEG dialdehyde was confirmed using the reverse-phase HPLC system and parameters as described in Example 1. This reaction produces a mixed product of PEG monoaldehyde and PEG dialdehyde. PEG dialdehyde had an elution time of approximately 11.5 min. and was approximately 80 wt % of the final product.
  • The lysyl amino groups of gelatin samples (Sigma, St. Louis, Mo.; Type A, from porcine skin, 300 bloom, cell culture tested) were modified by PEGdial to form PEG-modified gelatin (PG). Gelatin samples were also modified using EDTAD (Aldrich) to form EDTAD-modified gelatin (EG). Still further gelatin samples were modified with PEGdial and EDTAD to yield PEG-modified-EDTAD-modified gelatin (P/EG). PG or P/EG was created by adding PEGdial dissolved in 10 ml of H2O (Milli-Q synthesis, 18.2 MΩ-cm, Millipore) and NaCNBH3 dissolved in 10 ml of H2O separately and simultaneously to a 5% (w.v) gelatin or EG solution at 50 to 60° C. for 24 hours in a wt ratio of gelatin/EG: PEGdial: NaCNBH3 of (1:0.66:0.186). The theoretical maximum percent modification using this method is 100% modification of gelatin lysyl residues, based on an average 300 bloom gelatin molecular weight and average lysine content of the gelatin. See, e.g., Merck Index, 12th Ed. (1996) #4388, p. 742. EG was created by adding EDTAD to a 1% (w/v) gelatin solution at pH 10, 40° C. for 3 hours in a wt ratio of gelatin:EDTAD of 1:0.034. The theoretical maximum percent modification of gelatin lysyl residues using this method is 38%. Thus, modifications larger than this indicate that both functional groups of the added EDTAD have bonded to lysyl residues in the gelatin, thereby cross-linking the gelatin chains. The level of gelatin modification was quantified using the 2,4,6-trinitrobenzene sulfonic acid spectrophotometric method. See Hwang & Damodaran, supra, and Offner & Bubnis (1996) Pharm. Res. 13:1821-1827.
  • To make the hydrogels, 10% (w/v in H2O) solutions of gelatin (G), 10% PG, 40% EG and 60% P/EG were heated to approximately 70° C. and poured into petri dishes (60×15 mm, Cole-Parmer) to a thickness of 6 mm and allowed to set at room temperature overnight. Hydrogels were cut into 1 cm diameter circular discs or into 0.5×0.5 cm squares, and cross-linked with 0.1, 0.01 or 0.001% (v/v in H2O) gluteraldehyde (Electron Microscopy Sciences, EM grade, 10% (v/v) aqueous solution) for 6 hours with gentle shaking. Cross-linked hydrogels were washed with H2O ten times for 3-5 min. Washed hydrogels were left overnight in H2O for continued leaching of the gluteraldehyde. Hydrogels were then dried at room temperature in ambient air for 48 hours and weighed. Separately, hydrogels of 10% by wt gelatin were dried in ambient air for 48 hours, frozen in liquid nitrogen for 30 seconds to 1 minute and then baked at 130-135° C. for 8.5 hours (self-cross linked; LN2-baked G). Not all hydrogel formulations withstood the cross-linking, washing and drying steps, mainly due to hydrolysis. The hydrogel formulations that were included in the swelling/degradation and in vitro drug release studies were the 0.1% glutaraldehyde cross-linked G, PG, EG, and P/EG gels; the 0.01% glutaraldehyde cross-linked G, PG, and EG gels; the 0.001% glutaraldehyde cross-linked G and PG gels; and the self-cross linked LN2-baked G. Swelling study results for P/EG hydrogels and in vitro and in vivo drug release studies are ongoing and results are not included here.
  • For in vitro drug release studies, each hydrogel was loaded with chlorhexidine digluconate (CHD; Sigma, 20% (w/v) aqueous solution) using the same drug loading density used for dexamethasone in the in vivo studies (150 μg/kg/day, dosage of 21 d). Assuming a rat weight of 0.2 kg, this loading density is equivalent to 630 μg/hydrogel. Based on the maximum swelling weight ratios from the swelling studies, each hydrogel was loaded with 35 μL of CHD (18 mg/ml), a volume well below the maximum volume the hydrogel could absorb. Hydrogels (0.5×0.5×0.6 cm) were placed into individual wells in a 48-well tissue culture plate. CHD was added to each well, and the hydrogels were allowed to absorb the drug solution overnight (approximately 15 hours) with gentle shaking.
  • To evaluate swelling and degradation kinetics, dried hydrogels were placed in 5 ml of aqueous solutions of pH 4.5, pH 7.0 or pH 7.4 in a water bath at 37° C. Aqueous solutions were created by adjusting the pH of H2O with dilute HCl and NaOH. Hydrogels were transferred to fresh aqueous solutions at approximately 3 and 6 wks. Swollen hydrogels were weighed at 2, 4, and 6 hours, 1, 2, 3, 4, and 5 days, and 1, 2, 3, 4, 5, 6, 7, and 8 weeks to characterize the swelling/degradation kinetics. Extreme care was taken to preserve the integrity of the hydrogels at every step in the weighing process. The swelling weight ratio at each time point for each hydrogel was calculated as: (Ws−Wd)/Wd, where Ws is the weight of the swollen gel and Wd is the weight of the dry gel (in grams). The maximum swelling weight ratio that occurred over 8 weeks and the time it occurred was also calculated (Rmax & Tmax respectively). The last attainable swelling weight ratio (due to hydrogel dissolution) and the time it occurred was also calculated (Rfail & Tfail respectively). Statistical analysis was performed using ANOVA and Tukey multiple comparisons tests (p<0.05). Individual sample solutions from the swelling study were collected for ongoing GPC analysis of degradation products (results not shown) (20% (v/v) acetonitrile: 0.1 M NaNO3 at a flow rate of 0.7 ml/min, 60 min., using three Ultrahydrogel columns in series, Ultrahydrogel 250, 1000 and Linear, on a Waters system).
  • For in vivo studies, unmodified gelatin cross-linked in 0.1% and 0.01% gluteraldehyde were tested in vivo, following the established cage implant system. See Kao & Anderson (1999) “Handbook of Biomaterials Evaluation 2nd ed., Taylor & Frances Publishing, Philadelphia, Pa., pp. 659-671. Samples were placed inside a cylindrical cage (3.5 cm long×1 cm diameter) constructed from medical grade stainless steel wire mesh. Empty cages were implanted as controls. All cages were implanted subcutaneously in the back of 3-month-old female Sprague-Dawley rats. At 4, 7, 14 and 21 days post-implantation, the inflammatory exudates that collected in the cages were withdrawn and analyzed for the quantitative evaluation of cellular and humoral response to implantation using standard hematology techniques. The distributions of lymphocyte, monocyte, and polymorphonuclear leukocyte (PMN) subpopulations in the exudates were determined. Concurrently, the implanted materials were retrieved for analysis of changes in the sample physiochemical composition (e.g., percent mass loss).
  • Percent modification of the lysyl residues in gelatin by PEG and/or EDTAD was quantified using the TNBS method: The PG was found to be 10% modified, the EG 40% modified, and the P/EG 60% modified. All results reported here incorporate materials from the same batch of modified gelatin (i.e. 8% PG, 42% EG).
  • FIG. 5 is a graph depicting representative swelling/degradation kinetics. Time in hours is shown on the X-axis; swelling ratio is shown on the Y-axis. Key: G, 0.01% glutaraldehyde cross-linked=♦; 10% PG, 0.01% glutaraldehyde cross-linked=▪; 40% EG, 0.01% glutaraldehyde cross-linked=▴. Swelling/degradation studies showed that G modified with PEG significantly increased Tmax and Tfail, whereas G modified with EDTAD significantly increased Tmax. Hydrogels cross-linked in 0.01% or 0.001% gluteraldehyde showed a significant difference in Tmax and Tfail over gels cross-linked in 0.1% gluteraldehyde. The level of pH did not significantly affect Rmax, Tmax, Rfail and Tfail. Table 5 shows Rmax, Tmax, Rfail and Tfail for all levels of gluteraldehyde concentration, pH and gelatin backbone modification.
    TABLE 5
    RMAX, TMAX, RFAIL, AND TFAIL FOR ALL LEVELS
    OF GLUTERALDEHYDE/HEAT TREATMENT, PH AND
    GELATIN BACKBONE MODIFICATION
    %
    gluteraldehyde
    fixation/heat G
    treatment pH Modc R-max T-max R-fail T-fail
    0.1% 4.5 G 6.30 108  4.11 >1344
    PG 6.98 1344b  6.98 >1344
    EG 8.77 720  7.71 >1344
    7.0 G 5.94 108  2.88 >1344
    PG 6.64 1092  4.55 >1344
    EG 12.04  1008  6.24 >1344
    7.4 G 4.68 96 1.45  1092
    PG 6.60 1092  5.35 >1344
    EG 894.17  924  892.52 >1344
    0.01% 4.5 G 35.48  36 7.25  132
    PG 11.54b 24 5.80  420
    EG 31.53   2 14.07   84
    7.0 G 40.23  48 8.49   84
    PG 10.63  96 8.36  336
    EG 26.96   2 7.71  168
    7.4 G 26.29  36 8.21   72
    PG 10.48  96 5.06  336
    EG 30.88  12 6.47  168
    0.001% 4.5 G 0.10  1 −0.01   2
    PG 0   0 0   0
    EG — — — —
    7.0 G 0.33  1 0.17   2
    PG 0   0 0   0
    EG — — — —
    7.4 G 0.36  1 0.36   1
    PG 0   0 0   0
    EG — — — —
    LN2-baked G 4.5 G 3.96 24 2.06   252b
    7.0 G 4.76 24 0.40   72
    7.4 G 4.05 15 72   96

    aAll values expressed in mean (n = 2 − 3) with s.e.m. omitted for clarity.

    bSignificantly different from G under same experimental conditions; paired t-tests, p < 0.05.

    c10% PG or 40% EG
  • In vivo studies following the cage implant system allowed the duration and magnitude of the host foreign body reaction to the implanted gelatin-based hydrogels (0.1% G and 0.01% G) to be evaluated. The presence of a high concentration (relative to control) of polymorphonuclear leukocytes (PMNs) in the exudates indicates an acute inflammatory response, which occurs at the onset of implantation and attenuates with time. The presence of a high concentration (relative in control) of monocytes and lymphocytes in the exudates is indicative of the chronic inflammatory response. Thus, 0.1% G hydrogels elicited a slightly enhanced chronic inflammatory response at 7 days and an enhanced chronic inflammatory response at 14 days vs. the control and that of 0.01% G. 0.01% G elicited a slightly enhanced chronic inflammatory response at 7 days vs. the control (see Table 6). By day 21, all samples showed a comparable level of chronic inflammation vs. the controls the proceeded toward resolution. Percent mass loss of samples increased with increasing implantation time and was further increased with decreasing percentage of gluteraldehyde fixation (results not shown).
    TABLE 6
    TOTAL AND DIFFERENTIAL LEUCOCYTE CONCENTRATION
    IN THE INFLAMMATORY EXUDATES OF GELATIN HYDROGELS
    CROSS-LINKED IN 0.1 OR 0.01% GLUTERALDEHYDE
    Implantation Cell concentration (×cells/μL)a
    Sample time (day) Total Lymphocyte Monocyte PMN
    Empty cage 4 184 ± 25  168 ± 23  16 ± 7  1 ± 1
    (no sample) 7  57 ± 12c  49 ± 10c 7 ± 2 0 ± 0
    14 55 ± 7  36 ± 3  12 ± 4  7 ± 5
    21 91 ± 69 98 ± 54 20 ± 16 0 ± 0
    0.1% 4 597 ± 392 255 ± 116 126 ± 113 217 ± 21 
    7 183 ± 129 78 ± 40 26 ± 14 2
    14  235 ± 65b 118 ± 30b 40 ± 16  79 ± 74b
    21 200 167 33  77 ± 750
    0.01% 4 477 ± 195 412 ± 172 57 ± 28 8 ± 5
    7 178 ± 78b 157 ± 80  17 ± 1b 4 ± 3
    14 72 ± 36 60 ± 29 10 ± 7  2 ± 1
    21 93 ± 3  72 ± 5  9 ± 4 12 ± 11

    aAll values expressed in mean ± s.e.m. (n = 3 − 7).

    bRepresents p < 0.01 vs. respective values of “empty cage” controls.

    cRepresents p < 0.01 vs. respective values at day 4 of the same sample type.
  • This Example shows that gelatin backbone modifications and cross-linking agent selection affect the swelling/degradative kinetics of modified gelatin-based hydrogels. By modulating these material properties and monitoring how these changes affect drug release kinetics, a nonimmunogenic, bioresorbable cell/drug carrier matrix can be made that will have desirable release characteristics based on such considerations as the drug being used in the formulation, the length of the treatment, and the condition being treated, and the location of the implanted matrix.
    • Example 3 In Vivo Modulation of Host Response Using Gels Grafted with Fibronectin-Derived Biomimetic Oligopeptides
  • The host inflammatory reaction is a normal response to injury and the presence of foreign objects. The magnitude and duration of the inflammatory process have a direct impact on biomaterial biostability and biocompatability. Thus, this Example investigates the performance of gels fabricated according to the present invention that include fibronectin-derived biomimetic oligopeptides. Fibronectin in known to adsorb on a variety of biomaterials and play an important role in the host-foreign body reaction. The RGD (SEQ. ID. NO: 1) and PHSRN (SEQ. ID. NO: 2) amino acid sequences are particularly interesting because these sequences are present on adjacent loops of two connecting FIII modules and bind synergistically to a host of integrins.
  • Oligopeptides were designed based on the primary and tertiary structure of human plasma fibronectin to study the structure-functional relationship of RGD and PHSRN regions of fibronectin in regulating the host inflammatory response and macrophage behavior in vivo. Peptides included RGD and PHSRN sequences alone or in combination. The tertiary structure of fibronectin was utilized as a guide in the formulation of peptides. The distance between the PHSRN sequence and the RGD sequence within the natural fibronectin molecule in solution was approximated using the structural coordinates archived in the SwissProt Database® (sequence FINC_HUMAN P02751). Based on the measurement, a hexamer of glycine (G6) of approximately the same length was used to link the two bioactive sequences in both possible orientations. A terminal trimeric glycine domain (G3) was employed as a spacer in all peptides. Oligopeptides were synthesized using solid-resin methods on an automated peptide synthesizer (Millipore) using conventional 9-fluorenylmethyloxycarbonyl chemistry without further purification and with a final coupling efficiency of approximately ≧85% purity. Peptides were characterized and analyzed using mass spectroscopy and reverse phase HPLC coupled to photodiode array, evaporative light scatter, and UV/Vis detectors. The following oligopeptides were synthesized: G3RGDG (SEQ. ID. NO: 3), G3PHSRNG (SEQ. ID. NO: 4), G3RGDG6PHSRNG (SEQ. ID. NO: 5), G3PHSRNG6RGDG (SEQ. ID. NO: 6), and G3RDGG (SEQ. ID. NO: 7) as a nonspecific control. Peptides were covalently grafted onto hydrogels as described in Example 1 to investigate the influence of peptides on the host response and macrophage behavior in vivo.
  • The gels used in this Example were random co-polymers of monomethoxy polyethyeneglycol monoacrylate (mPEGmA), acrylic acid (Ac), trimethylolpropane triacrylate (TMPTA). As noted above, these gels are hydrophilic, nonionic, low swelling, glassy, optically transparent, and colorless. Differential scanning calorimetry analysis showed that these materials are completely amorphous and the mPEGmA component is completely phase-mixed in the cross-linked TMPTA matrix. The bioactive oligopeptides were grafted onto mPEGmA-co-Ac-co-TMPTA hydrogels and the resulting gels mediated cell adhesion in a receptor-peptide specific manner. The peptide surface density was found to be dependent on the number of amino acids per peptide. For example pentapeptides were grafted at 66±6 pmol/cm2 surface density; whereas, peptides containing 30 residues were grafted at approximately one-fifth of that surface density. In this Example, oligopeptides containing one bioreactive region (i.e., G3RGDG, G3PHSRNG, and G3RDGG) were grafted at about twice the density of oligopeptides containing two bioreactive regions (i.e., G3RGDG6PHSRNG and G3PHSRNG6RGDG).
  • The well-established subcutaneous cage-implant system was utilized to study the effect of implanted materials on the host foreign body reaction. Briefly, mPEGmA-co-Ac-co-TMPTA networks grafted with or without fibronectin-derived peptides were placed in sterile water for at least 48 hours to remove low molecular weight leachable residual molecules from the polymerization process and to achieve hydration equilibrium. The polymer samples were then inserted under sterile conditions into an autoclaved cylindrical cage measured 3.5 cm long, 1 cm in diameter, and constructed from medical grade stainless steel wire mesh. Cages containing various polymer samples were subcutaneously implanted at the back of 3-month old female Sprague-Dawley rats. Empty cages were employed and implanted as controls. The inflammatory exudate that collects in the cage was withdrawn at 4, 7, 10, 14, and 21 days post-implantation and analyzed for the quantitative evaluation of cellular and humoral response to the test material using standard and conventional hematology techniques. Specifically, the distribution of lymphocyte, monocyte, and PMN subpopulations in the exudate was determined. The presence of a high concentration of PMNs in the inflammatory exudate indicates an acute inflammatory response, which occurs from the onset of implantation and attenuates with time. This is followed by the chronic inflammatory response, which is characterized by the presence of a high concentration of monocytes and lymphocytes in the exudate. Hence, the cage implant system allows the host inflammatory reaction to the test sample to be observed as a function of time and material property. A drop of each exudate sample was also cultured on brain-heart infusion agar plates to check for incidence of infection. No infection was observed at any retrieval time for any sample. At 4, 7, 14, 21, 35, and 70 days post-implantation, test polymer samples were retrieved and the adherent cell morphology and density were quantified using a video analysis system coupled to a light microscope.
  • A previously developed mathematical model describing the in vivo kinetics of macrophage fusion on various biomaterials was employed to provide insights into the effect of materials and peptides on foreign body giant cell (FBGC) formation. The model was formulated based on Flory's most-probable molecular weight distribution of polymer chains. In the analysis, each adherent macrophage is analogous to a monomer and the process of cell fusion is analogous to the polymerization process. Two initial premises are necessary: (1) the FBGC size is directly proportional to the number of nuclei in a given FBGC; and (2) the ability for each cell to fuse is constant and independent of the cell size. The FBGC size-distribution equation (Nx=pax-3(1−p)) was applied to the measured FBGC size-distribution result of each sample at each retrieval time. Nx is the cell size number-fraction of FBGCs with area x; p is the probability of cell fusion or the ratio of the number of cell fusion to the initial adherent macrophage density; a is a constant relating to the number of nuclei per FBGC to the cell area (FBGC/mm2) and has been found to be constant for various clinically relevant biomaterials under different mechanical stress conditions. See Kao et al. (1994) J. Biomed. Mater. Res. 28:73-79; Kao et al. (1995) J. Biomed. Mater. Res. 29(10);1267-75; and Kao et al. (1994) J. Biomed. Mater. Res. 2:819:829. Values for p and a were obtained through a curve-fit iteration until r2>0.98. The resulting values of p for each sample at each retrieval time were utilized to calculate two kinetic parameters that characterize the process of cell fusion: the density of adherent macrophages that participate in the FBGC formation (d0=df/[p2(1−p)] and the rate constant of cell fusion (1/(1−p)=d0tk+1). d0 is the calculated density of adherent macrophages that participate in the FBGC formation process (macrophages/mm2), df the measured adherent macrophage density at 4 days post-implantation (macrophages 1mm−2), t the implantation time (week), and k the inverse rate constant of cell fusion (mm2cell−week−1).
  • All experimental results are expressed in mean±standard error of the mean. Each sample was independently repeated 3 times (n=3). Comparative analyses were performed with Statview® 4.5 using analysis of variance and Fisher's protective t-test at 95% confidence level (p<0.05).
  • Total and differential leukocyte analysis was performed at several post-implantation periods (Table 7). No PMNs were observed at any time point for all samples, indicating that the presence of empty cages and networks grafted with or without fibronectin-derived biomimetic oligopeptides elicited a rapid acute inflammatory response that was resolved within 4 days of implantation. For the empty cage control, total leukocyte and lymphocyte concentrations decreased rapidly between 4 and 7 days post-implantation and remained steady thereafter up to 21 days. Monocyte concentration remained constant from 4 to 21 days post-implantation. These results indicate that the presence of the empty cage elicited a rapidly decreasing chronic inflammatory response by 7 days post-implantation that turned toward resolution with increasing implantation time. The presence of mPEGmA-co-Ac-co-TMPTA gels within the cage showed a constant total leukocyte concentration from 4 to 21 days of implantation. However, the presence of the gels increased monocyte concentration and lowered lymphocyte concentration at days 4 and 7 when compared with that of empty cage controls, suggesting a comparable level of chronic inflammatory response that turned toward resolution but with an altered leukocyte sob-population distribution. When comparing the trends between mPEGmA-co-AC-co-TMPTA networks and empty cage controls, the presence of immobilized peptides on the polymer network did not significantly affect the total and differential leukocyte concentrations up to 14 days post-implantation, except that the decreased lymphocyte concentration was not observed for G3RGDG-grafted networks at days 4 and 7 and for other peptide-grafted surfaces at day 7 of implantation.
  • These results indicate that the presence of polymer networks with or without immobilized peptides did not significantly modify the host acute and chronic inflammatory reactions up to 14 days of implantation. By 21 days of implantation, the presence of grafted G3RGDG or G3RDGG slightly decreased the total and lymphocyte concentrations when compared with respective values of “no grafted peptides” and “empty cage” controls. This trend was not observed for surfaces grafted with G3PHSRNG6RGDG. Conversely, the presence of grafted G3PHSRNG or G3RGDG6PHSRNG slightly increased the total and lymphocyte concentrations when compared with respective values of “no grafted peptides” controls (p<0.05). At 21 days post-implantation and thereafter, extensive fibrous encapsulation at the exterior of all implanted cages and the absence of the inflammatory exudate inside the cage were observed for all samples, indicating the progression of tissue healing. These data suggest that the identity of grafted peptides did not significantly alter the temporal variation and intensity of the host acute and chronic inflammatory reaction.
  • Adherent macrophage density on implanted mPEGmA-co-AC-co-TMPTA networks grafted with or without fibronectin-derived oligopeptides was quantified at different retrieval times. In general, adherent macrophages on all surfaces decreased with increasing implantation time (see Table 8). Adherent macrophage densities for all samples were comparable and were higher than respective values of G3RDGG or “no grafted peptide” controls at each retrieval time up to 14 days post-implantation. Adherent macrophage density on all samples was comparable from 21 to 70 days post-implantation. Adherent macrophages on all surfaces showed an extensive spread morphology with pseudopodial extension. These results indicate that peptides containing RGD and/or PHSRN motifs do not affect adherent macrophage density.
  • At each retrieval time up to 70 days post-implantation, no surface cracking, pitting, nor other evidence of physical degradation were observed under polarized light microscope at 40× magnification on any polymer sample with or without grafted peptides.
  • The morphology of FBGCs on all samples was that of foreign-body type, i.e., random arrangements of nuclei numbered more than three nuclei per cell with widely variable, extensive cytoplasmic forms. In general, FBGC density increased with increasing implantation time for all samples except that on surfaces grafted with G3RGDG or G3PHSRNG6RGDG at which the adherent FBGC density remained constant with increasing implantation time (data not shown). In addition, the average FBGC size increased with increasing implantation time for all samples (data not shown).
  • These results showed that hydrogels grafted with fibronectin-derived peptides mediated extensive FBGC coverage that increased with increasing implantation time. Specifically, surfaces grafted with G3RGDG6PHSRNG showed the highest FBGC coverage at about 90% of the total sample area when compared with other sample types and controls at 70 days post-implantation. These in vivo findings indicate that the RGD motif, specifically in the configuration of G3RGDG or G3PHSRNG6RGDG, but not G3RGDG6PHSRNG, modulates a rapid macrophage fusion to form FBGCs. This phenomenon is observed at the early stage of implantation (i.e., within 4 days of implantation).
  • A previously developed mathematical model describing the in vivo kinetics of macrophage fusion to form FBGCs on biomaterials was employed to provide insights into the effect of peptide identity on the kinetics of FBGC formation. FBGC cell size distributions on all samples were measured at 4, 7, 14, and 21 days post-implantation. The FBGC cell size-distribution equation was fitted to the measured results of each sample at each retrieval time to obtain values for p and 1/a. Values for p increased with increasing implantation time for all samples except for that of the “no grafted peptide” controls. Thus, these results indicate that the probability of cell fusion increased with increasing implantation time. The calculaitons also showed that the density of adherent macrophages that participate in the FBGC formation was significantly higher for mPEGmA-co-Ac-co-TMPTA gels grafted with G3PHSRNG, and G3PHSRNG6RGDG than that for gels grafted with G3RDGG nonspecific controls and gels without peptide grafting.
  • This Example shows that the hydrogels of the present invention can be used to support peptide, proteins, and the like, within a modified, three-dimensional hydrogel matrix.
    TABLE 7
    Total and different leukocyte concentration in the inflammatory
    exudate of mPEGmA-co-AC-co-TMPTA networks grafted with
    various fibronectin-derived oligopeptidesa
    Implantation Cell concentration (×10 cells/μl)
    Peptide (days) Total Lymphocyte Monocyte PMN
    G3RGDG 4 127 ± 25  71 ± 22  56 ± 5b 0 ± 0
    7  67 ± 13  24 ± 4c  43 ± 9b 0 ± 0
    14  74 ± 18  21 ± 4  53 ± 25 0 ± 0
    21  31 ± 8c,d,b  27 ± 8c,b  5 ± 1d 0 ± 0
    G3PHSRNG 4  63 ± 32  25 ± 22b  38 ± 17b 0 ± 0
    7  61 ± 9  25 ± 6  36 ± 3b 0 ± 0
    14  56 ± 19  33 ± 15  24 ± 4 0 ± 0
    21  77 ± 2c  69 ± 2c,d  7 ± 3 0 ± 0
    G3RGDG6PHSRNG 4 129 ± 52  29 ± 10b  99 ± 62b 1 ± 1
    7  68 ± 23  24 ± 6  44 ± 17b 0 ± 0
    14  57 ± 12  21 ± 9  36 ± 10 0 ± 0
    21  74 ± 2c  67 ± 3c,d  7 ± 3 0 ± 0
    G3PHSRNG6RGDG 4 109 ± 16  53 ± 14b  56 ± 5b 0 ± 0
    7  49 ± 11d  21 ± 8  28 ± 3b,d 0 ± 0
    14  87 ± 23  38 ± 12  49 ± 29 0 ± 0
    21  60 ± 11  55 ± 8  5 ± 3d 0 ± 0
    G3RDGG 4  91 ± 11  51 ± 1b  40 ± 10b 0 ± 0
    7  66 ± 16  30 ± 11  36 ± 6b 0 ± 0
    14  48 ± 9d  23 ± 6d  25 ± 6 0 ± 0
    21  35 ± 10c,d,b  32 ± 9c,b  4 ± 2d 0 ± 0
    No grafted 4  94 ± 32  42 ± 27b  52 ± 16b 0 ± 0
    peptide 7  41 ± 10  11 ± 2b  30 ± 6b 0 ± 0
    14  89 ± 21  56 ± 18  33 ± 15 0 ± 0
    21  63 ± 4  55 ± 4  7 ± 2d 0 ± 0
    Empty cage 4 135 ± 22 129 ± 22  6 ± 1 0 ± 0
    7  42 ± 8d  38 ± 8d  4 ± 1 0 ± 0
    14  51 ± 10d  35 ± 6d  15 ± 10 0 ± 0
    21  82 ± 22d  80 ± 25d  2 ± 2 0 ± 0

    aAll values expressed in (mean ± s.e.m. (n = 3).

    bRepresents p < 0.05 vs. respective values of “empty cage” controls.

    cRepresents p < 0.05 vs. respective values of “no grafted peptide” controls.

    dRepresents p < 0.05 vs. respective values at day 4 of the same sample type.
  • TABLE 8
    Adherent macrophage density on cage-implanted mPEGmA-co-AC-co-TMPTA
    networks grafted with various fibronectin-derived oligopeptidesa
    Adherent macrophage density (×10 macrophages/mm2)
    at various post-implantation time (days)
    Peptide 4 7 14 21 35 70
    G3RGDG 138 ± 22b 85 ± 12b,c 33 ± 12b,c 15 ± 3c 14 ± 2c 4 ± 2c
    G3PHSRNG 124 ± 12b 57 ± 10b,c 31 ± 11b,c 10 ± 0c  9 ± 1c 4 ± 2c
    G3EGDG6PHSRNG 126 ± 8b 58 ± 12b,c 23 ± 4b,c 14 ± 4c  6 ± 5c 0 ± 0c
    G3PHSRNG6RGDG 183 ± 27b 69 ± 6b,c 30 ± 5b,c 16 ± 4c 12 ± 5c 3 ± 1c
    G3RDGG  75 ± 16 36 ± 5c 15 ± 3c 15 ± 6c  9 ± 3c 3 ± 2c
    No grafted  74 ± 26 37 ± 4c 14 ± 2c 19 ± 3c  6 ± 3c 1 ± 1c
    peptide

    aAll values expressed in mean ± s.e.m. (n = 3).

    bRepresents p < 0.05 vs. respective values of “no grafted peptide” controls.

    cRepresents p < 0.05 vs. respective values at day 4 of the same sample type.
    • Example 4 Interpenetrating Membranes Comprising Modified Hydrogels
  • Interpenetrating networks (IPNS) are hydrogels synthesized by reacting a first polymer around a second material to form an intermeshing structure. IPNs are free of cross-linkers used to create other biomedical hydrogels. In addition to the benefit of being free of potentially toxic chemicals used in conventional cross-linking procedures, photopolymerization has the advantages that the desired amount of drug can be easily loaded into the matrix, and the cross-linking density, which can affect the drug release rate, can be controlled. Furthermore, IPNs can be formed in situ and used in places less suitable for prefabricated materials.
  • The focus of this Example was to investigate the swelling and drug release kinetics of gelatin-based IPNs of varying gelating backbone modification, weight percent of gelatin, pH, and the molecular weight of polyethylene glycol diacrylate (PEGdA). Based on our results, these IPNs are quite suitable for tissue scaffolds and drug release vehicles.
  • Polyethyleneglycol (PEG) (Aldrich; 2, 4.6, and 8 kDa) was modified with acrylolyl chloride (Aldrich) and TEA (Aldrich) in a 1:4:6 molar ratio at room temperature for 3 hours to produce polyethylene glycol diacrylate (PEGdA). The final PEGdA product purity was checked with the same reverse phase HPLC system as used in Example 1. The elution time of the PEGdA was approximately 13.2 minutes with a purity of approximately 100 wt % PEGdA.
  • Monomethoxypolyethyleneglycol (mPEG) (Fluka; 2 kDa) was modified with acetic anhydride (Aldrich) and DMSO (Fisher) in a 1:80:140 molar ratio at room temperature to form an mPEG monoaldehyde (mPmA). The reaction takes 8 to 24 hours and was monitored periodically with HPLC. The mPmA had an elution time of approximately 11.9 minutes and a purity close to 75 wt % mPmA. The compositions of PEGdA and mPEGmonoaldehyde were also confirmed with 1H-NMR.
  • Gelatin (G) (Sigma, Type A: from porcine skin, 300 bloom) lysyl groups were modified with EDTAD in a 1:0.034 weight ratio for 3 hours at pH=10 to form EDTAD-G (EG). Gelatin lysyl groups were also modified with mPmA and sodium cyanoborohydride (NaCNBH3) (Aldrich) in a 1:0.66:0.186 weight ratio for 24 hours at 50 to 60° C. to form mPmAG (FIG. 4). EG was further modified with mPmA in a procedure similar to the mPmAG procedure. The percent of the gelatin lysyl residues modified by EDTAD and/or mPmA was determined using the trinitrobenzene sulfonic acid spectrophotometric method. The IPNs used in this study were prepared from the same modified gelatins.
  • IPNs were created using modified and unmodified gelatin, PEGdA (2, 4.6, or 8 kDa molecular weight), initiator (2,2-dimethoxy-2-phenylacetophenone, DMPA), and a long wavelength UV source. Gelatin was dissolved in deionized water with heat (80° C.) to form a 20 wt % gelatin solution. PEGdA was dissolved in deionized water, without heat, in an aluminum foil wrapped glass vial to form a 100 wt % PEGdA solution. The gelatin solution was then added to the PEGdA solution and the mixture was agitated thoroughly. DMPA was then added to the gelatin/PEGdA mixture and this final mixture was again agitated and then heated (80° C.) throughout the rest of the procedure. IPNs were created through injection molding. The final gelatin/PEGdA/DMPA mixture was injected with a Pasteur pipette into a Teflon mold that was clamped between 2 glass slides. The mold has the approximate dimensions of 20 mm long by 10 mm wide by 1.6 mm thick. The mold/IPN mixture was then irradiated with UV light from the top and bottom for approximately 3 minutes. During this time, the UV light initiates the cross-linking of PEGdA, entrapping the gelatin within the PEGdA cross-links. The mold/IPN was allowed to cool before the IPN was removed from the mold.
  • IPNs were named based on the weight percent of gelatin, the type of gelatin, the weight percent of PEGdA, and the molecular weight of the PEGdA used to synthesize the IPN. For example, 4G6P2k indicates 40 wt % gelatin, 60 wt % PEGdA, 2 kDa PEGdA. The following key describes the code used to identify IPN formulations.
  • Key: Each formulation is identified by a code of the formula “XYZk”, where X is the wt % gelatin, Y is the type of gelatin, Z is the wt % PEGdA, and k is the molecular weight of the PEGdA:
  • X wt % gelatin
      • 4=40 wt %
      • 6=60 wt %
  • Y=type of gelatin
      • G=gelatin
      • EG=EDTAD-modified gelatin
      • mPMaG=mPmA-modified gelatin
      • mPmAEG=mPmA/EDTAD-modified gelatin
  • Z=wt % PEGdA
      • 4=40wt %
      • 6=60 wt %
  • k=molecular weight PEGdA
      • 2 k=2000 Da
      • 4.6 k=4,600 Da
      • 8 k=8,000 Da
  • The swelling/degradation kinetics of the IPNs were characterized by weighing swollen IPNs at predetermined times (up to 8 weeks). The IPNs were added to test tubes containing 5 ml deionized water with environmental pHs of 4.5, 7.0, and 7.4. The test tubes were then placed in water baths at 37° C. At the predetermined times, the samples were removed with extreme caution from the test tubes using a bent spatula, blotted dry, weighed, and then placed back in the same test tube. This was done until the sample had degraded completely or until the sample had degraded into too many pieces and they could no longer be removed from the test tube. The swelling weight ratio at each time point for each IPN was calculated as: (Wa−Wo/Wo), where Ws is the weight of the swollen IPN and Wo is the original weight of the IPN. The maximum swelling weight ratio that occurred over 8 weeks and the time it occurred was calculated (Rmax, Tmax). The last attainable swelling weight ratio (due to IPN degradation) and the time it occurred was also calculated (Rfail, Tfail).
  • The level of host biocompatibility and inflammatory reaction of the IPNs was determined via the in vivo subcutaneous cage implant system described in the previous Examples. IPNs were placed inside cylindrical (1 cm diameter by 3.5 cm long) medical grade stainless steel wire mesh cages. These cages along with empty cages, controls, were implanted subcutaneously at the back of 3-month old female Sprague-Dawley rats. Inflammatory exudates that collected in the cages were withdrawn at 4, 7, 14, and 21 days post-implantation and analyzed for the quantitative evaluation of cellular and humoral response to the IPN samples using standard hematology techniques. Using these techniques the distributions of polymorphonuclear leukocyte (PMN), lymphocyte, and monocyte subpopulations in the exudates were determined. In addition to the host response, the degradation of the IPNs was determined as percent weight lost ((final IPN weight/initial IPN weight)×100).
  • The IPNs fabricated as described hereinabove were opaque, flexible, rubbery, and slightly tacky. The opacity increased with decreasing gelatin concentration and with increasing PEGdA molecular weight. Increasing the gelatin concentration increased the flexibility and the tackiness of the IPN. The flexibility of the IPNs also seemed to increase with increasing PEGdA molecular weight.
  • The mechanical properties of the IPNs were tested using ASTM testing standards. The IPNs for mechanical testing were made in a similar fashion as stated above, however the molds used were made of polydimethylsiloxane and the IPN final dimensions were 280 mm thick, 11 mm gauge length, and 2 mm neck width (the dimensions required for ASTM D38-98 type IV specimens). The IPNs were subjected to tensile testing per ASTM D638-98 standards, using an Instron Model 5548 testing machine.
  • The preliminary mechanical tests indicated that the average Young's Modulus of the 4G6P2K IPNs was 1.26±0.14 N/nm2. The ultimate tensile stress and strain were 0.39±0.10 N/nm2 and 0.49±0.07 mm/mm, respectively.
  • Swelling/degradation studies (Table 9) showed that increasing the molecular weight of the PEGdA to 4.6 kDa and 8 kDa increased the maximum swelling ratio (Rmax). Modifying gelatin with EDTAD and mPmA did not appear to affect Rmax. The time to Rmax (Tmax) increased with increasing PEGdA molecular weight and by modifying gelatin. The swelling ratio at failure (Rfail) decreased when the wt % of gelatin was decreased from 60 to 40 when PEGdA molecular weight was held constant at 2 kDa. In addition, when the PEGdA molecular weight was 2 kDa and the gelatin was 60 wt %, modifying the gelatin did not improve Rfail. The time to reach Rfail (Tfail) was not affected by increasing the molecular weight of PEGdA or by modifying the gelatin. Table 9 shows Rmax, Tmax, Rfail, and Tfail for each composition of IPNs tested at pH=7. These trends were comparable at pH of 4.5 and 7.4 (results not shown). The release kinetics and bioactivity of human serum albumin, chlorhexidine gluconate, and b-FGF (1%) from these IPNs in vitro are currently being quantified.
    TABLE 9
    Rmax, Tmax, Rfail, and Tfail FOR VARIOUS
    IPN FORMULATIONS AT pH 7.0
    Formulation Rmax Tmax Rfail Tfail
    6G4P2K 0 0 −0.736 9
    4G6P2K 0.754 1 <0.444 >1344
    6G4P4.6K 1.733 225.667 <0.505 >1344
    4G6P4.6K 2.2 4.333 <1.538 >1344
    6G4P8K 1.646 225 0.758 451.333
    4G6P8K 3.911 227.333 <1.542 >1344
    6EG4P2K 0.128 1 −0.214 336.33
    4EG6P2K 0.712 27 <0.532 >1344
    6EG4P4.6K 2.288 35.333 <0.818 >1344
    4EG6P4.6K 1.452 17.667 <0.773 >1344
    6EG4P8K 2.639 5 0.794 960
    4EG6P8K 3.026 1 −0.252 1097.3
    6mPmAG4P2K 0.469 1.667 <−0.23 >1344
    4mPmAG6P2K 0.891 672 <0.827 >1344
    6mPmAG4P4.6K 2.467 226.667 <0.621 >1344
    4mPmAG6P4.6K 2.578 616 <2.445 >1344
    6mPmAG4P8K 3.854 336.667 2.717 944
    4mPmAG6P8K 6.075 337 <2.626 >1344
    6mPmAEG4P8K 2.715 2.333 <1.265 >1344
    4mPmAEG6P8K 4.224 192.333 <1.472 >1344
  • 40 wt % gelatin, 60 wt % PEGdA 2 kDa (4G6P2K) IPNs were used in a preliminary in vivo study. The presence of a high concentration of PMN in the exudates, relative to the control, indicates an acute inflammation response, due to the onset of implantation, which attentuates with time. Acute inflammation is followed by a high concentration of monocytes and lymphocytes in the exudates, chronic inflammation. The study showed that there was a statistically higher inflammatory response to the IPNs after 4, 7, and 14 days of implantation compared to the empty cage controls. The study also revealed that almost 70% of the sample mass was lost after 4 days, and decreased another 10% after 21 days.
  • Currently an in vivo study is underway. The study is investigating the drug release and effect of dexamethasone from IPNs of composition 40 wt % gelatin, 60 wt % PEGdA 2 kDa, and 60 wt % PEGdA 2 kDa.
  • The Example illustrates that IPNs made according to the present invention can serve as tissue scaffolds and drug delivery vehicles.

Claims (52)

1. A hydrogel comprising:
a first polymer matrix; and
a bifunctional modifier comprising a poly(alkylene glycol) molecule having a substituted or unsubstituted α-terminus and a substituted or unsubstituted ω-terminus, and wherein at least one of the α- or ω-termini is covalently bonded to the first polymer matrix.
2. The hydrogel of claim 1, further comprising a pharmacologically-active agent covalently bonded to one of the α- or ω-termini that is not bonded to the first polymer matrix.
3. The hydrogel of claim 1, wherein the first polymer matrix is proteinaceous.
4. The hydrogel of claim 1, wherein the first polymer matrix contains an amino group and wherein at least one of the α- or ω-termini is covalently bonded to the amino group.
5. The hydrogel of claim 1, wherein the first polymer matrix is selected from the group consisting of gelatin, calcium alginate, calcium/sodium alginate, collagen, oxidized regenerated cellulose, carboxymethylcellulose, amino-modified cellulose, and whey protein.
6. The hydrogel of claim 1, wherein the first polymer matrix is selected from the group consisting of gelatin and collagen.
7. The hydrogel of claim 1, wherein the first polymer matrix is cross-linked with a cross-linking reagent.
8. The hydrogel of claim 1, wherein the first polymer matrix is cross-linked with glutaraldehyde.
9. The hydrogel of claim 1, wherein the first polymer matrix further comprises EDTAD moieties bonded to it.
10. The hydrogel of claim 1, wherein the α-terminus and the ω-terminus of the poly(alkylene glycol) molecule are different from one another.
11. The hydrogel of claim 1, wherein the α-terminus and the (ω-terminus are substituted with a moiety selected from the group consisting of halo, hydroxy, C1-C24-alkyl, C1-C24-alkenyl, C1-C24-alkynyl, C1-C24-alkoxy, C1-C24-heteroalkyl, C1-C24-heteroalkenyl, C1-C24-heteroalkynyl, cyano-C1-C24-alkyl, C3-C10-cycloalkyl, C3-C10-cycloalkenyl, C3-C10-cycloalkynyl, C3-C10-cycloheteroalkyl, C3-C10-cycloheteroalkenyl, C3-C10-cycloheteroalkynyl, acyl, acyl-C1-C24-alkyl, acyl-C1-C24-alkenyl, acyl-C1-C24-alkynyl, carboxy, C1-C24-alkylcarboxy, C1-C24-alkenylcarboxy, C1-C24-alkynylcarboxy, carboxy-C1-C24-alkyl, carboxy-C1-C24-alkenyl, carboxy-C1-C24-alkynyl, aryl, aryl-C1-C24-alkyl, aryl-C1-C24-alkenyl, aryl-C1-C24-alkynyl, heteroaryl, heteroaryl-C1-C24-alkyl, heteroaryl-C1-C24-alkenyl, heteroaryl-C1-C24-alkynyl, sulfonate, arylsulfonate, and heteroarylsulfonate.
12. The hydrogel of claim 11, wherein the moiety on the α-terminus is different from the moiety on the ω-terminus.
13. The hydrogel of claim 11, wherein the moieties on the α-terminus and the ω-terminus are substituted or unsubstituted, and when substituted bear a substituent selected from the group consisting of alkyl, aryl, acyl, halogen, hydroxy, amino, alkoxy, alkylamino, acylamino, thioamido, acyloxy, aryloxy, aryloxyalkyl, mercapto, thia, aza, oxo, saturated cyclic hydrocarbon, unsaturated cyclic hydrocarbon, heterocycle, aryl, and heteroaryl.
14. The hydrogel of claim 1, further comprising a pharmacologically-active agent entrained within the hydrogel.
15. The hydrogel of claim 1, further comprising living cells entrained within the hydrogel.
16. The hydrogel of claim 1, further comprising a second polymer matrix, wherein the second polymer matrix interpenetrates with the first polymer matrix.
17. The hydrogel of claim 16, wherein the second polymer matrix comprises a photopolymerized poly(acrylate).
18. The hydrogel of claim 16, wherein the second polymer matrix comprises one or more monomers selected from the group consisting of α-acrylate-ω-acrylate-poly(alkylene glycol), trimethylolpropane triacrylate, acrylic acid, and acryloyl halide.
19. The hydrogel of claim 16, further comprising a pharmacologically-active agent covalently bonded to one of the α- or ω-termini that is not bonded to the first polymer matrix.
20. The hydrogel of claim 16, further comprising a pharmacologically-active agent entrained within the hydrogel.
21. The hydrogel of claim 16, further comprising living cells entrained within the hydrogel.
22-35. (canceled)
36. A hydrogel comprising:
a first polymer matrix containing reactive amino acid moieties;
a bifunctional modifier comprising a compound of formula:
Figure US20060100369A1-20060511-C00015
wherein at least one of the “A” or “Z” moieties is covalently bonded to the reactive amino moieties of the polymer matrix; and wherein “A” and “Z” are independently selected from the group consisting of hydrogen halo, hydroxy, C1-C24-alkyl, C1-C24-alkenyl, C1-C24-alkynyl, C1-C24-alkoxy, C1-C24-heteroalkyl. C1-C24-heteroalkenyl, C1-C24-heteroalkynyl, cyano-C1-C24-alkyl, C3-C10-alkyl, C3-C10-cycloalkenyl, C1-C10-cycloalkynyl, C3-C10-cycloheteroalkyl, C3-C10-cycloheteroalkenyl, C3-C10-cycloheteroalkynyl, acyl, acyl-C1-C24-alkyl, acyl-C1-C24-alkenyl, acyl-C1-C24-alkynyl, carboxy, C1-C24-alkylcarboxy, C1-C24-alkenylcarboxy, C1-C24-alkynylcarboxy, carboxy-C1-C24-alkyl, carboxy-C1-C24-alkenyl, carboxy-C1-C24-alkynyl, aryl, aryl-C1-C24-alkyl, aryl-C1-C24-alkenyl, aryl-C1-C24-alkynyl, heteroaryl, heteroaryl-C1-C24-alkyl, heteroaryl-C1-C24-alkenyl, heteroaryl-C1-C24-alkynyl, sulfonate, arylsulfonate, and heteroarylsulfonate;
“m” is an integer of from 2 to 8;
“n” is an integer equal to or greater than 100; and
further comprising a second polymer matrix, wherein the second polymer matrix interpenetrates with the first polymer matrix.
37. The hydrogel of claim 36, wherein the second polymer matrix comprises a photopolymerized poly(acrylate).
38. The hydrogel of claim 36, wherein the second polymer matrix comprises one or more monomers selected from the group consisting of α-acrylate-ω-acrylate-poly(alkylene glycol), trimethylolpropane triacrylate, and acrylic acid.
39. The hydrogel of claim 36, further comprising a pharmacologically-active agent covalently bonded to one of the “A” or “Z” moieties that is not bonded to the first polymer matrix.
40. The hydrogel of claim 36, further comprising a pharmacologically-active agent entrained within the hydrogel.
41. The hydrogel of claim 36, further comprising living cells entrained within the hydrogel.
42. A hydrogel comprising:
a first polymer matrix;
a bifunctional modifier comprising a poly(alkylene glycol) molecule having a substituted or unsubstituted α-terminus and a substituted or unsubstituted ω-terminus, and wherein at least one of the α- or ω-termini is covalently bonded to the first polymer matrix; and
a second polymer matrix, wherein the second polymer matrix interpenetrates with the first polymer matrix.
43. The hydrogel of claim 42, wherein the first polymer matrix is proteinaceous and the second polymer matrix comprises a photopolymerized poly(acrylate).
44. The hydrogel of claim 42, wherein the first polymer matrix is selected from the group consisting of gelatin and collagen, and the second polymer matrix comprises a photopolymerized poly(acrylate).
45. The hydrogel of claim 42, further comprising a pharmacologically-active agent covalently bonded to one of the α- or ω-termini that is not bonded to the first polymer matrix.
46. The hydrogel of claim 42, further comprising a pharmacologically-active agent entrained within the hydrogel.
47. The hydrogel of claim 42, further comprising living cells entrained within the hydrogel.
48. A method of making a hydrogel comprising:
reacting a first polymer matrix with a bifunctional modifier comprising a poly(alkylene glycol) molecule having a substituted or unsubstituted α-terminus and a substituted or unsubstituted (a-terminus, whereby at least one of the α- or ω-termini is covalently bonded to the polymer matrix.
49. The method of claim 48, further comprising cross-linking the first polymer matrix with a cross-linking reagent.
50. The method of claim 49, wherein the first polymer matrix is cross-linked with glutaraldehyde.
51. The method of claim 48, further comprising reacting EDTAD with the first polymer matrix for a time and under conditions wherein the EDTAD binds to the polymer matrix.
52. The method of claim 48, further comprising reacting the bifunctional modifier with a pharmacologically-active agent, whereby the pharmacologically-active agent is covalently bonded to one of the the α- or ω-termini that is not bonded to the first polymer matrix.
53. The method of claim 48, wherein the α-terminus and the ω-terminus of the bifunctional modifier are different from one another.
54. The method of claim 48, wherein the first polymer matrix is selected from the group consisting of gelatin, calcium alginate, calcium/sodium alginate, collagen, oxidized regenerated cellulose, carboxymethylcellulose, amino-modified cellulose, and whey protein.
55. The method of claim 48, wherein the first polymer matrix is selected from the group consisting of gelatin and collagen.
56. The method of claim 48, further comprising entraining a pharmacologically-active agent within the hydrogel.
57. The method of claim 48, further comprising contacting the first polymer matrix with a plurality of monomers and then polymerizing the monomers to yield a second polymer matrix, wherein the second polymer matrix interpenetrates with the first polymer matrix.
58. The method of claim 57, wherein the plurality of monomers comprises photopolymerized poly(acrylates) and the monomers are polymerized by exposure to infrared, visible, or ultraviolet radiation.
59. The method of claim 57, wherein the plurality of monomers comprises one or more monomers selected from the group consisting of α-acrylate-ω-acrylate-poly(alkylene glycol), trimethylolpropane triacrylate, acrylic acid, and acryloyl halide.
60. The method of claim 57, further comprising covalently bonding a pharmacologically-active agent to one of the α- or ω-termini that is not bonded to the first polymer matrix.
61. The method of claim 57, further comprising entraining a pharmacologically-active agent within the hydrogel.
62. The method of claim 57, further comprising entraining living cells within the hydrogel.
63. A method of administering pharmacologically-active agents or cells to a patient in need thereof, the method comprising entraining pharmacologically-active agents or cells within a hydrogel as recited in claim 1, and then administering the hydrogel to a patient in need of the pharmacologically-active agent or cells.
64. A method of administering pharmacologically-active agents or cells to a patient in need thereof, the method comprising entraining pharmacologically-active agents or cells within a hydrogel as recited in claim 22, and then administering the hydrogel to a patient in need of the pharmacologically-active agent or cells.
65. A method of administering pharmacologically-active agents or cells to a patient in need thereof, the method comprising entraining pharmacologically-active agents or cells within a hydrogel as recited in claim 42, and then administering the hydrogel to a patient in need of the pharmacologically-active agent or cells.
US11/273,393 2001-04-23 2005-11-14 Bifunctional-modified hydrogels Abandoned US20060100369A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/273,393 US20060100369A1 (en) 2001-04-23 2005-11-14 Bifunctional-modified hydrogels

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28578201P 2001-04-23 2001-04-23
US10/128,198 US7615593B2 (en) 2001-04-23 2002-04-23 Bifunctional-modified hydrogels
US11/273,393 US20060100369A1 (en) 2001-04-23 2005-11-14 Bifunctional-modified hydrogels

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/128,198 Division US7615593B2 (en) 2001-04-23 2002-04-23 Bifunctional-modified hydrogels

Publications (1)

Publication Number Publication Date
US20060100369A1 true US20060100369A1 (en) 2006-05-11

Family

ID=23095662

Family Applications (3)

Application Number Title Priority Date Filing Date
US10/128,198 Expired - Fee Related US7615593B2 (en) 2001-04-23 2002-04-23 Bifunctional-modified hydrogels
US11/273,393 Abandoned US20060100369A1 (en) 2001-04-23 2005-11-14 Bifunctional-modified hydrogels
US12/615,859 Expired - Fee Related US8025901B2 (en) 2001-04-23 2009-11-10 Bifunctional-modified hydrogels

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/128,198 Expired - Fee Related US7615593B2 (en) 2001-04-23 2002-04-23 Bifunctional-modified hydrogels

Family Applications After (1)

Application Number Title Priority Date Filing Date
US12/615,859 Expired - Fee Related US8025901B2 (en) 2001-04-23 2009-11-10 Bifunctional-modified hydrogels

Country Status (6)

Country Link
US (3) US7615593B2 (en)
EP (1) EP1423093A4 (en)
JP (1) JP4340067B2 (en)
AU (1) AU2002258913A1 (en)
CA (1) CA2444880C (en)
WO (1) WO2002085419A2 (en)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030083389A1 (en) * 2001-04-23 2003-05-01 Kao Weiyun John Bifunctional-modified hydrogels
US20050276858A1 (en) * 2001-04-23 2005-12-15 Kao Weiyuan J Bifunctional-modified hydrogels
US20080287633A1 (en) * 2007-05-18 2008-11-20 Drumheller Paul D Hydrogel Materials
US20090191626A1 (en) * 2008-01-30 2009-07-30 Christopher Bankole Shogbon Synthetic Surfaces for Culturing Stem Cell Derived Oligodendrocyte Progenitor Cells
US20090191633A1 (en) * 2008-01-30 2009-07-30 Christopher Bankole Shogbon Synthetic Surfaces for Culturing Stem Cell Derived Cardiomyocytes
US20090191634A1 (en) * 2008-01-30 2009-07-30 Arthur W Martin (meth)acrylate surfaces for cell culture, methods of making and using the surfaces
US20090191627A1 (en) * 2008-01-30 2009-07-30 Andrei Gennadyevich Fadeev Synthetic surfaces for culturing cells in chemically defined media
US20090191632A1 (en) * 2008-01-30 2009-07-30 Fadeev Andrei G Swellable (meth)acrylate surfaces for culturing cells in chemically defined media
US20100017972A1 (en) * 2006-12-19 2010-01-28 Luciana Sartore Biodegradable polymeric derivatives
US20110071262A1 (en) * 2008-05-20 2011-03-24 Id Biochem, Inc. Method for preparing high-purity polyethyleneglycol aldehyde derivatives
US20110152455A1 (en) * 2009-05-21 2011-06-23 Martin Arthur W Monomers for making polymeric cell culture surface
US9200084B2 (en) 2010-06-08 2015-12-01 Dow Global Technologies Llc Method for the preparation of a particulate reversibly crosslinked polymeric material
CN109481730A (en) * 2018-11-27 2019-03-19 五邑大学 Calcium alginate/polyethylene glycol three-dimensional fiber network gel and its preparation method and application
CN112007210A (en) * 2020-08-24 2020-12-01 上海颐盏生物科技有限公司 Photoinitiated polyethylene glycol-based hydrogel dressing and preparation method thereof

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6969367B2 (en) * 2000-02-02 2005-11-29 Xepmed, Inc. Extracorporeal pathogen reduction system
EP1419191B1 (en) * 2001-08-22 2007-10-17 Bioartificial Gel Technologies Inc. Process for the preparation of activated polyethylene glycols
US7605231B2 (en) * 2002-04-26 2009-10-20 Yasuhiko Tabata Gelatin derivatives and high-molecular micelle comprising the derivatives
SI1656410T1 (en) * 2003-07-22 2010-07-30 Nektar Therapeutics Method for preparing functionalized polymers from polymer alcohols
US7815561B2 (en) 2003-09-25 2010-10-19 Xoft, Inc. Brachytherapy applicator
US20050214376A1 (en) * 2003-10-21 2005-09-29 Marie-Pierre Faure Hydrogel-containing medical articles and methods of using and making the same
ES2404682T3 (en) 2003-12-11 2013-05-28 Isto Technologies Inc. Particle Cartilage System
US7351787B2 (en) * 2004-03-05 2008-04-01 Bioartificial Gel Technologies, Inc. Process for the preparation of activated polyethylene glycols
WO2005115489A2 (en) * 2004-05-24 2005-12-08 Genzyme Corporation Adherent polymeric compositions
US9561309B2 (en) * 2004-05-27 2017-02-07 Advanced Cardiovascular Systems, Inc. Antifouling heparin coatings
WO2006013612A1 (en) * 2004-06-18 2006-02-09 Hokkaido Technology Licensing Office Co., Ltd. Artificial semilunar cartilage
US8329958B2 (en) * 2004-07-02 2012-12-11 Biocon Limited Combinatorial synthesis of PEG oligomer libraries
US7968085B2 (en) * 2004-07-05 2011-06-28 Ascendis Pharma A/S Hydrogel formulations
US20070207209A1 (en) * 2004-08-27 2007-09-06 Murphy Christopher J Trophic factor combinations for nervous system treatment
US20060074182A1 (en) * 2004-09-30 2006-04-06 Depuy Products, Inc. Hydrogel composition and methods for making the same
US20090088846A1 (en) 2007-04-17 2009-04-02 David Myung Hydrogel arthroplasty device
US8821583B2 (en) 2004-10-05 2014-09-02 The Board Of Trustees Of The Leland Stanford Junior University Interpenetrating polymer network hydrogel
US8609131B2 (en) * 2005-01-25 2013-12-17 3M Innovative Properties Company Absorbent dressing comprising hydrophilic polymer prepared via Michael reaction
JP4685090B2 (en) * 2005-02-14 2011-05-18 株式会社メドジェル Medical hydrogel
WO2006127865A2 (en) * 2005-05-24 2006-11-30 Georgia Tech Research Corporation Bioresponsive hydrogels
WO2007005754A2 (en) * 2005-07-01 2007-01-11 Alza Corporation Liposomal delivery vehicle for hydrophobic drugs
US20070055200A1 (en) 2005-08-10 2007-03-08 Gilbert Scott J Needle-free jet injection drug delivery device
GB0516846D0 (en) * 2005-08-17 2005-09-21 Knight David P Meniscal repair device
EP1922355B1 (en) * 2005-08-26 2009-03-11 Novo Nordisk A/S A method of modifying a macromolecular system
WO2007025290A2 (en) 2005-08-26 2007-03-01 Isto Technologies, Inc. Implants and methods for repair, replacement and treatment of joint disease
EP1764117A1 (en) * 2005-09-20 2007-03-21 Zimmer GmbH Implant for the repair of a cartilage defect and method for manufacturing the implant
US20110166247A1 (en) * 2006-12-07 2011-07-07 David Myung Interpenetrating polymer network hydrogel contact lenses
US8163549B2 (en) 2006-12-20 2012-04-24 Zimmer Orthobiologics, Inc. Method of obtaining viable small tissue particles and use for tissue repair
CN101220090B (en) * 2007-01-09 2010-10-13 上海百瑞吉生物医药有限公司 Multi-modification derivant of glutin and crosslinked material thereof
US8334044B2 (en) * 2007-02-06 2012-12-18 The Board Of Trustees Of The Leland Stanford Junior University Hydrogel-metal assembly
WO2008100617A1 (en) * 2007-02-16 2008-08-21 The Board Of Trustees Of The Leland Stanford Junior University Strain-hardened interpenetrating polymer network hydrogel
WO2008128075A1 (en) 2007-04-12 2008-10-23 Isto Technologies, Inc. Compositions and methods for tissue repair
ITMI20071236A1 (en) * 2007-06-20 2008-12-21 Sicit Chemitech Spa PRODUCTION OF LEATHER AND FABRIC FROM MATERIALS CONTAINING HYDROLYSED PROTEINS AND GELATINS
US20100280147A1 (en) * 2008-02-15 2010-11-04 Laura Hartmann High refractive index interpenetrating networks for ophthalmic applications
US8668863B2 (en) 2008-02-26 2014-03-11 Board Of Regents, The University Of Texas System Dendritic macroporous hydrogels prepared by crystal templating
US20090220578A1 (en) * 2008-02-28 2009-09-03 Depuy Products, Inc. Hydrogel composition and method for making the same
US20090240337A1 (en) * 2008-03-21 2009-09-24 David Myung Methods, Devices and Compositions for Adhering Hydrated Polymer Implants to Bone
US20090280182A1 (en) * 2008-04-30 2009-11-12 Stayce Beck Devices for the treatment of wounds and methods and kits therefor
WO2010005992A1 (en) * 2008-07-07 2010-01-14 Biomimedica, Inc. Hydrophilic interpenetrating polymer networks derived from hydrophobic polymers
US20120209396A1 (en) 2008-07-07 2012-08-16 David Myung Orthopedic implants having gradient polymer alloys
CA2731698A1 (en) 2008-08-05 2010-02-11 Biomimedica, Inc. Polyurethane-grafted hydrogels
US8999378B2 (en) * 2008-09-24 2015-04-07 President And Fellows Of Harvard College Porous electroactive hydrogels and uses thereof
WO2010120108A2 (en) * 2009-04-14 2010-10-21 서울대학교산학협력단 Method for forming a microsphere having a structural color
WO2011014605A1 (en) 2009-07-29 2011-02-03 Corning Incorporated Functionalized cell binding peptides and cell culture articles
US20110183418A1 (en) 2009-07-29 2011-07-28 Arthur Winston Martin Peptide-Polymer Cell Culture Articles and Methods of Making
DK2459171T3 (en) 2009-07-31 2017-09-25 Sanofi Aventis Deutschland Long-acting insulin composition
NZ598021A (en) 2009-07-31 2014-05-30 Sanofi Aventis Deutschland Prodrugs comprising an insulin linker conjugate
NZ599524A (en) 2009-11-09 2014-04-30 Spotlight Technology Partners Llc Polysaccharide based hydrogels
NZ599527A (en) 2009-11-09 2014-04-30 Spotlight Technology Partners Llc Fragmented hydrogels
US9758558B2 (en) 2010-04-01 2017-09-12 Board Of Supervisors Of Louisiana State University And Agriculture And Mechanical College Whey protein isolate hydrogels and their uses
US20120003192A1 (en) * 2010-07-02 2012-01-05 Zimmer Orthobiologics, Inc. Hydrogel-forming composition comprising protein and non-protein segments
US20130217829A1 (en) 2010-08-27 2013-08-22 David Myung "hydrophobic and hydrophilic interpenetrating polymer networks derived from hydrophobic polymers and methods of preparing the same"
EP2438930A1 (en) 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Prodrugs comprising an exendin linker conjugate
US8946194B2 (en) 2010-10-08 2015-02-03 Board Of Regents, University Of Texas System One-step processing of hydrogels for mechanically robust and chemically desired features
US9095558B2 (en) 2010-10-08 2015-08-04 Board Of Regents, The University Of Texas System Anti-adhesive barrier membrane using alginate and hyaluronic acid for biomedical applications
WO2012148953A1 (en) * 2011-04-25 2012-11-01 Stc.Unm Solid compositions for pharmaceutical use
US20130103157A1 (en) 2011-10-03 2013-04-25 Lampros Kourtis Polymeric adhesive for anchoring compliant materials to another surface
KR20140113655A (en) 2011-11-21 2014-09-24 바이오미메디카, 인코포레이티드 Systems, devices, and methods for anchoring orthopaedic implants to bone
KR101269423B1 (en) * 2011-12-22 2013-05-30 오스템임플란트 주식회사 Hydrogel with controllable biodegradation behavior and the manufacturing method thereof
US20140178343A1 (en) 2012-12-21 2014-06-26 Jian Q. Yao Supports and methods for promoting integration of cartilage tissue explants
JPWO2016204258A1 (en) * 2015-06-19 2018-04-05 日産化学工業株式会社 Gel forming polymer and adhesive material for skin
US11077228B2 (en) 2015-08-10 2021-08-03 Hyalex Orthopaedics, Inc. Interpenetrating polymer networks
CN109790371B (en) * 2016-10-03 2021-07-20 Dic株式会社 Manufacturing method of semi-IPN type complex
IT201600108137A1 (en) 2016-10-26 2018-04-26 Sicit Chemitech S P A BIODEGRADABLE POLYMER DERIVATIVES
US11980700B2 (en) 2017-03-08 2024-05-14 Alafair Biosciences, Inc. Hydrogel medium for the storage and preservation of tissue
CZ308284B6 (en) * 2018-03-15 2020-04-15 Ústav makromolekulární chemie AV ČR, v. v. i. Preparation based on interpenetrating polymer networks for healing wounds
US10869950B2 (en) 2018-07-17 2020-12-22 Hyalex Orthopaedics, Inc. Ionic polymer compositions
CN109078391B (en) * 2018-08-03 2024-07-26 闽江学院 Composite filter element prepared from hydrogel filled porous filter material
WO2020181393A1 (en) * 2019-03-13 2020-09-17 Susmita Bose Enzyme-degradable hydrogel for delivery of a payload
CN113398321B (en) * 2020-03-17 2022-04-12 天津大学 A porous hemostatic sponge with high liquid absorption rate and high resilience and its preparation method and application
CN112870432B (en) * 2021-01-14 2021-12-10 东华大学 Photorepairable nanofiber hydrogel dressing and preparation method thereof
IL316454A (en) * 2022-04-22 2024-12-01 The Univ Of Vermont And State Agricultural College Polymer/milk-protein hydrogels, cell scaffolds and cultured meat products made therewith, and associated methods

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4390519A (en) * 1978-05-19 1983-06-28 Sawyer Philip Nicholas Bandage with hemostatic agent and methods for preparing and employing the same
US5153265A (en) * 1988-01-20 1992-10-06 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
US5672662A (en) * 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US5847089A (en) * 1995-06-07 1998-12-08 Wisconsin Alumni Research Foundation Carboxyl-modified superabsorbent protein hydrogel
US5863984A (en) * 1995-12-01 1999-01-26 Universite Laval, Cite Universitaire Biostable porous material comprising composite biopolymers
US6043328A (en) * 1995-05-19 2000-03-28 Novartis Ag Polysiloxane-polyol macromers, their preparation and their use
US6129761A (en) * 1995-06-07 2000-10-10 Reprogenesis, Inc. Injectable hydrogel compositions
US6132765A (en) * 1996-04-12 2000-10-17 Uroteq Inc. Drug delivery via therapeutic hydrogels
US6258351B1 (en) * 1996-11-06 2001-07-10 Shearwater Corporation Delivery of poly(ethylene glycol)-modified molecules from degradable hydrogels
US6310105B1 (en) * 2000-02-15 2001-10-30 Wisconsin Alumni Research Foundation Carboxyl-modified superabsorbent protein hydrogel
US6323278B2 (en) * 1995-10-05 2001-11-27 Cohesion Technologies, Inc. Method of making crosslinked polymer matrices in tissue treatment applications
US20030083389A1 (en) * 2001-04-23 2003-05-01 Kao Weiyun John Bifunctional-modified hydrogels
US6730299B1 (en) * 1999-07-21 2004-05-04 Imedex Biomateriaux Adhesive protein foam for surgical and/or therapeutic uses
US6818018B1 (en) * 1998-08-14 2004-11-16 Incept Llc In situ polymerizable hydrogels
US20050276858A1 (en) * 2001-04-23 2005-12-15 Kao Weiyuan J Bifunctional-modified hydrogels

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04500799A (en) * 1988-10-26 1992-02-13 ソロキン，アナトリ　ヤコフレビチ Copolymer of vinyl acetate and vinyl alcohol crosslinked with glutaraldehyde, method for producing the same, and pharmaceuticals based on the same
US5162430A (en) 1988-11-21 1992-11-10 Collagen Corporation Collagen-polymer conjugates
US5936035A (en) 1988-11-21 1999-08-10 Cohesion Technologies, Inc. Biocompatible adhesive compositions
JPH06503840A (en) * 1991-07-09 1994-04-28 ヴィタフォア　コーポレイション Collagen composites for controlled drug release
IT1260154B (en) * 1992-07-03 1996-03-28 Lanfranco Callegaro HYALURONIC ACID AND ITS DERIVATIVES IN INTERPENETRATING POLYMERS (IPN)
JP3536186B2 (en) * 1995-02-27 2004-06-07 独立行政法人 科学技術振興機構 Biodegradable polymer hydrogel
JPH1085318A (en) * 1996-09-18 1998-04-07 Terumo Corp Medical material and skin ulcer filling/recovering material
WO1998028364A1 (en) 1996-12-20 1998-07-02 The Chinese University Of Hong Kong Novel polymer gel composition and uses therefor
US5904927A (en) * 1997-03-14 1999-05-18 Northeastern University Drug delivery using pH-sensitive semi-interpenetrating network hydrogels
US5906997A (en) * 1997-06-17 1999-05-25 Fzio Med, Inc. Bioresorbable compositions of carboxypolysaccharide polyether intermacromolecular complexes and methods for their use in reducing surgical adhesions
US6521431B1 (en) * 1999-06-22 2003-02-18 Access Pharmaceuticals, Inc. Biodegradable cross-linkers having a polyacid connected to reactive groups for cross-linking polymer filaments
AU6679400A (en) * 1999-08-27 2001-03-26 Department Of National Defence Hydrogel wound dressing containing liposome-encapsulated therapeutic agent
US6348558B1 (en) * 1999-12-10 2002-02-19 Shearwater Corporation Hydrolytically degradable polymers and hydrogels made therefrom
AU2001255716B2 (en) * 2000-04-28 2006-02-02 Fziomed, Inc. Hemostatic compositions of polyacids and polyalkylene oxides and methods for their use

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4390519A (en) * 1978-05-19 1983-06-28 Sawyer Philip Nicholas Bandage with hemostatic agent and methods for preparing and employing the same
US5153265A (en) * 1988-01-20 1992-10-06 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
US6043328A (en) * 1995-05-19 2000-03-28 Novartis Ag Polysiloxane-polyol macromers, their preparation and their use
US6129761A (en) * 1995-06-07 2000-10-10 Reprogenesis, Inc. Injectable hydrogel compositions
US5847089A (en) * 1995-06-07 1998-12-08 Wisconsin Alumni Research Foundation Carboxyl-modified superabsorbent protein hydrogel
US5672662A (en) * 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US6323278B2 (en) * 1995-10-05 2001-11-27 Cohesion Technologies, Inc. Method of making crosslinked polymer matrices in tissue treatment applications
US5863984A (en) * 1995-12-01 1999-01-26 Universite Laval, Cite Universitaire Biostable porous material comprising composite biopolymers
US6132765A (en) * 1996-04-12 2000-10-17 Uroteq Inc. Drug delivery via therapeutic hydrogels
US6258351B1 (en) * 1996-11-06 2001-07-10 Shearwater Corporation Delivery of poly(ethylene glycol)-modified molecules from degradable hydrogels
US6818018B1 (en) * 1998-08-14 2004-11-16 Incept Llc In situ polymerizable hydrogels
US6730299B1 (en) * 1999-07-21 2004-05-04 Imedex Biomateriaux Adhesive protein foam for surgical and/or therapeutic uses
US6310105B1 (en) * 2000-02-15 2001-10-30 Wisconsin Alumni Research Foundation Carboxyl-modified superabsorbent protein hydrogel
US20030083389A1 (en) * 2001-04-23 2003-05-01 Kao Weiyun John Bifunctional-modified hydrogels
US20050276858A1 (en) * 2001-04-23 2005-12-15 Kao Weiyuan J Bifunctional-modified hydrogels

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030083389A1 (en) * 2001-04-23 2003-05-01 Kao Weiyun John Bifunctional-modified hydrogels
US20050276858A1 (en) * 2001-04-23 2005-12-15 Kao Weiyuan J Bifunctional-modified hydrogels
US8025901B2 (en) 2001-04-23 2011-09-27 Wisconsin Alumni Research Foundation Bifunctional-modified hydrogels
US20100209509A1 (en) * 2001-04-23 2010-08-19 Wisconsin Alumni Research Foundation Bifunctional-modified hydrogels
US7615593B2 (en) 2001-04-23 2009-11-10 Wisconsin Alumni Research Foundation Bifunctional-modified hydrogels
US20100017972A1 (en) * 2006-12-19 2010-01-28 Luciana Sartore Biodegradable polymeric derivatives
US20080287633A1 (en) * 2007-05-18 2008-11-20 Drumheller Paul D Hydrogel Materials
US20090191632A1 (en) * 2008-01-30 2009-07-30 Fadeev Andrei G Swellable (meth)acrylate surfaces for culturing cells in chemically defined media
US20090191626A1 (en) * 2008-01-30 2009-07-30 Christopher Bankole Shogbon Synthetic Surfaces for Culturing Stem Cell Derived Oligodendrocyte Progenitor Cells
US20090191627A1 (en) * 2008-01-30 2009-07-30 Andrei Gennadyevich Fadeev Synthetic surfaces for culturing cells in chemically defined media
US20090191634A1 (en) * 2008-01-30 2009-07-30 Arthur W Martin (meth)acrylate surfaces for cell culture, methods of making and using the surfaces
US20090191633A1 (en) * 2008-01-30 2009-07-30 Christopher Bankole Shogbon Synthetic Surfaces for Culturing Stem Cell Derived Cardiomyocytes
US8563312B2 (en) 2008-01-30 2013-10-22 Geron Corporation Synthetic surfaces for culturing stem cell derived cardiomyocytes
US20090203065A1 (en) * 2008-01-30 2009-08-13 Jennifer Gehman Cell culture article and screening
US9745550B2 (en) 2008-01-30 2017-08-29 Asterias Biotherapeutics, Inc. Synthetic surfaces for culturing stem cell derived cardiomyocytes
US8168433B2 (en) 2008-01-30 2012-05-01 Corning Incorporated Cell culture article and screening
US8241907B2 (en) 2008-01-30 2012-08-14 Geron Corporation Synthetic surfaces for culturing stem cell derived cardiomyocytes
US8329469B2 (en) 2008-01-30 2012-12-11 Geron Corporation Swellable (meth)acrylate surfaces for culturing cells in chemically defined media
US8513009B2 (en) 2008-01-30 2013-08-20 Geron Corporation Synthetic surfaces for culturing stem cell derived oligodendrocyte progenitor cells
US8354274B2 (en) 2008-01-30 2013-01-15 Geron Corporation Synthetic surfaces for culturing cells in chemically defined media
US10221390B2 (en) 2008-01-30 2019-03-05 Asterias Biotherapeutics, Inc. Synthetic surfaces for culturing stem cell derived oligodendrocyte progenitor cells
US8349969B2 (en) * 2008-05-20 2013-01-08 Id Biochem, Inc. Method for preparing high-purity polyethyleneglycol aldehyde derivatives
US20110071262A1 (en) * 2008-05-20 2011-03-24 Id Biochem, Inc. Method for preparing high-purity polyethyleneglycol aldehyde derivatives
US20110152455A1 (en) * 2009-05-21 2011-06-23 Martin Arthur W Monomers for making polymeric cell culture surface
US8362144B2 (en) 2009-05-21 2013-01-29 Corning Incorporated Monomers for making polymeric cell culture surface
US9200084B2 (en) 2010-06-08 2015-12-01 Dow Global Technologies Llc Method for the preparation of a particulate reversibly crosslinked polymeric material
CN109481730A (en) * 2018-11-27 2019-03-19 五邑大学 Calcium alginate/polyethylene glycol three-dimensional fiber network gel and its preparation method and application
CN112007210A (en) * 2020-08-24 2020-12-01 上海颐盏生物科技有限公司 Photoinitiated polyethylene glycol-based hydrogel dressing and preparation method thereof

Also Published As

Publication number Publication date
WO2002085419A2 (en) 2002-10-31
US7615593B2 (en) 2009-11-10
EP1423093A2 (en) 2004-06-02
AU2002258913A1 (en) 2002-11-05
JP2004534111A (en) 2004-11-11
CA2444880A1 (en) 2002-10-31
JP4340067B2 (en) 2009-10-07
EP1423093A4 (en) 2005-11-30
US8025901B2 (en) 2011-09-27
WO2002085419A3 (en) 2004-03-18
US20030083389A1 (en) 2003-05-01
US20100209509A1 (en) 2010-08-19
CA2444880C (en) 2009-11-24

Similar Documents

Publication Publication Date Title
US8025901B2 (en) Bifunctional-modified hydrogels
US5565519A (en) Clear, chemically modified collagen-synthetic polymer conjugates for ophthalmic applications
CN1328319C (en) Synthetic matrix for controlled cell ingrowth and tissue regeneration
US5446091A (en) Collagen-polymer conjugates containing an ether linkage
KR100293043B1 (en) Photocurable glycosaminoglycan derivatives, cross-linked glycosaminoglycans and methods for preparing the same
EP0359996B1 (en) Synthetic amino acid-and/or peptide-containing graft copolymers
US7052711B2 (en) Nitric oxide-producing hydrogel materials
US7291673B2 (en) Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
EP2150282B1 (en) Compositions and methods for scaffold formation
Atienza-Roca et al. Visible light mediated PVA-tyramine hydrogels for covalent incorporation and tailorable release of functional growth factors
US20070264227A1 (en) Synthetic Matrix for Controlled Cell Ingrowth and Tissue Regeneration
US20020192182A1 (en) Polysaccharide-based polymerizable hydrogels
CA2134745A1 (en) Glycosaminoglycan-synthetic polymer conjugates
MXPA02007938A (en) Delivery systems using preformed biodegradable polymer compositions and methods.
JP2009102383A (en) Growth factor-modified protein matrix for tissue manipulation
US20050276858A1 (en) Bifunctional-modified hydrogels
CZ20011899A3 (en) Hydrogel materials producing nitrogen oxide
US20230159623A1 (en) Modified gelatins
Lok et al. c12) United States Patent

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载